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Thesis Abstract 
Pentameric ligand-gated ion channels (pLGICs) are important therapeutic targets for 
a wide range of neurological disorders that include cognitive impairment, stroke, psychiatric 
conditions and peripheral pain. They are also targets for treating parasite infections and 
controlling pest species in agriculture, veterinary practice and human health. Here we focus 
on one family of the pLGICs i.e., the glutamate-gated chloride channel receptors (GluClRs) 
which are expressed at inhibitory synapses of invertebrates. Ivermectin (IVM) is one of the 
main drugs used to control pest species and parasites, and it works by activating GluClRs in 
nematode and arthropod muscle and nerves. IVM resistance is becoming a major problem in 
many invertebrate pathogens, necessitating the development of novel anti-parasitic drugs. 
This project started with the simple aim of determining the sensitivity to glutamate and IVM 
of GluClRs from two different pest species: the parasitic nematode Haemonchus contortus 
(HcoGluClRs) and the mosquito malaria vector Anopheles gambiae (AgGluClRs).  
In chapter 3, we found that the β homomeric GluClRs of H.contortus were insensitive 
to IVM (EC50> 10 µM), whereas α homomeric HcoGluClRs were highly sensitive (EC50 = 20 nM). 
Heteromeric αβ HcoGluClRs exhibited an intermediate sensitivity to IVM (EC50 = 135 nM). By 
contrast, the EC50 values for glutamate at α homomeric and αβ heteromeric receptors were 
not distinguishable; falling between 20-30 µM. GluClR-mediated IPSCs were significantly 
different for α relative to αβ receptors, with αβ GluClRs exhibiting a faster decay rate of 17 
ms in contrast to α GluClRs which had a decay rate of 40ms. 5 nM IVM slowed the decay rates 
of IPSCs mediated by both isoforms with α GluClRs reaching a mean decay rate of 100 ms and 
αβ GluClRs decaying at a mean rate of 72ms. Evaluating the biophysical properties of single 
heteromeric αβ and homomeric β GluClRs revealed that different stoichiometric GluClR 
isoforms exhibited different open state amplitudes. The α GluClR had the biggest current (1.8 
pA) followed by the αβ (1:1) GluClR (two different amplitudes – 1.2 pA, 90% and 0.7 pA, 10%) 
and the smallest being β homomer (0.4 pA). The β and αβ GluClRs had mean active durations 
of 5.5 ms and 43 ms, respectively, in response to 2 µM glutamate. This duration increased to 
126 ms and 876 ms, respectively, when 2 µM glutamate was co-applied with 5 nM IVM. 
Collectively, the data from both the IPSCs and the single channel measurements show a 
correlation between shorter active periods; faster IPSC decay rates and decreased IVM 
sensitivity. 
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For better drug optimisation, a quantitative understanding of activation and 
modulation mechanisms of the GluClR is necessary. For this purpose, in chapter 4 we 
evaluated the biophysical properties of the α homomeric HcoGluClR and a mutation to a 
position that confers IVM resistance in several pest species (TM3-36’) in presence of 
glutamate and IVM. We showed that the G36’A mutation decreased the duration of active 
periods and increased receptor desensitisation. As the results showed a common effect for 
both glutamate- and IVM-gated currents, we infer that the intrinsic properties of the receptor 
were affected by the G36’A mutation and not the IVM binding mechanism as previously 
proposed.  
In Chapter 5, we looked to characterize the effects of glutamate, IVM, lindane, fipronil 
and picrotoxin on 2 splice isoforms of GluClRs expressed by A. gambiae. The two splice 
isoforms AgGluCl-a1 and AgGluCl-b when evaluated as homomeric GluClRs for effects of 
glutamate and IVM disclosed something interesting. We found that the AgGluCl-b was 
sensitive to IVM, contrary to what was reported by (Meyers et al. 2015). Lindane and fipronil 
both block glycine receptors (Islam and Lynch 2012), which, like the GluClR, is an inhibitory 
member of pLGIC family. In addition, many insecticides target GluClRs, this prompted us to 
investigate how lindane and fipronil affected the two GluClR isoforms. Both compounds were 
effective at inhibiting glutamate-gated currents mediated by both isoforms. Glutamate-gated 
currents completely recovered in a time dependent manner for AgGluClR-a1. By contrast, only 
a partial recovery of currents was observed for AgGluClR-b, suggesting a greater affinity of 
lindane and fipronil at AgGluClR-b. This differential affinity implies different binding 
mechanisms between the two isoforms. Picrotoxin, a classical pore blocker, equally blocked 
glutamate currents for both the isoforms. 
In chapter 6, we screened libraries of natural marine extracts against the 
hippocampal-dominant α5 GABAAR isoform (α5β3γ2L) using an automated yellow fluorescent 
protein-based screening assay to identify fractions with selective activity. Hits were confirmed 
using electrophysiology. Although the hits were potent, further screening of the compounds 
was not proceeded due to low compound availability. 
In conclusion, we demonstrated that reduced IVM sensitivity is due to shorter active 
periods and faster decay rates. This conclusion was supported by the findings from chapter 3 
that showed that heteromeric population of αβ HcoGluClRs were less sensitive to the 
potentiating effects of IVM compared to α HcoGluClRs. The briefer single receptor periods 
v 
 
seen in β-containing GluClRs correspond closely with, faster IPSC decay rates. All the results 
point towards β HcoGluClRs being responsible for reduced IVM sensitivity.  
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1. Introduction 
1.1 Pentameric ligand-gated ion channels (pLGICs) 
 Intercellular communication mediated by pLGICs is a result of conversion from binding 
of a neurotransmitter that is released from the presynaptic terminal into ion flux in the 
postsynaptic membrane (Lemoine et al. 2012). The members of this superfamily include 
nicotinic acetylcholine receptors (nAChRs), the serotonin type 3 receptors (5-HT3Rs), the γ-
aminobutyric acid type A receptors (GABAARs), the glutamate gated chloride channel 
receptors (GluClRs) and the glycine receptors (GlyRs). When a neurotransmitter binds to the 
above-mentioned receptors, it leads to activation of channels causing fast excitatory or 
inhibitory neurotransmission in the peripheral and the central nervous systems (CNS) (Lynch 
2004). 
 Having a broad distribution in the CNS, the pLGICs are involved in a number of 
biological processes. From the above-mentioned superfamily, some of them are cation 
selective which are involved in depolarisation of neurons through conducting Na+ and K+ such 
as nAChRs and 5HT3Rs. On the other hand, the anion selective receptors such as GluClRs, 
GABAARs and GlyRs are involved in hyperpolarisation, mainly conducting Cl- ions (Hille 2001).  
 Drugs involved in treating disorders such as epilepsy, anxiety and use in anaesthetics 
involve GABAARs as their targets (Sigel and Steinmann 2012). On the contrary, a review by 
(Webb and Lynch 2007) has proposed GlyR subtypes as potential targets for treating chronic 
inflammatory pain and hyperekplexia.  
 GluClRs on the other hand, are only found in invertebrates (Wolstenholme 2012) and 
are targets for treating parasitic infections caused by invertebrate pest species such as 
Haemonchus contortus (Chiejina et al. 2015). In addition to being used widely in agriculture, 
aquaculture and veterinary practice, drugs that target invertebrate GluClRs are also used to 
treat human conditions such as river blindness (Sneader 2005), lymphatic filariasis (Mehlhorn 
2008) and scabies (Panahi et al. 2015). Anthelminthics such as ivermectin (IVM) are one class 
of drugs that target the GluClR where they bind in the transmembrane domain of the receptor 
and keep the channel open for a long duration resulting in a Cl- influx. This causes 
hyperpolarization of muscle and nerve cells resulting in paralysis and death of the organism 
(Cully et al. 1994; Arena et al. 1991; Hibbs and Gouaux 2011). However, IVM resistance is 
becoming a major problem in pest species (Wolstenholme et al. 2004), especially in the 
parasitic nematode H. contortus (McCavera et al. 2009).  One focus of my PhD is to understand 
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one of the possible mechanisms by which the H. contortus develops resistance to 
anthelmenthics.  
1.2 General structure and features of pLGICs 
 As the name suggests, pLGICs consist of five subunits, which are arranged around a 
central ion-conducting pore. Using techniques such as X-ray crystallography, cryo electron 
microscopy (cryo-EM) and nuclear magnetic resonance (NMR) spectroscopy, various 
structures from the pLGIC family have been resolved. Channels from the prokaryotic bacteria 
Erwinia chrysanthemi (ELIC) and Gleobacter violaceus (GLIC) were the first complete 
structures to be resolved in their open and closed conformations using these techniques (Hilf 
and Dutzler 2008, 2009; Bocquet et al. 2009; Nury et al. 2010). (Basak et al. 2018) resolved 
the crystal structure of 5-HT3AR in its resting confirmation using cryo-EM. Also (Hibbs and 
Gouaux 2011) crystallized the GluClRs from C. elegans in its apo and IVM bound state. The 
high-resolution crystal structure of the extracellular domain of nAChR α1 bound to α-
bungarotoxin was solved using these techniques (Dellisanti et al. 2007). The crystal structure 
of human GlyR α3 bound to antagonist strychnine, human GlyR α3 bound to IVM and a novel 
class of analgesic potentiator bound to human GlyR α3 were solved using crystallographic 
techniques (Huang et al. 2015; Huang, Chen, et al. 2017; Huang, Shaffer, et al. 2017). All these 
crystallized structures share a similar structure. Using X-ray crystallography (Miller and 
Aricescu 2014) recently solved the structure of human GABAAR. Using cryo-EM, (Phulera et 
al. 2018) presented a new benzodiazepine sensitive α1β1γ2S triheteropentameric GABAAR in 
complex with GABA. Crystallographic techniques helped in revealing a new endogenous 
neurosteroid-binding site on GABAAR chimera (Laverty et al. 2017). The data from these 
resolved structures indicate that the large N-terminal ligand-binding domain of pLGIC 
receptors are rich in β-sheets. Four α-helical regions form the transmembrane domains (TM1-
TM4). A large intracellular loop connects the TM3 and TM4. Each subunit contributes the TM2 
domain to form the channel pore (Figure 1.1).  
1.2.1 Ligand binding domain 
 The ligand-binding domain is made up of an α helix near its N-terminal which is 
followed by a number of β-strands which organise themselves as three strand outer and seven 
strand inner sheets that form a sandwich. The subunit interfaces form the ligand-binding 
pockets. Three loops (A, B and C) from a single subunit situated on the clockwise side of the 
interface forms the (+) side of the pocket whereas the three β-sheets (loop D, E and F) from  
4 
 
Figure 1.1: General structure of pLGICs. (A) Crystal structurer of C. elegans of α GluClR 
showing the channel pore and pentameric arrangement of the channel viewed from the 
top. (B) Parallel view of two individual subunits, red molecule showing the glutamate 
binding in the extracellular domain and IVM in orange binding in the TM domain. (C) A single 
GluClR subunit from two different angles. Loops of particular relevance to agonist binding 
and allosteric gating linkage are also shown. Image generated from PyMOL, Delano 
scientific LLC (PDB: 3RIF) (Hibbs and Gouaux 2011). 
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the adjacent subunit make up the complementary (-) side (Brejc et al. 2001; Lynch 2004) 
(Figure 1.1). A series of conformational rearrangements take place upon binding of a ligand 
in the pocket between the two subunits thereby causing the channel to open. Protruding 
towards the transmembrane region of the channel is the conserved cys-loop and the loop 
that connects the β sheets 2 and 3 (loop 2). Ligand-binding information is transmitted from 
the ligand-binding pocket to the channel gate via loop 2, which leads to the opening of the 
pore for review see (Lynch 2004; Webb and Lynch 2007). The ligand-binding pocket is rich in 
aromatic residues, which have been shown by previous studies to contribute to the ligand 
binding through cation-π interactions with the ligand (Pless et al. 2008). 
1.2.2 Transmembrane (TM) Domains 
 Made of four α-helical structures the TM domains in the pLGICs are embedded in 
the lipid membrane making a passageway through the apolar lipid bilayer for the aqueous ion 
permeation pathway. Connected to each other through three flexible linkers, the TM domains 
consists of an intracellular TM1-TM2 and TM3-TM4 linkers and an extracellular TM2-TM3 
linker (Hibbs and Gouaux 2011; Miller and Aricescu 2014; Miyazawa et al. 2003). The water 
filled pore is formed by the TM2 domains. Surrounding the TM2 domain are the other three 
domains TM1, TM3 and TM4, working as a barrier in separating the TM2 from the 
hydrophobic environment of the lipid bilayer (Lynch 2004; Miller and Aricescu 2014). 
 TM1 plays a role as a linker between the binding site and the channel activation 
gate due to its direct contact with the ligand-binding domain. A number of studies have 
determined the role of pre-TM1 residues in channel gating (Keramidas et al. 2006; Mercado 
and Czajkowski 2006). Spitzmaul et. al, showed that mutations of TM1 residues lead to an 
increased current desensitization and altered channel gating (Spitzmaul et al. 2004).  
 TM2 helices are slightly kinked towards the axis of the channel pore, forming an 
impenetrable hydrophobic girdle due to side-by-side hydrophobic interactions of the hefty 9’ 
leucine side chain as suggested by the nAChR crystal structure (Miyazawa et al. 2003). The 
general importance of 9’ residues in the TM2 domain in forming the channel gate were 
supported by the recent crystal structures of the β3 GABAAR and α GluClR (Hibbs and Gouaux 
2011; Miller and Aricescu 2014). Many pharmacological and physiological probes bind to the 
TM2 domain, making a drug-binding site of interest.  
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 The TM2 and TM3 domains are connected by a short flexible linker. The crucial role 
of this linker in coupling the agonist-binding site to the channel gate has been investigated by 
various studies (Pless et al. 2007; Bera et al. 2002). 
 The TM3 domain is involved the lining of a water-filled pocket distinct from the 
channel pore (Williams and Akabas 1999, 2001, 2002). The role of TM3 residues as 
determinants for the binding of molecules such as alcohol, IVM and anaesthetics has been 
demonstrated by several studies (Lynch 2004). Mutational studies of the TM3 residues and 
the recent GluClR crystal structure have yielded a rational picture of the IVM binding site 
(Lynagh and Lynch 2012; Hibbs and Gouaux 2011). The role of the TM3 mutation, G36’A in 
changing the intrinsic properties of the receptor has recently been studied as part of the 
current project (Atif et al. 2017).  
 There is also a large intracellular linker connecting the TM3 with the TM4 domain 
called the TM3-TM4 loop. Wild-type (WT) like activity was seen when this loop was replaced 
with a heptapeptide in chimeric receptors of GABAARs and 5HT3R, suggesting that this loop 
does not have much of a role in receptor assembly and function (Jansen et al. 2008). 
Nevertheless, this loop plays a role in phosphorylation and modulation of receptor function. 
For example, PGE2 – mediated phosphorylation of the S346 residue in the TM3-TM4 loop of 
α3 GlyR results in current inhibition leading to chronic inflammatory pain sensitization (Harvey 
et al. 2004). In addition, phosphorylation of the same residue in the TM3-TM4 intracellular 
loop produces a conformational change at the extracellular ligand-binding domain (Han, 
Talwar, Wang, et al. 2013).  
 Making close contact along its entire length with the TM3 are the TM4 and TM1 
domains (Hilf and Dutzler 2008). A difference in the glycine efficacy is observed at the 
homomeric α1 and α3 GlyRs due to non-conserved residues in the TM4 domain (Chen et al. 
2009). The TM3 and TM4 domain in α1 and α3 GlyRs were compared for structural 
interactions, in order to get a clear picture of how the non-conserved residues from TM4 
domain gave rise to a difference in receptor function. The results indicated a differential 
orientation of TM4 around α1 and α3 GlyRs (Han, Talwar, and Lynch 2013).  
1.3 Glutamate-gated chloride channel receptors (GluClRs) 
First identified in invertebrate phyla, such as insects and crustaceans (Cull-Candy 
1976; Gration et al. 1979; Marder and Paupardin-Tritsch 1978), GluClRs are closely related to 
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mammalian GlyRs (Wolstenholme 2012). They are found at neuronal and neuromuscular 
inhibitory synapses that selectively permeate anions (Wolstenholme 2012). Platyhelminthes, 
nematodes (e.g., H. contortus) and arthropods (e.g., A. gambiae) also express GluClRs 
(Wolstenholme 2012) however there is no evidence for their expression in vertebrates. 
GluClRs can assemble as homomers or heteromers (Cully et al. 1994). GluClRs are involved in 
a number of functions in these organisms that can range from feeding to mediating sensory 
inputs and locomotion. IVM, a drug belonging to the class of macrocyclic lactones, selectively 
targets GluClRs making them an important therapeutic target. The following section will 
discuss the different roles of GluClRs in these organisms.  
1.3.1 Physiological role of GluClRs 
 In the invertebrate nervous system the GluClRs account for a number of different roles 
including, a) governing and regulation of movement, b) control of feeding and 3) intercession 
of sensory inputs (Wolstenholme 2012). The GluClRs are also involved in reproduction and 
maturation of nematodes, however these functions have not been studied in detail 
(Wolstenholme 2012). The main reason for choosing nematodes, as a model to study the 
function of GluClRs is the abundant expression of these channels in motor neurons, sensory 
neurons and interneurons and their importance as parasitic pest species (Horoszok et al. 
2001; Cook et al. 2006). The below section highlights the role of GluClRs in nematodes as well 
as arthropods.  
a) Locomotion 
Role of GluClRs in nematode locomotion 
There is an increased frequency in direction changes of C. elegans in response to odour 
and temperature; this increase is linked to the mutations in genes of GluClR such as avr-15, 
RNAi of avr-15 and glc-1, however an opposite effect is observed after knocking down the 
expression of glc-3 (Glendinning et al. 2011). Treatment of C. elegans worms with 
macrocyclic lactones inhibited locomotion and pharyngeal pumping (Wolstenholme and 
Rogers 2005; Kotze et al. 2012).  
Role of GluClRs in arthropod locomotion 
The expression of GluClRs is abundant in insect neurons including the dorsal unpaired 
median neurons of locusts and cockroaches (Janssen et al. 2007; Janssen et al. 2010; Washio 
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2002). As these neurons innervate the leg and flight muscles, it is likely that GluClRs have an 
effect on the flight and movement control in these organisms. 
b) Feeding  
Role of GluClRs in foraging behaviour of nematodes 
Mutations in avr-14 and other GluClR genes like avr-15, glc-1, and glc-3, which are widely 
expressed in C. elegans motor neurons and interneurons, affect the feeding patterns of the 
worm (Dent et al. 2000; Horoszok et al. 2001; Cook et al. 2006). It is clearly understood that 
maintenance of hydrostatic pressure and feeding of the worms in nematodes involves 
pharyngeal pumping, which is controlled by GluClRs. GluClRs expressed from the avr-15 gene 
mediate rapid relaxation of pharyngeal muscles which is facilitated by M3 glutamatergic 
motor neurons (Avery 1993; Raizen and Avery 1994) through a Cl- dependent 
hyperpolarization (Pemberton et al. 2001).  
Role of GluClRs in feeding pattern of arthropods.  
Human head lice hatched from eggs treated with IVM exhibited reduced feeding 
suggesting a role of GluClRs in regulation of feeding (Strycharz et al. 2011). 
c) Sensory inputs 
Apart from being expressed in the muscle cells of pharynx, avr-15 gene is also diversely 
expressed in the nervous system (Dent et al. 1997; Pemberton et al. 2001) along with glc-2 
(Laughton et al. 1997). Gustatory plasticity is affected by mutations in avr-15 (Hukema et al. 
2008) which mediates mechanosensory inhibition of pharyngeal pumping along with avr-14 
(Keane and Avery 2003). Responses to odour (Chalasani et al. 2007) and temperature (Ohnishi 
et al. 2011) are regulated by amphid wing “C” cell (AWC) neurons and amphid neurons with 
finger like ciliated endings (AFD neurons) respectively which receive inputs from amphid 
interneurons (AIY interneurons) that expresses glc-3.  
Table 1.1: The GluClR genes of C. elegans and H. contortus and the subunits they encode 
Gene (C. elegans) Gene (H. contortus) Subunits encoded Properties 
avr-14 avr-14 GluCl α3A Alternatively spliced to form 2 subunits. 
avr-14B forms glutamate and IVM-
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GluCl α3B gated channels (Jagannathan et al. 
1999; Laughton et al. 1997; Dent et al. 
2000; McCavera et al. 2009).  
avr-15 avr-15# GluCl α2A 
GluCl α2B 
Alternatively spliced to form 2 subunits. 
Forms glutamate and IVM sensitive 
channels (Dent et al. 1997; Vassilatis et 
al. 1997) # (Doyle et al. 2019) 
glc-1 -  GluCl α1 When expressed alone forms IVM 
sensitive channels, forms glutamate 
channels when co-expressed with GLC-
2 (Cully et al. 1994). 
glc-2 glc-2 GluCl β GLC-2 from C. elegans forms glutamate 
channels that are sensitive to IVM 
when co-expressed with GlC-1 (Cully et 
al. 1994). 
glc-3 glc-3 GluCl α4 Both glutamate and IVM channels are 
formed with C. elegans GLC-3. Hco-glc-
3 has been recently identified 
(Horoszok et al. 2001). 
glc-4 glc-4 No data No functional data 
-  glc-5 GLC-5a 
GLC-5b* 
Forms IVM and GluClRs (Forrester et al. 
2004; Beech et al. 2010). 
-  glc-6 GLC-6 Forms IVM sensitive GluClRs 
(Glendinning et al. 2011) 
*=has not been localised yet 
1.3.2 H.contortus 
a) Introduction 
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This parasite of ruminant animals is also known as barber’s pole worm due to the 
characteristic stripes that are present on its body. This parasite is mostly active during 
summer in warm humid climates where it infects the gastrointestinal tracts of  sheep, cows 
and goats resulting in death due to anaemia and oedema (Burke 2005). Farmers around the 
world experience huge economic losses due the infection by H. contortus i.e., haemonchosis. 
Drugs belonging to the group of macrocyclic lactones are used to treat these and other worm 
infections, however resistance is becoming a major problem (Chiejina et al. 2015).  
b) Life cycle of H. contortus 
The adult female H. contortus worm lays 5,000-15,000 eggs every day, which is then 
excreted in the faeces (Emery et al. 2016). By feeding on the bacteria present in the moist 
dung, the eggs continue to develop into L1 (rhabditiform) and L2 juvenile stages. Under 
optimal conditions of 24-29oC, it takes about four to six days for the eggs to reach L1 stage 
(CRC 2017). The eggs then develop into L3 infective larvae by shedding the cuticle of the L2 
rhabditiform (Rahman and Collins 1990; El-Ashram and Suo 2017; CRC 2017). It is during 
grazing that sheep, goats and other ruminants are infected with L3 infective larvae. Passing 
through the three stomachs, they reach the abomasum followed by shedding the cuticle and 
burrowing into the internal layer of abomasum and develop into L4 in about 48hrs. These 
then molt and develop into L5 adult form where they live, mate and feed on the blood of the 
animal (El-Ashram and Suo 2017; CRC 2017).   
c) Pathogenicity, prevention and treatment 
In order to prevent infection in the ruminants, prophylactic anthelmintic treatment is 
necessary however, given the rapid rise of anthelmintic resistance a reduction on reliance on 
chemical treatment is warranted. The only observation of acute infection is the sudden death 
of the animal. Apart from this, there are other symptoms such as anaemia, oedema, pallor 
and lethargy (Villarroel 2013). A common phenomenon called “bottle jaw” (in sheep and 
goats, also in cattle) may be observed wherein there is accumulation of fluid in submandibular 
tissue (Villarroel 2013). 
Reducing the egg count and thereby pasture contamination can be done by vaccines that 
are commercially available, such as Barbevax or Wirevax available in Australia and South 
Africa respectively (Anderson 2013). An increased demand for cheap organic meat and dairy 
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products devoid of drug residues has motivated research on management strategies that are 
independent of anthelmintics. This is achieved by culling the animal that is most susceptible 
or by using parasite-resistant breeds (Villarroel 2013; Besier et al. 2012). In order to resist 
parasitic infections, selective breeding of sheep and goats seems to be a sustainable solution 
for small ruminant population. Over the past decade, a number of studies have shown 
different breeds that are resistant to parasitic infection (Alba-Hurtado and Munoz-Guzman 
2013). A relatively fewer number of eggs were shed by St. Croix lambs and they harboured 
less than 1% of worms in their abomasum when compared with age-matched Dorset lambs 
both in vivo and in vitro (Gamble and Zajac 1992). South African Dorper breed were more 
prone to H. contortus infection than the Red Maasai sheep during natural exposure to 
parasites in Kenya (Mugambi et al. 1997). 
d) Different types of GluClR isoforms from H.contortus and their distribution pattern 
The different isoforms and the way they are distributed in the organism would help us to 
understand how and where the drugs targeting these genes would act. In H. contortus, to 
date three genes encoding four GluClR subunits have been identified. Two subunits of 
HcoGluClR α3A and –α3B are encoded by Hcgbr-2 which are orthologous to avr-14, both in 
gene structure and sequence (Portillo et al. 2003; Jagannathan et al. 1999). A β subunit gene 
that is orthologous to its C. elegans counterpart glc-2 was also identified i.e., HcoGluClR 
β (Delany et al. 1998). HcoGluClR α is third gene encoded by an α subunit which is not 
orthologous to any of the C. elegans GluClR genes and binds IVM when expressed in 
mammalian cultured cells (Forrester et al. 1999; Forrester et al. 2002; Cheeseman et al. 2001).  
• HcoGluClR α and HcoGluClR β 
HcoGluClR α subunits were detected on H. contortus motor neuron commissures (MNCs), 
this was done using immunofluorescence (Table 1.2). Apart from that, a brighter HcoGluClR 
α immunostaining was observed at the point where motor neurons made contact with nerve 
cords (Table 1.2) (Delany et al. 1998; Jagannathan et al. 1999). Adult H. contortus worms when 
treated with anti-HcoGluClR α and anti-GABAAR antibodies showed that HcoGluClR α subunit 
is expressed on inhibitory motor neurons (Portillo et al. 2003). Avermectin sensitive receptors 
contain both subunits of, HcoGluClR α and HcoGluClR β, as suggested by their similar 
expression pattern in the motor nervous system that innervate the body-wall muscles of H. 
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contortus (Delany et al. 1998). The point where commissures made contact with the nerve 
cords showed brighter staining when labelled with anti-HcoGluClR α. The motor neuron 
commissures in the anterior and middle parts of H. contortus were completely co-localised 
with HcoGluClR α and –β antibodies (Table 1.2), confirming the presence of these two 
avermectin receptor subunits at this site.  
MNCs of H. contortus were also stained with rat HcoGluClR β antibodies suggesting their 
presence in this cell type (Table 1.2).  Sub-lateral and lateral nerve cords were stained anti-
HcoGluClR β rat antibody in the midanterior region of the worm, showing new sites of 
expression for HcoGluClR β  (Table 1.2).  
• HcoGluClR α3A and HcoGluClR α3B 
Experiments with immunofluorescence techniques suggested the expression of HcoGluClR 
α3A splice variants along different parts of the worm. Lateral neurons in the worm head were 
stained with an anti-HcoGluClR α3A antibody (Table 1.2). Cell bodies with a pair of nerve 
processes coming out of them could be easily identified. These nerve processes correspond 
to the bipolar sensory neurons from amphids. Based on the staining of cell bodies that were 
about 300 µm from the anterior tip of the worm, it is suggested that the amphidial neurons 
are located possibly on the lateral ganglion, posterior of the nerve ring. HcoGluClR α3 
expression in the head was confirmed by (Portillo et al. 2003) (Table 1.2).  
About 500 µm from the anterior tip, anti-HcoGluClR α3B antibodies were found to stain 
with the structures present in the head of the worm. MNCs in the anterior and middle regions 
of worms were stained with both HcoGluClR α3A and HcoGluClR α3B antibodies. However, 
expression of HcoGluClR α3B is much higher in the MNCs than that of HcoGluClR α3A (Table 
1.2). Interestingly, HcoGluClR α3B expresses in nerve cords whereas HcoGluClR α3A does not 
(Portillo et al. 2003).  
 Even though there have been a number of studies done to describe the expression of 
GluClR subunits in nematodes and arthropods, the physiological combination of these 
subunits either in vivo or in vitro is not known. Part of the work in my thesis will work to 
address this question. 
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Table 1.2: Different locations of avermectin receptor subunits in parasitic nematode H. 
contortus. Taken from (Portillo et al. 2003). 
Subunits Location of avermectin receptor subunits in H.contortus 
GluClR α Motor neuron commissures (MNCs) 
GluClR β MNCs, lateral and sublateral nerve cords. 
GluClR α3A Amphidial neurons, MNCs, nerve cord and nerve rings 
GluClR α3B Pharyngeal neurons, MNCs, sublateral and ventral nerve cords, and 
nerve rings 
Figure 1.2: The above figure depicts the schematic distribution of different GluClR subunits 
in H. contortus. (A) A side view of the complete worm. (B) A side view of the complete 
dorsal-ventral extent of the motor nervous system, without the cuticle showing the 
expression of individual subunits and a combination of different subunits. (C) A top view of 
pharynx exhibiting the possible expression of GluClR α3 subunits in the pharyngeal motor 
neurons (M1, M2l and M2r) and in amphid neurons (A). Anterior end of the worm is towards 
the right in all the panels and in panel A and B; the dorsal side is towards the top. 
c = Cuticle, dc = dorsal nerve cord, dslc = dorsal sublateral cord, lc = lateral cord, mnc = motor 
neuron commissures, ph = pharynx, vc = ventral nerve cord, vslc = ventral sublateral cord.  
Figure from (Portillo et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3 A. gambiae 
a) Introduction 
 There were around 198 million cases of malaria reported worldwide in the year of 
2013, from 584,000 resulted in death according to the 2014 WHO world malaria report. Africa 
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accounted for approximately 90% of these deaths where A. gambiae is the primary vector of 
malaria (WHO 2014). Spraying of pyrethroid-based insecticides forms one of the current 
malaria control programs. Pyrethroid resistance however is becoming widespread among the 
A.gambiae population across Africa (Ranson et al. 2011; Trape et al. 2011). 
b) Life cycle of A. gambiae 
 A. gambiae like any other species of mosquitoes has four life stages i.e., egg, larva, 
pupa and adult.  Apart from feeding on the nectar from plants, female mosquitoes also 
bloodfeed on vertebrates which provides the nutrients for her eggs (Foster and Walker 2009). 
These mosquitoes prefer to bloodfeed from humans and are therefore called as anthrophilic 
(White 1974) thereby making them efficient carriers of human malaria parasite (CDC. 2010). 
Larvae hatch from the eggs that have been laid on water surfaces in different aquatic habitats 
(Gillies and Meillon 1968). After the fourth instar, the larvae pupate (Foster and Walker 2009) 
and this stage encompasses a non-feeding stage during which the pupa develops into the 
adult mosquito (Gillies and Meillon 1968).  
c) Malaria – its medical significance and management 
 In order to control the mosquito population and limit malaria transmission, a number 
of management techniques are in place. These include educating the community about 
malaria and the way it spreads and different modifications that can be done to prevent the 
entry of the mosquitoes in the house, such as using nets on the windows, bed nets, spatial 
repellents and use of insecticides as indoor residual spraying (IRS) (Takken and Knols 2009). 
However, continuous use of insecticides can cause the mosquitoes to develop resistance 
(Brogdon and McAllister 1998; Mawejje et al. 2013). A. gambiae have already been found to 
develop resistance to insecticides in the regions of eastern Uganda (Mawejje et al. 2013), 
thereby leading to the decreased efficacy of the bed nets that were treated with pyrethroid. 
e) Different GluClR splice isoforms from A.gambiae  
 Four splice isoforms were discovered from the cloning of AgGluClR gene from the 
mRNA of A. gambiae (Meyers et al. 2015). These four genes were labelled as AgGluClR a1, a2, 
b and c. A protein structure that corresponds to the Cl-  permeable members of the pLGICs 
was disclosed upon the analysis of AgGluClR gene (Meyers et al. 2015). A protein with 
conserved residues that is associated the glutamate and IVM binding sites was revealed after 
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aligning the gene product from the recently crystallised GluClR α from C. elegans (CeGluClR) 
with the GluClR from Drosophila melanogaster (DmGluClR) (Hibbs and Gouaux 2011).  
f) Expression profile of GluClR genes in mature A. gambiae  
 Studies using immunolabelling found that AgGluClR genes were expressed all over 
the body of the mosquito, it was found at Johnston’s organ, antennal segments, thoracic 
ganglia, supraesophageal ganglion and the optic lobe (Meyers et al. 2015). Antennal segments 
that might be associated with antennal sensilla were found to have small puncta of AgGluClR 
staining. They were found in each layer of the optic lobe and at the photoreceptors. Involved 
in the audition and flight coordination, the Johnston’s organ which is a mechanosensory organ 
was found to have specific AgGluClR staining. The staining was also prominent at the cell 
bodies along supraesophageal ganglion as well as on the neuronal processes. As the three 
thoracic ganglia showed AgGluClR staining, it suggested that AgGluClRs are involved in 
locomotion and flight of the mosquito, as thoracic ganglia comprises of motor neurons that 
govern the flight and the leg muscles (Meyers et al. 2015). 
1.3.4 Agonists of GluClRs 
1.3.4.1 Glutamate and ibotenate 
 Glutamate is a neurotransmitter that activates GluClRs by binding in the orthosteric 
ligand-binding pocket present in the extracellular domain where it lodges itself between two 
subunits (Hibbs and Gouaux 2011).  
 Ibotenate also called, as ibotenic acid is a psychoactive compound from the plant 
Amanita muscaria and acts as a non-selective agonist for GluClRs because of its structural 
similarity with the neurotransmitter glutamate (Becker et al. 1999; Isacson et al. 1984).  
Figure 1.3: (A) Chemical structure of the neurotransmitter glutamate. (B) Glutamate binding site looking 
parallel to the membrane with loop C removed for clarity. Blown up image showing different interactions of 
glutamate with the residues in the binding pocket with hydrogen bonds shown in dashed lines and a cation-π 
interaction Y200 from (Hibbs and Gouaux 2011). 
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1.3.4.2 IVM 
 Belonging to a class of broad-spectrum pesticides, IVM binds and potentiates GluClR 
activity. The impact of IVM on human and veterinary health has been extraordinary, from its 
discovery on a Japanese golf course to winning a Nobel Prize.  
a) Discovery and synthesis  
In the year 1970, on the southeast coast of Honshu, Japan, a microbiologist Satoshi 
Omura collected a soil sample from the woods near a golf course in Kawana (Van Voorhis et 
al. 2015). From this soil sample, the then unknown species of a Gram-positive bacteria, 
Streptomyces (named as sample NRRL 8165-a) was isolated and cultured by S. Omura. 
Heligomosoides polygyrus infection in mice was significantly reduced when tested against 
NRRL 8165 cultures and when these cultures were purified to get the active compound, it was 
revealed to be from a family of macrocyclic lactones. In order to reflect the worm free 
averminous conditions produced by these naturally occurring compounds, they were named 
avermectins and subsequently the bacteria as, Streptomyces avermitilis (Burg et al. 1979; 
Campbell 1981).  
Avermectins that exists naturally are a mixture of four different compounds i.e., 
avermectin A1, A2, B1 and B2 (Campbell 1981; Campbell et al. 1983). These four compounds 
had different biological properties as they differed from each other subtly in their structural 
properties. Although, all the four compounds showed some efficacy against nematodes, the 
most significant effect was seen with avermectins belonging to the B series (Blair and 
Campbell 1979). Moreover, a difference in efficacy was seen when there was a change in the 
mode of drug administration. That is, avermectin B1 was more effective when administered 
orally whereas avermectin B2 was more active when the dose was administered parenterally 
(Campbell et al. 1983). Commercial anthelmintic development then focused on the B series 
and changes in the chemical structure due to the fact that B series was more significant than 
the other series. Based on this, using the naturally occurring avermectin B1, IVM was 
synthesised which is comprised of  ̴80% 22, 23-dihydro-avermectin B1a and  ̴20% 22, 23 
dihydro-avermectin B1b. IVM has significant activity against parasitic nematodes when 
administered both orally and parenterally (Campbell 1981; Campbell et al. 1983).  
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b) Use of IVM in animal and human health 
Although IVM is licensed to control lungworm, ectoparasites in cows and in aquaculture 
industry, its market has remained particularly strong for the control of gastrointestinal 
roundworms such as H. contortus. Anthelmintics like IVM, at present are the most commonly 
sought after treatment in the UK sheep industry (Burgess et al. 2012) and cattle industry in 
the US (McArthur and Reinemeyer 2014). Apart from that, the control of equine roundworms 
also involves IVM (Relf et al. 2012; Stratford et al. 2014), and macrocyclic lactones forms a 
large market for the treatment and control of parasitic nematodes and ectoparasites in 
domestic pets. Control of gastrointestinal roundworms and canine heartworms involves the 
use of IVM. Transmission of malaria from the adult mosquito can be prevented by targeting 
the developing larvae with IVM (Laing et al. 2017).  
Even though the market for IVM in livestock and animal market was substantial from the 
start, there was very little thought that went into developing IVM for human health. Dr Roy 
Vagelos, CEO of Merck & Co., was moved by the efficacy of IVM against onchocerciasis and 
lymphatic filariasis and decided to donate as much IVM (licensed as Mectizan) that was 
needed, for anyone that needed it and for long as they needed it (Molyneux and Ward 2015). 
A single oral dose of IVM (150 mg/kg) given annually suppresses the production of microfilaria 
thereby preventing the disease progression however does not kill the adult Onchocerca 
volvulus (Taylor and Greene 1989). The same is the case in lymphatic filariasis by Wuchereria 
bancrofti, where IVM does not kill the adult organism but its microfilaria (Diallo et al. 1987; 
Endeshaw et al. 2015; Richards et al. 2005). Complete clearance of Wuchereria bancrofti 
microfilariae was observed when treated with a single dose of IVM in combination with 
albendazole and diethylcarbamazine (DEC) (Thomsen et al. 2016). 
c) GluClRs as targets for IVM 
The testing for the potentiating effects of IVM using electrophysiological investigations 
began as early as first reports of anthelmintic activity that suggested pLGICs as their target. 
IVM increases the Cl- conductance in lobster neurons that have ligand-gated sodium and Cl- 
channels (Fritz et al. 1979) and IVM diminished the responses of motor neurons to excitatory 
input in the nematode preparations (Kass et al. 1984). Two GluClR subunits from C. elegans 
were isolated, where one of it i.e., α, was sensitive to IVM whereas the other subunit, β, was 
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sensitive to glutamate, when expressed as homomeric GluClRs. The subunits also assembled 
as heteromers and were active against both glutamate and IVM (Cully et al. 1994). Sharing up 
to 40% of the amino acid sequence, the GluClRs from helminths clearly fit into pLGIC 
superfamily with the closest human relative being GlyRs (Vassilatis et al. 1997; Dent 2006). 
IVM has been shown to have variable activity at Histamine gated chloride channel receptors 
(HisClRs) and proton chloride channel receptors (pHClRs) which share up to 45% sequence 
identity with GlyRs (Zheng et al. 2002; Schnizler et al. 2005; Mounsey et al. 2007).  
d) Mode of action of IVM and its binding sites at GluClR 
Even though the efficacy of IVM against the infections from parasitic nematodes is clearly 
understood, the way it exerts is action at GluClRs is unclear because we do not know whether 
it is the diffusion properties or its partitioning parameters or both that exerts the action. The 
binding pocket for IVM is formed by the subunit interface of two transmembrane domains 
proximal to the extracellular region of the membrane bilayer (Figure 1.5 & 1.6). Like a foot 
wedged in the door, the IVM molecule wedges itself between the a helix from TM3 that makes 
up the principal or (+) subunit and the complimentary or (-) subunit that is formed from the a 
helix of TM1 of a different subunit (Hibbs and Gouaux 2011). IVM makes important contacts 
with the TM2-TM3 loop and the TM2 (+) pore lining a helix, by inserting itself deeply into the 
subunit interface (Figure 1.6) (Hibbs and Gouaux 2011). 
Figure 1.4: Chemical structure of IVM. IVM is a mixture of two homologues 5-O-dimethyl-
22, 23-dihydroavermectin B1a and B1b in a ratio of 80:20. 
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Figure 1.5: A cartoon representation showing the mechanism of allosteric activation and 
modulation by IVM. (A) Single subunit interface, parallel to membrane. (B) View from the 
top. IVM (shown as green block) binds at the subunit interface of TM3 and TM1 α-helices 
spreading it apart allowing for ion conductance. Adapted from (Hibbs and Gouaux 2011).  
 
Figure 1.6: IVM-binding sites and atomic interactions. (A) & (B) Different orientations of a 
GluClR subunit interface showing binding sites for IVM (shown as a yellow molecule) (Hibbs 
and Gouaux 2011). 
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e) Resistance to anthelmintics 
Mass drug administration of IVM has been used extensively in animals for prevention and 
treatment against parasitic nematodes, but unfortunately, they have often developed 
resistance due to the implementation of this strategy. This resistance towards anthelmintics 
is now a grave issue in controlling gastrointestinal roundworms in cattle, horses and sheep 
(Kaplan and Vidyashankar 2012). Concerns about IVM resistance evolving in human parasites 
have been raised in Ghana and Cameroon where there have been reports of reduced 
embryostatic effects of IVM on O. volvulus (Osei-Atweneboana et al. 2011; Osei-
Atweneboana et al. 2007; Nana-Djeunga et al. 2014). 
A number of genes involved in IVM resistance have been identified in C. elegans (Laing et 
al. 2017). High level of IVM resistance was conferred in C. elegans after a simultaneous 
mutation of three GluClR genes i.e., glc-1, avr-14 and avr-15 (Dent et al. 2000). A four amino 
acid deletion in glc-1 gene from field isolates of C. elegans resulted in resistance towards 
abamectin and IVM in multiple populations (Ghosh et al. 2012). More recently, a number of 
candidate genes like glc-1, avr-14 and avr-15 have been investigated in the parasitic 
nematode H. contortus to determine their link in IVM resistance, however, an association 
between IVM resistance and these candidate genes could not be proved (Gilleard 2013). Wild 
populations of Plutella xylostella (A30’V) (Wang et al. 2017; Wang et al. 2016) and 
Tetranychus urticae (G36’D and G36’E) (Dermauw et al. 2012; Kwon et al. 2010; Mermans et 
al. 2017) have been shown to be resistant IVM due to missense point mutations to GluClR 
subunits in their genome. Apart from this, many studies have focused on the role of drug 
uptake and their metabolism/excretion (Kotze et al. 2014) where a number of polymorphisms 
and/or changes in the expression pattern of the candidate gene were correlated with IVM 
resistance. However, to date studies have not been able to define the major mechanism 
behind IVM resistance.  
f) New targets and novel applications 
Having a wide safety margin, IVM affects the susceptible nematode at nanomolar 
concentrations but has a broad range of effects across different organisms at higher 
concentrations. There is an increased Cl- conductance in mammalian neuronal cells in 
response to a high IVM application, and based on this, patients with spinal cord injuries have 
been treated for severe muscle spasticity using a high dose of IVM (up to 1.6 mg/kg) (Costa 
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and Diazgranados 1994). In vitro experiments involving human leukaemia cells have shown 
that IVM induces an intracellular Cl- flux that selectively kills leukaemia cells (Sharmeen et al. 
2010). A deregulation of WNT-TCF (WNT-T cell factor) signalling pathway has been observed 
in many diseases, including cancers of breast, ovary, colon, prostate and skin. In vivo 
experiments showed that IVM is effective against lung carcinoma xenografts and WNT-TCF-
dependant human colon cancer, suggesting that IVM specifically blocks the WNT-TCF 
response (Melotti et al. 2014). A recent study by has shown that IVM possesses anti-
inflammatory properties against T cell-mediated skin disease (Ventre et al. 2017). By 
inhibiting a viral helicase, IVM stops the replication process of a number of flaviviruses 
(Mastrangelo et al. 2012). IVM activity has been reported against various species of 
Mycobacterium, including the causative agent of tuberculosis Mycobacterium tuberculosis 
(Lim et al. 2013). 
1.3.5 Antagonists 
Insecticides such as lindane, fipronil and a pore blocker picrotoxin which are non-
competitive antagonists have been shown to inhibit responses mediated by GABAARs, GlyRs 
and GluClRs (Chen et al. 2006; Islam and Lynch 2012; Hirata et al. 2008).  
a) Lindane 
An organochlorine chemical and an isomer of hexachlorocyclohexane, it is also called 
gamma-hexachlorocyclohexane. Used both as a pharmaceutical and an insecticide for scabies 
and lice treatment (Goldust et al. 2013; Panahi et al. 2015; Wooltorton 2003), lindane binds 
to the Drosophila melanogaster RDL GABAARs and acts a neurotoxin by interfering with the 
GABA neurotransmission (Cole et al. 1995) and also inhibits the GlyRs (Islam and Lynch 2012). 
It affects kidneys, liver and the nervous system in humans (Gerberding 2005).  
b) Fipronil  
A broad-spectrum insecticide, fipronil comes from the phenylpyrazole family. It blocks 
Drosophila melanogaster RDL GABAARs (Hosie et al. 1995) and GluClRs in the insect nervous 
system leading to hyperexcitation of the insects (Hirata et al. 2008). Fipronil has also been 
show to inhibit currents mediated by GlyRs (Islam and Lynch 2012). Its effectiveness towards 
insects is believed to be due to the GluClRs that are only present in invertebrates and not in 
the mammals (Raymond-Delpech et al. 2005) apart from its action on the insect GABA 
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receptors. Due to this, a large number of pharmaceuticals for controlling fleas incorporate 
fipronil as its active ingredient (Maddison et al. 2008).  
c) Picrotoxin 
Also called as cocculin, it is a mixture of two related compounds (picrotin and picrotoxin) 
and is found naturally in fruits of the plant Anamirta occulus. Picrotoxin conveys its action as 
a stimulant and a convulsant by interacting with neurotransmitter GABA thereby causing 
respiratory paralysis and seizures by influencing the CNS at high doses (Overington et al. 
2006). Picrotoxin inhibits α homomeric GlyRs but shows a reduced sensitivity at the 
heteromeric αβ GlyRs (Pribilla et al. 1992; Handford et al. 1996; Islam and Lynch 2012).  
Figure 1.7: Chemical structures for different GluClR antagonists 
 
1.4 GABAARs 
1.4.1 Physiological role of GABAARs 
 GABAARs belong to the pLGIC family, which mediates fast synaptic 
neurotransmission in the central nervous system (CNS). They permeate HCO3- and Cl- ions. 
When activated in adult neurons, where the intracellular Cl- concentration is low, they induce 
a Cl- influx thereby hyperpolarising the cell. GABAARs can also cause neuronal depolarization 
in some regions of CNS and in early embryonic development due to an increased resting 
intracellular Cl- concentration. K-Cl co-transporters maintain the low intracellular Cl- 
concentration in adults (Rivera et al. 2005). The low efficacy of GABAAR-mediated inhibition 
in nigral dopaminergic neurons could possibly be due to the level of KCC2 expression, which 
is low in adult dopaminergic neurons in the substansia nigra pars compacta (Gulacsi et al. 
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2003). Furthermore, the local Cl- gradients are affected due to varied expression levels of 
KCC2 in subdomains of neurons (Szabadics et al. 2006). 
1.4.2 GABAAR subunit composition and binding sites 
a) Different subunit composition of GABAARs 
 Being a member of the pLGIC family, functional GABAARs are comprised of five 
subunits symmetrically arranged around a central ion-conducting pore. So far, 19 subunits 
(α1–6, β1–3, γ1–3, δ, ɛ, θ, and π) of GABAARs have been identified in mammals with the most 
common composition being 2α, 2β and 1γ subunit (Sieghart 2006; Hedblom and Kirkness 
1997; Wisden et al. 1992). The neuroanatomical distribution of individual subunits reveal 
distinct but overlapping patterns based on in situ hybridization and immunohistochemical 
research. The α1 containing GABAARs are the most abundant isoforms of all the GABAARs 
present in the brain and accounts for 70%-90% of the total GABAARs and is involved in 
sedation (Sieghart and Sperk 2002; Pirker et al. 2000). About 50-70% of GABAARs contain β2 
and γ2 subunits (Pirker et al. 2000). Distributed widely throughout the brain are α1, β1-3 and γ2 
subunits, apart from that the other subunits have a limited distribution but may be locally 
enriched in certain brain regions. For example, 31% of GABAARs containing α5 subunits and 
13% of GABAARs containing α4 subunits are present in hippocampus (Sieghart and Sperk 
2002). 
 Because cerebellar granule cells are abundant and strongly express α6 subunits, this 
subunit accounts for about 56% of GABAAR subunits in the cerebellum (Sieghart and Sperk 
2002). Although they are highly expressed in the central and medial amygdaloid nuclei, the 
general distribution of γ1 subunit is extremely sparse in the brain (Sieghart and Sperk 2002). 
Although reported as being expressed in the brain, ρ subunits preferentially express in the 
retina whereas the distribution pattern of ε, π and θ subunits is still not clear (Moragues et al. 
2000; Moragues et al. 2002; Hedblom and Kirkness 1997; Sinkkonen et al. 2000). The common 
stoichiometric formation of GABAARs is two α subunits, two β subunits and one γ subunit, 
where the γ can be replaced with δ, ε, θ or π subunits. The most common stoichiometry of 
GABAARs in the brain is α1β2γ2 (Sieghart and Sperk 2002; Rudolph and Mohler 2006; Ernst et 
al. 2003). The most common combination containing the α5 GABAARs is α5β3γ2 and is 
implicated in autism (McCauley et al. 2004), cognitive impairment (Vithlani et al. 2011) and 
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stroke (Clarkson et al. 2010). Only about 100 combinations of GABAARs are thought to exist 
in the brain out of approximately 10,000 possible stoichiometries (Ernst et al. 2003). 
b) The GABAAR binding sites: GABA and BZDs. 
 The Ernst group made the first structural models of GABAAR binding pockets for 
GABA and BZDs. This was done by alignment and computation studies based on the crystal 
structure of AChBP (Ernst et al. 2003). The structure that was obtained was imprecise as the 
sequence alignment between GABAAR and AChBP was uncertain.  
 The subunit interface between β+ (loops A, B and C) and α- (loops D, E and F) forms 
the GABA binding pocket. The above mentioned loops incorporate the aromatic side chains 
that provide sites for the interaction with the ligands via cation-π interactions (Brejc et al. 
2001; Dougherty 2008). 
 γ2 knockdown experiments confirmed that γ subunit is necessary for the high 
affinity-binding BZD site (Gunther et al. 1995). The interface between α+ and γ- subunits 
forms the high affinity BZD binding pocket. Larger BZDs molecules can fit in this binding pocket 
as this BZD binding site is much deeper and more open that the GABA binding pocket, as 
suggested by modelling studies (Cromer et al. 2002; Ernst et al. 2003).   
1.4.3 Overview of GABAAR pharmacology 
 When the neurotransmitter GABA binds to the GABAAR, it results in the influx of Cl- 
through the pore via an inwards electrochemical gradient. The GABA-mediated 
hyperpolarization is antagonised by a plant alkaloid, bicuculline, which competes with GABA 
for its orthosteric site (Beitz and Larson 1985). There are several other allosteric sites present 
on the receptor in addition to the orthosteric site (Figure 1.8). For example, BZDs and 
barbiturates are called positive modulators or potentiators, as they potentiate the effect of 
GABA by binding to the allosteric sites (Johnston 2005). For the past 50 years BZDs have been 
used for a different range of therapeutic purposes such as sedatives in epilepsy, anxiolytic, 
hypnotics and muscle relaxation (Sigel and Buhr 1997). Drugs such as barbiturates, BZDs, 
neurosteroids, alcohols and anaesthetics have different sites of action on GABAARs such as on 
individual subunits or in clefts between two subunits. Barbiturates, BZDs and neurosteroids 
are used to treat conditions such as anxiety, sedation, insomnia, epilepsy and muscle spasms 
etc. Negative modulators or inverse agonists are the agents that bind to the allosteric site and 
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reduce the GABA induced response. Whereas there are some agents referred to as 
neutralising modulators due to their neutralising effect, where they inhibit the effects of both 
the positive and negative modulators, one such example is a drug that binds to the BZD site 
i.e., flumazenil (Johnston 2005). Modulators targeting the allosteric sites on GABAARs have 
been widely used as therapeutics; this is because GABAARs play consequential role in several 
neurological disorders such as autism spectrum disorder, cognitive impairment, stroke, 
epilepsy, Alzheimer’s disease, anxiety, insomnia and Down syndrome. However, currently 
available medications target different GABAAR subtypes non-selectively producing untoward 
effects such as sedation, memory impairment and tolerance. In order to minimise these 
undesirable side effects, increasing number of studies are trying to develop and discover 
modulators that target specific GABAAR subtypes selectively.  
Figure 1.8: Different binding sites on GABAARs. The Cl- ion channel as seen from parallel to 
the membrane has the orthosteric GABA and other allosteric binding positions. The β 
subunit in the front is removed for clarity. 
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Figure 1.9: Structures of GABAAR agonists and antagonists. The endogenous agonist GABA 
binds to the orthosteric site. The positive allosteric modulators, diazepam and 
pentobarbital, bind at the allosteric sites and the antagonists, bicuculline and PTX, bind in 
the orthosteric site and pore, respectively.  
 
 
1.4.4 Therapeutic significance of modulators specifically targeting α5 containing GABAARs 
 Drugs selectively targeting α5 containing GABAARs (α5 GABAARs) are of specific 
interest. α5 GABAARs have a relatively restricted distribution, being primarily expressed in the 
hippocampus, a region of the brain associated with learning and memory (Chambers et al. 
2003). Although the α5 receptors account for less than 5% of the total GABAAR population in 
the brain (McKernan and Whiting 1996), in the hippocampus they represent 20% of all 
GABAARs (Sieghart 1995), thereby implicating this GABAAR subtype in learning and memory 
(Sur et al. 1998). A number of disorders including stroke, cognitive enhancement, dementia-
related conditions and schizophrenia have been linked with α5 GABAARs as therapeutic 
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targets. Both positive and negative modulators of α5 GABAARs have the potential to be 
clinically useful, unlike other GABAAR subtypes (Soh and Lynch 2015). 
Autism 
Genetic studies conducted by (McCauley et al. 2004) reported the linkage of one 
autism subgroup to chromosome 15q11-13 in the α5 GABAAR coding regions. While the α5 
GABAAR has been postulated to be a candidate gene for autism spectrum disorder, no 
convincing evidence for a potential link of chromosome 15 to this disorder is available (Delong 
2007). Altered expression levels of GABAARs in the brains of subjects with autism suggested a 
GABA/glutamate system dysregulation (Esmaeili and Ghaedi 2010). A significant decrease in 
α1, α2, α3 and β3 in parietal cortex was seen (D'Hulst et al. 2006). These results revealed that 
GABAAR expression was reduced in the brain regions that have previously been associated 
with the pathogenesis of autism, suggesting a widespread GABAergic dysfunction in the brain 
of subjects with autism (Rice et al. 1996). In α5 GABAAR knockout mice, there were identified 
gamma frequency oscillations in the electroencephalogram, evoked by increased network 
drive, which were significantly greater than in wild type mice (Towers et al. 2004). Similar 
increased gamma activity is found in individuals with autism identifying the presence or 
absence of an illusory Kanizsa shape (an illusory shape shown to a patient suffering with 
autism to measure the gamma abnormalities) (Brown et al. 2005). Abnormal gamma activity 
has been hypothesized to underlie cognitive deficits in autism (Brock et al. 2002). Modulation 
of associative learning (acquisition and retention) involves hippocampal α5-containing 
GABAARs which supports the involvement of α5 GABAARs in cognitive dysfunction and 
memory impairment associated with ASD (Cellot and Cherubini 2014). 
Cognitive Impairment 
The α5 subunits have been implicated in learning and memory following the 
identification of a single point mutation (α5 H105R) that facilitates a particular form of 
associative learning in mice (Crestani et al. 2002). This impairs the interaction of α5 receptor 
subtype with diazepam, thereby abolishing its memory-impairing effects (Vithlani et al. 2011). 
α5 containing GABAARs have been suggested to play a potential role in hippocampal-
dependent learning and memory (Mohler and Rudolph 2017; Rudolph and Mohler 2014). 
Another study conducted by (Collinson et al. 2002) demonstrated that decreased GABA 
mediated synaptic inhibition in the hippocampus in α5 deficient mice is most likely the 
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underlying mechanism for the enhanced performance in learning and memory without having 
an effect on anxiety or sedation. A study done by (Atack 2010), upheld the findings by 
showing, triazolophthalazine, a negative modulator that decreases GABA responses 
particularly at α5 GABAARs, enhanced intellectual performance without causing anxiety or 
convulsions in rodents. Cognitive performance was impaired by the use of α5 GABAARs 
positive-allosteric modulators indicating the involvement of this subunit in learning and 
memory and cognitive tasks (Xu et al. 2018; Mohamad and Has 2019). Thus, compounds 
created to be specific for α5 GABAARs can possibly be utilized as memory enhancing 
medications without symptoms such as, sedation, which is caused by α1-containing GABAARs. 
This class of medications might be used to treat cognitive impairment, as is found in patients 
suffering from Alzheimer’s and other dementias. 
Stroke 
Stroke is one of the leading causes of disability, and is without any pharmacological 
therapy for promoting recovery (Clarkson et al. 2010). Current therapies that promote 
functional recovery after stroke are limited to physical rehabilitation (Dobkin 2008). After 
stroke, tonic inhibition mediated by extra synaptic GABAAR is increased in the peri-infarct 
zone through an impairment of GABA transporter (GAT-3/GAT-4) function (Clarkson et al. 
2010). In α5 knockout mice, motor recovery improved, suggesting that the use of α5-specific 
inverse agonists may be a novel approach to promote recovery after stroke (Clarkson et al. 
2010). 
The discrete localization of the α5 subtype mainly in the hippocampus and the 
excellent sensitivity of the inhibitory GABAergic system to pharmacological intervention 
makes the α5-containing GABAAR an attractive novel target for treatment of disorders 
associated with cognitive defects. 
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Aims 
The main aim of my PhD project was to determine whether the α HcoGluClR subunit 
in combination with β HcoGluClR affects IVM sensitivity. A subsidiary aim was to determine 
the possible mechanisms behind IVM resistance in H. contortus. As IVM, resistance is 
becoming a major problem and causing huge capital losses to farmers around the world, one 
of the ways to address this problem is to identify one of the mechanisms of how H. contortus 
develops resistance and thereby develop techniques that can address this issue. Previous 
studies on C. elegans have shown that changes in the subunit composition can have 
differential effects on IVM sensitivity. We hypothesised that one of the GluClR subunits could 
be the reason that H.contortus is developing resistance to IVM.  
 Thorough studies have been carried out on many pLGIC family members including 
nAChRs (Auerbach 2014; Purohit et al. 2013; Mukhtasimova et al. 2016). GlyRs (Burzomato et 
al. 2004), 5-HT3Rs (Corradi et al. 2009), and GABAARs (Keramidas and Harrison 2010; Dixon et 
al. 2014; Lema and Auerbach 2006), to determine how agonists bind to and activate the 
receptor. However, a detailed study on the biophysical properties of GluClRs has not been 
performed. The second part of this project was to investigate the biophysical properties of α 
homomeric GluClRs from H. contortus. Here we tried to determine how glutamate and IVM 
produce different activation properties and to delve into the way in which the mutation, TM3-
G36’A reduces IVM sensitivity to a level that is similar to vertebrates GlyRs and GABAARs 
(Lynagh and Lynch 2010; Estrada-Mondragon and Lynch 2015). 
 Two GluClR splice isoforms from A. gambiae were shown to have different sensitivities 
towards IVM (Meyers et al. 2015). As these splice variants only have a marginal difference in 
their amino acid sequence, in the third aim we wanted to see whether there would be 
differential effects towards different insecticides such as lindane, fipronil, PTX and also 
towards glutamate and IVM. 
 The last aim of my PhD was to discover and characterise new molecules that 
specifically targets α5 GABAARs. The eventual aim was to identify a novel lead compound as a 
potential treatment for neurological disorders including autism, age related cognitive 
impairment and stroke.  
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Aim 1:  To determine one of the possible mechanisms of IVM resistance in H. contortus 
Aim 2: To determine the biophysical properties of α HcoGluClR and a mutation in its TM3 
domain.  
Aim 3: To pharmacologically characterize the effects of a few insecticides as well as a classical 
pore blocker picrotoxin on two splice variants of GluClRs from A. gambiae. 
Aim 4: To discover new lead compounds that selectively target α5 GABAARs. 
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2.1 Tissue culture and transfection of HEK 293 cells 
HEK AD293 cells (American Type Culture Collection, Manassas, VA, USA) were cultured 
in 15 mL DMEM (supplemented with 10% FCS and 1% PenStrep), until approximately 90% 
confluent. The medium was aspirated before the cells were washed with PBS and dissociated 
using 0.05% trypsin-EDTA. For single channels and macropatches, HEK AD293 cells were 
seeded onto poly-D-lysine coated glass coverslips and transfected with cDNAs encoding the 
GluClR subunit avr-14B (pcDNA 3.1+) of H. contortus using a calcium phosphate-DNA co-
precipitate method previously described by (Chen and Okayama 1987). The cDNA encoding 
the CD4 surface antigen was also added to the transfection mixture and acted as a marker of 
transfected cells. Cells were used for experiments 2-3 days after transfection. The point 
mutation, TM3-G36’A, was incorporated into the subunit using the QuickChange site-directed 
mutagenesis method. Successful incorporation of mutation was confirmed by sequencing the 
mutated DNA. 
2.2 Patch clamp electrophysiology – whole cell, single channels and rapid application. 
All experiments were carried out at room temperature (21 – 24 oC). Single-channel 
and macropatch currents were recorded from outside-out excised patches at a clamped 
potential of −70 mV, unless indicated otherwise. The patches were continuously perfused via 
a gravity-fed double-barrelled glass tube. Out of one barrel flowed an extracellular bath 
solution containing (in mM), 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, and 10 D-glucose 
and titrated to pH 7.4. The adjacent barrel contained agonist dissolved in this extracellular 
solution. Glass electrodes were pulled from borosilicate glass (G150F-3; Warner Instruments), 
coated with a silicone elastomer (Sylgard-184; Dow Corning) and heat-polished to a final tip 
resistance of 4-15 MΩ when filled with an intracellular solution containing (in mM) 145 CsCl, 
2 MgCl2, 2 CaCl2, 10 HEPES, and 5 EGTA, pH 7.4. Stock solutions of L-glutamate were also pH-
adjusted to 7.4 with NaOH. Excised patches were directly perfused with extracellular solution 
by placing them in front of one barrel of the double-barrelled glass tube. Single channel 
currents were elicited by exposing the patch continuously to agonist containing solution, 
flowing through the adjacent barrel. Macropatches currents were elicited by lateral 
translation of the tube from the agonist free to agonist containing barrel using a piezo-electric 
stepper (Siskiyou). This achieved rapid solution exchange (<1 ms). Currents were recorded 
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using an Axopatch 200B amplifier (Molecular Devices), filtered at 5 kHz and digitized at 20 kHz 
using Clampex (pClamp 10 suite, Molecular Devices) via a Digidata 1440A digitizer. 
2.3 Isolation of oocytes from Xenopus frogs and expression of DNA 
Xenopus frogs were housed at the Australian Institute for Bioengineering and 
Nanotechnology University of Queensland, Australia. All animal handling procedure were 
conducted under conditions approved by the University of Queensland Animal Ethics 
Committee (approval number: QBI/AIBN/087/16/NHMRC/ARC) Adult female frogs were 
anaesthetized (in 1.3mg/ml MS-222) and oocytes were surgically removed via a small incision 
to the abdomen. Oocytes were then defolliculated with 1.5 mg/ml collagenase for 2 hours. 
Free oocytes were rinsed with calcium-free OR-2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM 
MgCl2.6H2O, 5 mM HEPES, pH 7.4) and mature oocytes stage V or VI were isolated for 
experiments. The DNAs coding for α and β HcoGluClRs subunits were nuclear injected into 
the oocytes at a ratio of 1:0, 0:1, 1:1, 1:50 (αβ), and also α and β AgGluClRs (1:0 and 0:1). 
Injected oocytes were incubated in ND96 storage solution (96 mM NaCl, 2 mM KCl, 1 mM 
MgCl2.6H2O, 1.8 mM CaCl2, 5 mM HEPES, 50 µg/ml gentamicin, 2.5 mM sodium pyruvate, 0.5 
mM theophylline, pH 7.4) at 16°C for 2-3 days before experiment.  
2.4 Two-electrode voltage clamp (TEVC) using frog oocytes 
During the recording, the oocyte was secured in a cell bath that was continually 
perfused with ND96 recording solution (ND96 storage solution without pyruvate, 
theophylline and gentamicin). Compounds diluted in ND96 recording solution were applied 
to the oocyte via bath perfusion. Two microelectrodes, the voltage and current electrodes, 
each containing 3 M KCl (0.2-2 MΩ resistance), clamped the oocytes, and the membrane 
voltage was kept constant at −40 mV. The change in glutamate and IVM-induced current was 
filtered at 200 Hz using an OC-725C Oocyte Clamp amplifier (Warner, Hamden, CT). The 
current analogs were then digitized by the Digidata 1440A interface and acquired at 2 kHz 
sampling rate using Clampex 10.2 software (Axon Instruments, Union City, CA). Current 
amplitudes were measured off-line using Clamp fit 10.2 (Axon Instruments, Union City, CA).  
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2.5 Heteroculture preparation and IPSC recording 
  Primary neuronal cultures were prepared from cortices of E18 rat embryos, which 
were triturated and plated at 100,000 cells per 18-mm poly-D-lysine-coated coverslip in 
DMEM with 10% fetal bovine serum. After 24 h, the entire medium was replaced with 
Neurobasal medium that included 2% B27 and 1% GlutaMAX supplements. After one week, 
half of this medium was replaced and the neurons were allowed to grow in vitro for 3-5 weeks 
before introducing the transfected HEK293 cells. Recordings of synaptic currents were done 
in whole-cell configuration (at −70 mV) using an Axopatch 200B amplifier (Molecular Devices), 
filtered at 5 kHz and digitized at 20 kHz using Clampex (pClamp 10 suite, Molecular Devices) 
via a Digidata 1440A digitizer. 
2.6 Fluorescence recovery after photobleaching (FRAP) 
Membrane partitioning and FRAP experiments were performed on an LSM 710 inverted 2-
photon confocal microscope equipped with a 40X water immersion objective lens (1.2 NA/280 
µM WD/0.208 µM/pixel and a GFP/Alexa 488 filter set. Untransfected HEK293 cells at a 
confluency of 50-75% were plated onto 35-mm glass bottom dishes one day prior to 
experiments. The IVM-bdpy fluorophore was dissolved in 100% DMSO and stored at −20 0C 
at a concentration of 24 mM. 
A Mai Tai eHP 2-photon laser/760-1040 nm was used as an excitation source (power 
at 920 nm) for the FRAP experiments. The laser and bleaching power were set to 7% and 75% 
respectively. Membrane partitioning images were taken for 35 min at 0.5 Hz after replacing 
the cell medium (extracellular solution) with one containing the IVM-bdpy probe at a 
concentration of 500 nM. FRAP images were taken at a frequency of 0.5 Hz for 10 min after a 
30 min equilibration period in 500 nM IVM-bdpy. 
2.7 Marine extracts library, extraction and isolation 
A library of around 180 Australian and Antarctic marine invertebrate and algae samples were 
collected, extracted and stored in the laboratory of Professor Rob Capon (Institute of 
Molecular Biology, The University of Queensland, Australia) according to the protocol 
described by (Balansa et al. 2010). When preparing whole extract samples for ToxFinder 
screening, small aliquots of the stock n-BuOH or H2O partitions previously stored in deep 96-
well plates were diluted with DMSO and transferred into new 384-well extract plates. These 
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plates were then stored at -20oC and thawed for use on the day of the experiment. A portion 
of the EtOH extracts that were hits from the ToxFinder experiments were further partitioned 
and the residue fractions were triturated according to the method outlined by (Balansa et al. 
2010). These fractions were subsequently prepared in 384-well plates for a second ToxFinder 
screen in order to discriminate the fractions containing only the active compounds, which 
were then purified for both ToxFinder and electrophysiological experiments. Results from 
these screenings are reported in Chapter 6. 
2.8 High-throughput yellow fluorescent protein (YFP)-based anion influx assay (ToxFinder) 
To prepare for ToxFinder, the crude extracts and fractions (previously dissolved in 
DMSO) were diluted with NaCl Ringer’s solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl2.6H2O, 
2 mM CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.4) to a final volume of 30 µl. 10 µl of each 
diluted extract or fraction was next added to the cells in each well to a final volume of 25 µl 
(cell plate) and incubated for 5-10 minutes prior to the experiment. For individual compound 
testing, the stock compounds were diluted to 1 µM and 100 µM in a final volume of 25 µL 
NaCl Ringer’s solution. The medium in each well of the cell plate was then replaced with the 
diluted compounds and incubated for 5-10 minutes before experiment. 60 µL of GABA 
solution, dissolved in NaI Ringer’s solution (equimolar concentration of NaI replaced NaCl) 
was prepared correspondingly in a separate 384-well plate (drug plate).  
ToxFinder experiments was conducted using an automated imaging system with a 
robot-controlled liquid handling system, as described by Kruger (Kruger et al. 2005). This high-
throughput assay has the advantage of screening the effect of a drug on thousands of cells at 
a time. The cell plate was first placed on a motorised stage (Prior ProScan II/III, GT Vision, 
Hagerstown, MD, USA) of an Olympus IX51/Nikon Eclipse Ti inverted microscope before the 
cells were imaged with 10x objective, once before and then 8 seconds after the addition of 
drugs. A mercury/halide arc lamp was used to excite the YFP, producing fluorescence that was 
magnified through a diopter 8 mineral glass lens and imaged by a monochrome/CCD camera 
before being digitised onto a personal computer. The maximum image acquisition rate was 
1.25 Hz and the images were formed with 696x520 pixels resolution. A 100-µl syringe of the 
LC PAL auto sampler (CTC Analytics, Zwingen, Switzerland) transferred the solution from drug 
to cell plate. All hardware control, image acquisition, storage, image analysis and data 
quantification were performed by LabView 8.2.1 software.  
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2.9 Automated electrophysiology 
The patch clamp technique permits single channel and whole cell electrophysiological 
recordings from small mammalian cells (Hamill et al. 1981). Electrophysiology recordings 
were performed using a high throughput automated planar patch clamp device developed by 
Nanion (Nanion Technologies GmbH, Munich, Germany). In addition to increasing 
throughput, this device permits complete exchange of the solution bathing the cells with 25 
μL of new solution. This later feature was particularly important as the Capon lab provided us 
with only minute amounts of extracts and pure compounds. For Patchliner experiments, the 
stable α1β2γ2L and α5β3γ2L GABAAR-HEK293 cells were suspended in the standard external 
solution containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES/NaOH and 5 glucose 
(pH 7.4). The final cell suspension, the pre-prepared internal solution containing (in mM) 50 
KCl, 10 NaCl, 60 KF, 2 MgCl2, 10 HEPES/KOH (pH 7.2), and 20 EGTA, the external solution and 
the compound-containing solutions were all placed at pre-defined positions on the patchliner 
workstation and were applied to cells via robotic pipette. The cell suspension was transferred 
to the cell hotel (i.e. a cell reservoir on the patchliner station) immediately before 
experiments. Intracellular solution, extracellular solution, seal enhancer, and compound 
(drug) solutions, were also placed in the allocated positions on the workstation. The 16-
channel chip was placed on the chip wagon. Briefly, the protocol comprises the following 
steps – the robotic pipette first applies internal solution into the chip, and then extracellular 
solution, the chip then is docked, and the machine then forms an electrical contact between 
intracellular and extracellular solutions. Then the cell suspension (from the cell hotel) was 
applied to the external side of the chip. Once a cell has been caught in each channel (i.e., 
sucked onto the aperture), seal enhancer solution was applied into the chip. Finally, the ‘Patch 
Control HT’ protocol performed several seal formation and optimisation steps before it 
established the whole-cell recording configuration. For concentration-response experiments, 
cells were voltage clamped at –40 mV at room temperature (~24 °C) (Balansa et al. 2010). 100 
mM GABA (Ajax Finechem, Seven Hills, NSW, Australia) stocks were prepared in water and 
kept at -20 ºC. Strychnine (Sigma-Aldrich, St Louis, MO, USA) and other compounds to be 
tested were dissolved in DMSO (Sigma-Aldrich) and kept at -20oC.  
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2.10 Data Analysis 
A. Two-electrode voltage clamp (TEVC) and whole cell electrophysiology 
Glutamate concentration-response was standardized as I% = I/Imax (%) x 100, where I 
is the peak current amplitude, and Imax is the maximal peak current produced by saturating 
glutamate in each oocyte. The responses were normalized as I% = I/IEC50 x 100, where IEC50 is 
the peak current produced by glutamate EC50. The responses of glutamate in the presence of 
diazepam and Zn2+ were normalized as ΔI% = I/Icontrol x 100, where I is the peak current 
amplitude, and Icontrol is the peak current produced by glutamate control (EC20). 
Concentration-responses were fitted using the four-parameter non-linear regression, I% = 
bottom + (top-bottom)/ (1 + 10^ ((log (EC50 or IC50) – x)*nH)), where top and bottom refers to 
the maximal and basal responses respectively. EC50 and IC50 refer to the concentration that 
gives half the maximal effective or inhibitory response respectively, x refers to the log 
concentration of the agonist or inhibitor, and nH refers to the Hill coefficient (SigmaPlot 13.0, 
Systat software, Inc. SigmaPlot for Windows). Unless stated otherwise, the pooled data were 
contrasted using unpaired t-test where appropriate, and considered significant when p<0.05. 
All results were expressed as mean ± S.E.M from n≥3 oocyte recordings.  
Group data were analysed in SigmaPlot 13.0 using one-way ANOVAs, where p < 0.05 
was taken as the significance threshold and expressed as mean ± SEM. 
B. Single channels and macropatches  
Single channel recordings were analysed in QuB software. Single channel currents were 
idealised and separated into discrete activations by applying critical shut times of 50 ms in 
glutamate alone or 50-100 ms in glutamate plus IVM to separate and define single receptor 
active periods. Patches yielded between 30-250 individual active periods. Critical shut times 
were determined by generating an initial shut duration histogram to continuous data that 
included inactive periods corresponding to receptor desensitisation. The selected critical 
times eliminated periods of receptor desensitisation while retaining singe receptor active 
periods. Mean active period duration and intra-activation open probability was estimated 
from each patch. Group means were obtained by averaging across multiple patches for each 
recording condition. 
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Background 
 Although there have been a number of drugs targeting GluClRs in invertebrates over the 
period of time parasites such as nematodes and arthropods have managed to increase their 
resistance to all the drugs available on the market. Drug discovery strategy now involves either to 
find a molecule that can overcome this barrier of resistance or to find one of the possible 
mechanisms by which parasitic organisms such as H. contortus develop resistance to these drugs. I 
sought to investigate the pharmacological properties of HcoGluClRs by two-electrode voltage clamp 
(TEVC). This is because we hypothesised that one of the HcoGluClR subunit is imparting resistance 
to the parasitic nematode. This study was undertaken in collaboration with Professor Robert 
Capon’s group (Institute of Molecular Biosciences, The University of Queensland). The results of this 
study are detailed below, and the manuscript has been submitted to PLOS Pathogens. 
Statement of contributions by authors 
I designed and carried out 80% of all the electrophysiological recordings and data analysis. I also put 
all the figures together which were later edited by Dr. Angelo Keramidas and edited the first draft. 
Dr. Jennifer Smith performed 10% of experiments where she performed single channel recordings 
and IPSCs recordings. Dr. Argel Estrada-Mondragon performed the membrane accumulation 
experiment and also helped in FRAP experiment. Dr. Xiao synthesised all the IVM analogues. Dr. 
Angela Salim helped us to gather all the supplementary data for all the analogues due to Dr. Xiao’s 
absence. Professor Joseph Lynch and Dr. Angelo Keramidas advised on the experimental design and 
made the first draft. All authors edited the subsequent draft equally. Other acknowledgments are 
included in the manuscript. The table below lists the percentage contribution by the individual 
authors.  
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Contributor Statement of contribution 
Author Mohammed Atif (Candidate) Electrophysiological recordings and data analysis (80%). 
Figure preparation (50%). 
Microscopy image experiment & analysis (50%). 
Subsequent draft editing (11%) 
Author Jennifer Smith Electrophysiological recordings (10%). 
Subsequent draft editing (11%) 
Author Argel Estrada-Mondragon Microscopy experiments (50%). 
Subsequent draft editing (11%) 
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Abstract 
Glutamate-gated chloride channel receptors (GluClRs) mediate inhibitory neurotransmission at 
invertebrate synapses and are primary targets of parasites that impact drastically on agriculture and 
human health. Ivermectin (IVM) is a broad-spectrum pesticide that binds and potentiates GluClR 
activity. Resistance to IVM is a major economic and health concern, but the molecular and synaptic 
mechanisms of resistance are ill-defined. Here we focus on GluClRs of the agricultural endoparasite, 
Haemonchus contortus. We demonstrate that IVM potentiates inhibitory input by inducing a tonic 
current that plateaus over 15 minutes and by enhancing post-synaptic current peak amplitude and 
decay times. We further demonstrate that IVM greatly enhances the active durations of single 
receptors. These effects are greatly attenuated when endogenous IVM-insensitive subunits are 
incorporated into GluClRs, suggesting a mechanism of IVM resistance that does not affect glutamate 
sensitivity. We discovered functional groups of IVM that contribute to tuning its potency at different 
isoforms and show that the dominant mode of access of IVM is via the cell membrane to the 
receptor. 
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Author Summary 
Glutamate-gated chloride channel receptors (GluClRs) mediate chemoelectric inhibition in 
invertebrate animals, and are targets for broad-spectrum pesticides such as ivermectin. However, 
resistance to ivermectin threatens the effective control of invertebrates that cause a range of 
agricultural and human diseases. This study investigates different isoforms of GluClR expressed by 
the major agricultural endoparasite, Haemonchus contortus, on a synaptic and single receptor level. 
We discovered that ivermectin enhances synaptic current amplitude and decay and lengthens single 
receptor activity. Furthermore, ivermectin is less efficacious at GluClRs that incorporate a naturally 
ivermectin-resistant subunit, suggesting a potential resistance mechanism. Finally, we identify two 
chemical interactions between the GluClR and ivermectin that determine its potency and show that 
ivermectin binds to GluClRs via cell membrane interactions. 
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Introduction 
Glutamate-gated chloride channel receptors (GluClRs) are a major class of pentameric ligand 
gated ion channels (pLGICs) (Cully et al. 1994) that mediate neuronal and muscular inhibition 
(Marder and Paupardin-Tritsch 1978; Marder and Eisen 1984). They are expressed exclusively 
in invertebrates, making them ideal targets for the development of pesticides with minimal 
risk of unwanted activity at vertebrate pLGICs. GluClRs are of interest because they are an 
excellent model for understanding pLGIC structure at high resolution (Althoff et al. 2014; 
Hibbs and Gouaux 2011), function and pharmacology (Lynagh and Lynch 2010; Callau-
Vazquez et al. 2018), and because many invertebrates that express them are commercially 
important pest species in agriculture (Paini et al. 2016; Fitzpatrick 2013; Tigchelaar et al. 
2018), aquaculture (Horsberg 2012) and in veterinary and human health (Wolstenholme 
2012). 
Ivermectin (IVM) is a highly effective, broad-spectrum anthelminthic drug that targets 
GluClRs. Its binding site is formed between the first (M1) and third (M3) transmembrane 
domains contributed by adjacent subunits (Hibbs and Gouaux 2011) (Fig. 1A, B). The drug is 
used extensively as an insecticide and anti-parasitic agent (Laing et al. 2017), where its 
mechanisms of action include paralysis of feeding structures, such as the pharynx, in adult 
organisms (Portillo et al. 2003; Wolstenholme and Rogers 2005; Geary et al. 1993) and 
impairment of larval viability (Wolstenholme et al. 2016; Laing et al. 2017). However, 
resistance to IVM and related macrocyclic lactones, such as abamectin, is an emerging 
concern that threatens food production (Oerke 2005; Fitzpatrick 2013) as well as human 
(Osei-Atweneboana et al. 2011) and animal health (Kaplan and Vidyashankar 2012) on a 
global scale. Underscoring the imperative for a greater understanding of the molecular 
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targets of pesticides and mechanisms of resistance, studies predict that increasing seasonal 
temperatures due to climate warming will significantly exacerbate agricultural loss that 
results from an increase in populations of herbivorous pests (Tigchelaar et al. 2018; Bebber 
et al. 2013) and veterinary parasites (Fitzpatrick 2013). The chemical synthesis of new IVM 
derivatives is a key strategy in overcoming IVM resistance as it has the potential to probe 
specific molecular groups of IVM (Michael et al. 2001) and their interactions with IVM 
sensitive and resistant forms of GluClR. 
Wild, IVM-resistant pest isolates that express missense point mutations to GluClR 
subunits have been identified in the herbivorous species, Plutella xylostella (Wang et al. 2017; 
Wang et al. 2016) (A30’V) and Tetranychus urticae (Dermauw et al. 2012; Kwon et al. 2010; 
Mermans et al. 2017) (G36’D, G36’E) and in a laboratory-induced mutation to a GluClR subunit 
of Drosophila melanogaster (P23’S) upon exposure to IVM (Kane et al. 2000) (Fig. 1B). Point 
mutations to GluClR subunits are also being reported in human head lice, Pediculus humanus, 
that include the A55’V, and S46P and H272R, the latter two mutations being located in the 
extracellular and intracellular domains of the receptor, respectively (Amanzougaghene et al. 
2018). 
In addition to mutations, the sensitivity of GluClRs to IVM is affected by subunit 
composition. Cully et al. 1994 first identified GluClR subunit isoforms in the nematode, 
Caenorhabditis elegans and demonstrated that they could assemble as homo- and 
heteromeric receptors with different pharmacological properties (Cully et al. 1994). C. 
elegans expresses a β subunit that is insensitive to IVM when expressed as a homopentamer, 
and acts to reduce IVM sensitivity when co-assembled with the IVM-sensitive α subunit (Cully 
et al. 1994) (Fig. 1B). A naturally IVM-resistant variant of an α subunit isoform has also been 
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discovered in a strain of C. elegans. IVM insensitivity can be overcome by overexpressing IVM-
sensitive subunits in the resistant C. elegans strain (Ghosh et al. 2012). Moreover, IVM 
effectively kills the larvae of the human pathogens, Onchocerca volvulus and Wuchereria 
bancrofti, but is less effective against the adult stages of these organisms (Laing et al. 2017), 
suggesting a developmental switch in GluClR subunit composition. Evidence for selection 
pressure on GluClR isoform expression that confers IVM insensitivity comes from IVM-
resistant isolates of the bovine pathogens, Cooperia oncophora and Ostertagia ostertagi, 
which demonstrate transcriptional downregulation of genes that encode IVM-sensitive 
GluClR subunits (El-Abdellati et al. 2011). 
H. contortus is one of the world’s most economically important agricultural parasites 
that infects domestic ruminant animals, and field resistance to IVM is well-documented (Laing 
et al. 2016). It has also been reported to infect wild ruminants, including species that are 
critically endangered (Rose et al. 2014). This endoparasitic nematode has six GluClR genes 
encoding at least eight subunits (Williamson et al. 2011). Functional expression of wild-type 
homomeric GluClRs comprising α (avr-14b) subunits have been reported previously, including 
mutations to this subunit that greatly reduce IVM sensitivity (Lynagh and Lynch 2010; Atif et 
al. 2017; McCavera et al. 2009). Although the β subunit of H. contortus was shown to have 
overlapping distribution patterns with the α (avr-14b) and other α subunit isoforms (Portillo 
et al. 2003), little is known about its function. Notably, it is not known if the β subunit forms 
functional homomeric receptors or whether it can combine with other subunits to form 
heteromers. It also remains to be determined which homomeric or heteromeric combinations 
of α and β subunits cluster at postsynaptic sites to mediate inhibitory postsynaptic currents 
(IPSCs). This deficiency represents an obstacle to understanding basic invertebrate 
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neurobiology and determining the effects of drugs on neuronal and muscular inhibitory input, 
including highly lipophilic drugs, such as IVM that exhibit quasi-irreversible effects on GluClRs 
(Lynagh and Lynch 2012). Due to its lipophilic nature, IVM is believed to diffuse through the 
body cuticle of nematodes (Alvarez et al. 2007) and partition into cell membranes of target 
organisms where it reaches a high local concentration (Martin and Kusel 1992). We have 
recently shown that single receptor active periods of homomeric α (avr-14b) GluClRs (α 
GluClRs) increase in duration over 1-2 minutes after exposure to IVM, suggesting that the 
drug equilibrates in the membrane over time to produce maximum receptor potentiation 
(Atif et al. 2017). 
In this study, our aims were to determine (1) whether the β subunit of H. contortus 
can assemble as both β homomeric and αβ heteromeric GluClRs (β GluClRs and αβ GluClRs), 
(2) whether subunit composition determines IVM sensitivity, (3) the potency of synthetically 
modified analogues of IVM (4) whether β and αβ GluClRs mediate IPSCs with different 
properties, and finally, (5) whether the membrane partitioning and diffusion properties of 
IVM correspond to the time-course of current potentiation. 
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Results 
GluClRs comprising homo- and heteromeric combinations of α and β subunits of H. 
contortus. To test for functional expression of β and αβ GluClRs, cDNA encoding the β subunit 
was injected into oocytes either alone or with cDNA encoding the α subunit, at a ratio of (α:β) 
1:1 or 1:50. Example glutamate-gated currents obtained from oocytes injected with the β 
subunit alone and the α and β subunits at a ratio of 1:50 are shown in Fig. 1C. These data 
clearly demonstrate that the β subunit can indeed form functional β GluClRs and, given the 
differential glutamate sensitivity of co-injected oocytes, can assemble with the α subunit to 
form αβ GluClRs. The maximal currents for the α, αβ and β GluClRs were (in µA) 3.7 ± 0.8, 2.0 
± 0.4 (1:1), 2.2 ± 0.4 (1:50) and 1.9 ± 0.3, respectively and were not statistically different. 
Complete glutamate concentration-response experiments were done in oocytes injected with 
the either cDNA encoding the α or β subunit and in oocytes co-injected with both cDNAs at 
ratios of 1:1 and 1:50 (Fig. 1D). These data show the β GluClRs are substantially less sensitive 
to glutamate with an EC50 of 394 µM compared to α homomers and the αβ heteromers (p < 
0.001), all of which exhibited similar glutamate sensitivities, with EC50s of 28 µM (α 
homomers), 40 µM (αβ, 1:1) and 44 µM (αβ, 1:50) (Table 1). Notably, the fitted 
concentration-response plots for both heteromeric combinations of receptors did not exhibit 
inflections typical of mixtures of distinct receptor stoichiometries with differential EC50s, as 
has been shown for GABA-gated pLGICs (Hartiadi et al. 2016). These data suggest that co-
injected oocytes express mostly homogeneous populations of heteromeric receptors, and 
that a given injection ratio gives rise to a particular homogeneous stoichiometry. (Refer to 
appendices section 1 for additional experiments that were done to determine why β 
HcoGluClRs were insensitive to IVM). 
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Table 1. Glutamate and IVM concentration-response parameters 
Ligand GluClR EC50 (nM) Hill co-efficient n 
Glutamate 
α 28 ± 6 1.9 ± 0.3 10 
αβ (1:1) 40 ± 6 1.7 ± 0.1 6 
αβ (1:50) 44 ± 3 1.7 ± 0.1 13 
β 394 ± 57*** 1.5 ± 0.1 8 
IVM 
α 22 ± 3 1.9 ± 0.1 11 
αβ (1:1) 86 ± 14**# 1.0 ± 0.1 6 
αβ (1:50) 141 ± 11*** 1.6 ± 0.1 14 
β >10 µM − 6 
One-way ANOVA **p < 0.01, ***p < 0.001 compared to α GluClRs, # p < 0.05 compared to 
αβ (1:50) GluClRs. cDNA injection ratios in parentheses. 
IVM concentration-response experiments were carried out to obtain additional 
evidence of populations of receptors that were a function of the oocyte injection ratio. 
Example IVM-induced currents for α GluClRs and αβ GluClRs at both injection ratios are 
shown in Fig. 2A-C. The corresponding group concentration-response data for four 
combinations of GluClRs are shown in Fig. 2D. These plots indicate that α GluClRs are highly 
sensitive to IVM with an EC50 of 22 nM and a maximal response equivalent to 59% of that 
seen with saturating glutamate. Conversely, β GluClRs were effectively insensitive to IVM with 
an EC50 > 10 µm. The heteromeric combinations exhibited intermediate IVM sensitivities with 
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the 1:1 injected oocytes being more sensitive (EC50 of 86 nM, 26% of saturating glutamate 
response) than the 1:50 injected oocytes (EC50 of 141 nM, 33% of saturating glutamate 
response). The % of saturating glutamate response was not significantly different between 
the two injection ratios. However, the EC50s for the two heteromeric combinations were 
statistically different from the α GluClRs and from each other (Table 1). 
Together these data demonstrate that β subunits of H. contortus and C. elegans (Cully 
et al. 1994) exhibit some functional similarities. They both form homomeric receptors that 
are insensitive to IVM and can combine with α subunits to reduce IVM sensitivity. However, 
unlike the β GluClRs of C. elegans, those of H. contortus are responsive to glutamate, albeit 
with a reduced sensitivity. The data also show that the β subunit can co-assemble with the α 
subunit without reducing the sensitivity of the receptors to the neurotransmitter, glutamate. 
Furthermore, IVM potency is reduced when oocytes are injected with an excess of β subunit 
cDNA, implying that GluClRs with a greater content of β subunit are less sensitive to IVM. This 
later inference also suggests that heteromeric αβ GluClRs of H. contortus can increase the 
proportion of β subunit as a function of its expression level. This is in contrast to the reported 
fixed stoichiometry of heteromeric GluClRs of C. elegans (Degani-Katzav et al. 2016). 
IVM analogue potency at α and αβ GluClRs. In our next series of experiments, we wished to 
see if modifying the IVM molecule might alter its potency differentially at α and αβ GluClRs. 
Three analogues were screened (Fig. 3A) at α and αβ GluClRs (1:50) using a standard 
concentration of 30 nM (Fig. 3B). Changes to the IVM parent molecule were made on the 
basis of IVM and receptor or lipid membrane interactions as revealed by the crystallographic 
structure of the C. elegans α GluClR (Hibbs and Gouaux 2011). 
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The maximum current elicited by each IVM analogue was normalised to that induced 
by a saturating concentration of glutamate (5 mM, Fig. 3B) and its efficacy (Ratio of saturating 
IVM current relative to saturating glutamate current) was compared to that of IVM and 
between α and αβ GluClRs (Fig. 3C). The disaccharide moiety is predicted to protrude into the 
upper leaflet of the cell membrane (Fig. 1A) and to form van der Waal (VDW) interactions 
with the loop that links the M2 and M3 domains of the α subunit of C. elegans (Hibbs and 
Gouaux 2011) and H. contortus. Hydrolysis of IVM yielded the aglycone IVM-1 (synthesis 
details are given in Supporting Information, S1). IVM-1 retained differential efficacy between 
the two receptor isoforms but was significantly less efficacious than IVM only at α GluClRs (p 
< 0.05). Replacing the disaccharide with a methoxymethyl ether group (MOMO) produced 
IVM-2 (Supporting Information, S1). This derivative restored efficacy at α but not αβ GluClRs 
and abolished the differential sensitivity between the receptors. This result suggests that in 
addition to the predicted M2-M3 loop interactions, steric factors also contribute to the 
potentiating effects of IVM. IVM-2 (and IVM and IVM-1), with a β-configured 5-OH moiety, is 
predicted to form VDW interactions and hydrogen bonds with residues of the M2 and M1 
domains (Hibbs and Gouaux 2011). The α-configured 5-OH epimer (IVM-3, Supporting 
Information, S1), prepared from IVM-2, produced the most marked reduction in efficacy (p < 
0.001 for both GluClRs) relative to IVM. Moreover, this change also ablated the differential 
efficacy between the two GluClR isoforms (Fig. 3C). This result is in accord with the predicted 
role of the 5–OH moiety, which forms a hydrogen bond with the polar residues within the 
pore-lining M2 domain (S15’ in C. elegans α (Hibbs and Gouaux 2011) or S16’ and Q15’in H. 
contortus α and β, respectively (Fig. 1B). A previous study also found this position was 
important, as subtle changes to 5-O or 5-NOH resulted in dramatic decreases in activity when 
tested in an H. contortus larval assay (Michael et al. 2001). 
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Overall, the maximal efficacies of α and αβ GluClRs were maintained for IVM and IVM-
1 whereas IVM-2 and IVM-3 exhibited similar maximal efficacies at both receptors. The 
preservation of efficacy of IVM-1 and IVM-2 compared to IVM at αβ GluClRs suggests that the 
β subunit likely contributes to IVM binding sites. The disaccharide and the 5-OH moiety of 
IVM are salient determinants of the potentiating potency of IVM. The data reveal two IVM-
receptor interactions that accord well with predictions from structural studies (Hibbs and 
Gouaux 2011) and suggest that with rational drug design it may be possible to develop IVM 
analogues to selectively target specific GluClR isoforms. 
IPSCs mediated by α and αβ (1:1) GluClRs. Evidence suggesting the existence of glutamate-
gated anion-selective post-synaptic receptors was first noted in arthropods over 40 years ago 
via observing membrane potential changes (Marder and Paupardin-Tritsch 1978; Cull-Candy 
1976; Marder and Eisen 1984). However, to our knowledge direct recordings of GluClR-
mediated IPSCs have not been made in any invertebrate species. We have recently developed 
a heteroculture consisting of primary (mammalian) neurons and HEK293 cells transfected 
with defined post-synaptic receptors of vertebrates, along with the trans-synaptic protein 
neuroligin (Dixon et al. 2014; Chen et al. 2017; Zhang et al. 2015). 
This heterosynapse preparation was used to examine if α and αβ GluClRs of H. 
contortus cluster at post-synaptic sites and respond to synaptically released glutamate. Cells 
transfected with the α (Fig. 4A) or α and β (1:1, Fig. 4B) subunits in co-culture with neurons 
exhibited prominent currents typical of those expressed at vertebrate synapses, consisting of 
a fast rise to peak followed by a slower, exponential decay back to baseline (Fig. 4C, D). These 
IPSCs were only observed in transfected cells and were blocked by picrotoxin (Fig. 4E), 
confirming that the receptors were anion-selective GluClRs (Hibbs and Gouaux 2011; 
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McCavera et al. 2009). These data clearly demonstrate that α and αβ GluClRs of H. contortus 
generate classic, picrotoxin-sensitive IPSCs. A clear, observable difference between IPSCs 
mediated by the two receptor isoforms was that αβ GluClRs decayed faster than those 
mediated by α GluClRs (Fig. 4C, D). The mean rise-times, peak amplitudes and decay times 
were measured and plotted as bar plots (Fig. 4F-H). The group averages confirmed that only 
the decay times between the two receptor isoforms were significantly different, with those 
of the α GluClRs decaying with a time constant of 40 ± 2 ms (n = 17), whereas the decay time 
constant for the αβ GluClRs was 17 ± 2 ms (n = 8). The rise times were 4.6 ± 0.7 ms for the α 
GluClRs and 3.2 ± 0.3 ms for the αβ GluClRs. The peak amplitudes were the most variable of 
the three parameters, being 60 ± 9 pA and 34 ± 8 pA for the α and αβ GluClRs, respectively, 
likely reflecting variable expression levels of receptors. 
The effects of IVM at IPSCs of α and αβ (1:1) GluClRs. After validating the heterocultures as 
a reliable preparation for investigating IPSCs mediated by GluClRs, we made synaptic 
recordings while continuously applying IVM (5 nM) to cells similarly transfected with α and 
αβ GluClRs. Two salient effects were observed in these recordings. Firstly, there was a steady 
downward deflection in baseline current over the course of the recording that was not 
different between cells expressing α (Fig. 5A) and αβ (1:1, Fig. 5B) GluClRs. These data were 
subsequently pooled for analysis of the tonic current component. The tonic currents 
plateaued at 17 ± 1 minutes (n = 13), had a fitted time constant of 483 ± 72 s and a mean 
amplitude of 304 ± 54 pA. Changes to the kinetic properties of IPSCs were also observed upon 
IVM application (Fig. 5C-G). These were analysed 15 minutes after the commencement of the 
IVM application to ensure that the effects had equilibrated. For both receptor types, the 
decay and rise times and peak amplitudes increased significantly in the presence of IVM 
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relative to IVM naïve cells. The decay time constant for α GluClRs slowed from 40 ± 2 ms to 
100 ± 3 ms (n = 6) and for αβ GluClRs from 17 ± 2 ms to 72 ± 4 ms (n = 6, Fig. 5E). The increase 
in activation times were from 4.6 ± 0.7 ms to 19 ± 1 ms for α GluClRs and from 3.0 ± 0.3 ms 
to 10 ± 1 ms for the αβ heteromers (Fig. 5F). Again, the peak IPSC amplitudes were variable 
but increased significantly in the presence of IVM from 60 ± 9 pA to 122 ± 39 pA and from 34 
± 8 pA to 124 ± 18 pA for α and αβ GluClRs, respectively (Fig. 5G). A comparison of the 
magnitude changes of IPSC parameters was also made between the two receptor isoforms. 
Consistently greater decay and rise times were observed for the α GluClRs (Fig. 5E, F), 
suggesting that IPSCs mediated by these receptors produce greater inhibitory input than αβ 
GluClRs in the presence of IVM. 
Single receptor properties of β and αβ (1:1) GluClRs. The decay times of IPSCs mediated by 
αβ GluClRs were consistently and significantly faster than those of α GluClRs, in both the 
absence and presence of IVM. We previously showed that the decay times of macropatch 
currents mediated by α GluClRs incorporating an IVM-insensitive mutation (G36’A) were 
faster than those mediated by wild-type α GluClRs, and that this was due to briefer single 
receptor active periods and enhanced receptor desensitisation (Atif et al. 2017). 
To explore whether a similar mechanism applies to β-containing GluClRs, we recorded 
single receptor currents in excised patches from cells transfected with either the α and β 
subunits (1:1) or the β subunit alone. These experiments were recorded in 2 µM and 3 mM 
glutamate as well as 2 µM glutamate plus 5 nM IVM at a clamped potential of −70 mV 
(reversal potential = 4.0 mV, liquid junction potential = 4.7 mV and membrane potential = 
78.7 mV) (Atif et al. 2017). Patches from cells transfected with both subunits revealed that 
the majority (~90%) of single αβ receptors opened to an amplitude of 1.2 pA (Fig. 6A) with 
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the remainder opening to 0.7 pA (Fig. 6B). By contrast, patches from cells transfected with 
the β subunit alone invariably opened to an amplitude of 0.4 pA (Fig. 6C). Amplitude 
histograms confirmed two amplitude levels for αβ GluClRs and a single amplitude for the β 
GluClRs (Fig. 6D). Our data suggest that a 1:1 transfection ratio of α and β subunits results in 
a predominant stoichiometry, which exhibits an amplitude of 1.2 pA and a less frequent 
subunit combination that opens to an amplitude of 0.7 pA. We infer that the αβ GluClRs that 
open to 0.7 pA likely contain a greater proportion of β subunits. This is consistent with β 
GluClRs having the smallest amplitude and α GluClRs having the greatest amplitude (1.8 pA) 
under similar recording conditions (Atif et al. 2017). The calculated conductance values for 
the corresponding amplitudes for αβ GluClRs was 15.2 pS and 8.9 pS and for the β GluClRs 
was 5.1 pS. 
Single receptor active periods were analysed for mean duration and intra-activation 
open probability (PO). For αβ GluClRs the activations from both stoichiometries were pooled 
to obtain mean active periods of 43 ± 12 ms (n = 5) in 2 µM glutamate and 152 ± 27 ms (n = 
5) in 3 mM glutamate. Consistent with the example recordings presented in Fig. 6A, B the 
respective POs were 0.49 ± 0.04 and 0.87 ± 0.03 in 2 µM and 3 mM glutamate (Fig. 6E). Current 
potentiation by IVM did not change the proportion of activations to 1.2 pA compared to 0.7 
pA, but manifested as a marked increase in the mean duration of the active periods (pooled, 
876 ± 178 ms, n = 6) (Fig. 6A, B, E). This represents an over 20-fold increase compared to 2 
µM glutamate alone and 6-fold increase compared to 3 mM glutamate. The PO in 2 µM 
glutamate plus 5 nM IVM was similar to that in 3 mM glutamate, being 0.83 ± 0.02 (Fig. 6E). 
β GluClRs exhibited the briefest active periods (Fig. 6C). At 2 µM glutamate, β GluClRs opened 
for a mean duration of 5.5 ± 2.0 ms and had a PO of 0.56 ± 0.09 (n = 5) (Fig. 6F). The active 
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durations increased in 3 mM glutamate to 164 ± 40 ms, whereas the PO remained unchanged 
(0.67 ± 0.14, n = 5) (Fig. 6F). In contrast to the supersaturating effects IVM has at α and αβ 
GluClRs, it was ineffective at increasing the duration of active periods of β GluClRs beyond 
that measured in 3 mM glutamate. The active periods in 2 µM glutamate plus 5 nM IVM were 
126 ± 26 ms in duration and the PO was 0.65 ± 0.04 (n = 5) (Fig. 6F). 
Our single receptor measurements show that by increasing the active durations and 
PO of single GluClRs, IVM produces an increase in IPSC decay times and peak amplitude, 
respectively. Our data also demonstrate a correlation between single receptor active 
duration, IPSC decay times and IVM potentiation of IPSCs. 
Partitioning and diffusion of IVM in cell membranes. Our IPSC and single channel data 
suggest that the potentiating effect of IVM at GluClRs requires several minutes to stabilise 
(Atif et al. 2017). This relatively long delay could reflect the slow binding of IVM directly from 
the aqueous solution or slow IVM-induced conformational effects at GluClRs once bound 
(Sykes et al. 2014; Degani-Katzav et al. 2017). Alternatively, it may reflect a slow accumulation 
rate of IVM into the membrane, possibly coupled with a slow lateral diffusion rate within the 
membrane that controls its access to receptor binding sites. To help distinguish between 
these possibilities, we synthesised a fluorescent IVM-bodipy probe (IVM-bdpy, Fig. 7A, 
Supporting Information, S1) to monitor the interaction of IVM with the cell membrane. This 
probe consisted of IVM-1, which retains its activity at GluClRs (Fig. 3), attached to a bodipy 
fluorophore. The resulting IVM-bdpy derivative exhibited spectral emission properties similar 
to free bdpy (Fig. 7B) and was active at α GluClRs (Fig. 7C), albeit with a reduced potency (Fig. 
7D). 
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Two types of experiments were conducted with IVM-bdpy. The first was aimed at 
monitoring the time-course of membrane accumulation. Untransfected HEK293 cells were 
incubated in extracellular solution containing 500 nM IVM-bdpy and time-lapse images were 
taken over a period of 30 min (Fig. 8A). The change in total membrane fluorescence averaged 
from 5 repeat experiments was then plotted against time and fitted to a standard exponential 
function (Fig. 8B). In a control experiment, the corresponding accumulation rate was also 
determined for bdpy. To obtain the net membrane partitioning time-course for IVM-1, the 
data for the bdpy alone was subtracted from the data obtained for IVM-bdpy (Fig. 8B). The 
time constants for the three plots were 6.5 min for the IVM-bdpy, 8.2 min for the bdpy 
fluorophore and 6.0 min for IVM-1. As the lipophilic properties of IVM and IVM-1 are similar 
(logPs of 5.4 and 5.1, respectively), we infer this analysis quantitatively reflects the membrane 
partitioning properties of IVM. Notably, the resultant plot plateaued at about 18-20 minutes, 
which was similar to the estimated time to plateau for the IVM-activated current as presented 
in Fig. 5A and B. It should be noted, however, that the IVM-bdpy experiment was done using 
a 100-fold higher concentration of drug in un-transfected cells and represents passive 
membrane accumulation, whereas the current plateau involved IVM binding to and activating 
receptors. Nevertheless, these data suggest that membrane partitioning of IVM is the rate 
limiting factor controlling the activation rate of GluClRs. 
The second experiment was aimed at determining the lateral membrane diffusion 
properties of IVM using the fluorescence recovery after photobleaching (FRAP) technique. 
After a 30-min equilibration time, 5 cells were monitored for fluorescence recovery within a 
bleached circular patch of membrane of 3.7 µm diameter (Fig. 8C). Any bleaching and 
recovery of the surrounding area of the cell was measured, using a similar circular patch and 
used to correct the recovery rate of the membrane delineated by the bleached area. We also 
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noted that the recovery reached 98 ± 2% of control. The resultant plot, fitted to a standard 
exponential, is shown in Fig. 8D. The time constant (τ) for recovery of 1.3 minutes was used 
to calculate the diffusion coefficient (D), using the radius (r) of the bleached patch, according 
to D = r2/4τ. The calculated value of D was 1.1 x 10−2 µm2s−1. Over the course of 1 s, the IVM-
bdpy probe would traverse 0.2 µm along the membrane surface (lateral diffusion rate of 0.2 
µms−1). This value is comparable to that calculated using a similar probe that was used to 
measure partitioning and lateral diffusion in muscle membranes of A. suum (Martin and Kusel 
1992). We infer that this slow lateral diffusion rate coupled to membrane partitioning are the 
major contributors to local increases of IVM around its target binding sites and the slow quasi-
irreversible actions of IVM at GluClRs. 
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Discussion 
Resistance to IVM in pest species is a growing problem worldwide. Previous research efforts 
have identified mutations and allelles of GluClRs associated with resistance to IVM, however, 
there is a lack of information regarding the mechanisms that underlie resistance. In this study, 
we investigated the synaptic and biophysical properties of different GluClR subtypes and 
detailed a possible mode of resistance in the pest species H. contortus. 
We found that β subunits of H. contortus can assemble both as homomers and as 
heteromeric combinations with the α subunit. Given that both subunits have common 
distribution patterns in motor neuron commissures and nerve cords (Portillo et al. 2003), it is 
possible that these two subunits combine to form heteromeric receptors, which are less 
sensitive to IVM but retain high sensitivity to neurotransmitter. Our data also support the idea 
that the subunit stoichiometry of heteromeric GluClRs is variable and that receptors with a 
greater proportion of β subunits are less sensitive to IVM. With a high EC50 (400 µM) for 
glutamate, a low unitary conductance and brief active periods, homomeric β GluClRs are not 
likely to be efficacious post-synaptic receptors. Moreover, given that our single channel 
recordings reveal little homomeric β GluClR activity in patches expressing both α and β 
subunits, homomeric β GluClRs are likely to be scarce in cells that also express α subunits. 
Using heterocultures of neurons and transfected HEK cells, we demonstrate that α 
and αβ GluClRs mediate IPSCs in response to presynaptic glutamate release. HEK293-
neuronal co-cultures have been shown to recapitulate synaptic current profiles in excitatory 
glutamatergic synapses expressing NMDA or AMPA receptors (Fu et al. 2003) suggesting that 
glutamate release in heterosynapses is likely to be physiological. To our knowledge, no 
published reports are available describing the properties of IPSCs mediated by native GluClRs 
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in invertebrate neurons or muscle cells. Our preparation therefore represents a technological 
advance with the potential to improve our understanding of (1) the kinetics of IPSCs mediated 
by defined GluClR isoforms, (2) the effects of drugs on IPSCs mediated by defined GluClR 
isoforms, (3) the effect of posttranslational modifications (e.g., phosphorylation) and 
resistance mutations on the formation and function of synapses, and (4) synaptogenesis and 
synaptic clustering mechanisms. We observed a substantial increase in IPSC peak amplitude 
and a general slowing of IPSC kinetics, particularly the decay times. IPSC experiments also 
revealed a tonic inhibitory component, which is a well-studied mode of inhibition in 
vertebrates that may also involve extrasynaptic pLGICs (Jia et al. 2008). In the presence of 
IVM we demonstrate that whereas the tonic component of inhibition is similar in cells 
expressing α and αβ GluClRs, the phasic IPSC component is potentiated to a smaller degree 
in αβ GluClRs. This lower sensitivity is mostly due to the intrinsic activation properties of β-
containing receptors. Hence, the net inhibitory signal mediated by αβ GluClRs in the presence 
of IVM would be less than that of α GluClRs, thereby underlying a possible mechanism of IVM 
resistance.  
Our single channel recordings showed that β-containing GluClRs had briefer active 
periods and a smaller conductance, both of which render receptors less sensitive to the 
potentiating effects of IVM when compared to α GluClRs (Atif et al. 2017).  
Single receptor active durations also accord well with ensemble decay times as 
revealed in macropatches (Atif et al. 2017) and IPSCs (this study). GluClRs with faster decay 
times are potentiated to a lesser extent by IVM in absolute terms and thus produce less 
inhibitory input to target cells. The decay times for the α GluClRs were 67 ms (macropatch) 
(Atif et al. 2017) and 40 ms (IPSCs). For GluClRs that exhibited reduced IVM sensitivity the 
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decay times were 11 ms (macropatch) for α(G36’A) (Atif et al. 2017) and 17 ms (IPSCs) for the 
αβ GluClRs. It is also noteworthy that vertebrate pLGICs, such as glycine and GABA-gated 
receptors that are much less sensitive to IVM also exhibit relatively brief single receptor active 
periods and faster ensemble decay times (Dixon et al. 2014; Scott et al. 2015). 
We hypothesised that a noteworthy component of the mode of action of IVM was its 
interactions with cell membranes. A fluorescently tagged IVM (IVM-bdpy) was used to 
measure the time-course of drug accumulation and lateral diffusion in membranes that was 
compared to the onset of current potentiation. Single channel currents recorded from small, 
~2 µM diameter patches equilibrated over 1-2 minutes (Atif et al. 2017). IVM-bdpy required 
about 18 minutes to saturate whole cell membranes, which was similar to the time taken for 
baseline currents to plateau (17 minutes) in our IPSC recordings. In addition to the 
concentrating effects of membrane partitioning, a slow lateral diffusion rate (0.2 µms−1) of 
IVM would also contribute to the apparent association rates of IVM to binding sites at GluClRs 
(Sykes et al. 2014). The recovery after bleaching reached near control levels, but was not at 
100 % for each cell, suggesting the presence of membrane compartments of relatively 
immobile lipid rafts (Lingwood and Simons 2010). Our experiments suggest that the dominant 
pathway for IVM to reach its binding sites at GluClRs is by membrane partitioning and 
diffusion rather than inducing slow conformational rearrangements to the receptors after 
binding directly from the aqueous compartment. 
Finally, we sought to identify a new IVM analogue with a differential effect on α and αβ 
GluClRs as proof of principle that this pharmacophore may be useful in refining anthelminthic 
treatments by targeting particular GluClR isoforms. We identified key receptor-drug 
interactions that determine drug potency that include (1) the disaccharide group of IVM and 
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(2) the significance of the C-5 configuration of IVM, which is a key determinant of differential 
potency between GluClR isoforms. 
In summary, we describe the functional properties of α homomeric and αβ 
heteromeric GluclRs using conventional whole cell recording, single channel analysis and 
heterosynaptic analysis. Our key findings support the general inference that the intrinsic 
activation properties of the inhibitory pLGICs is a critical determinant and predictor of the 
potentiating potency of IVM. Informed by our findings, drug design strategy may be directed 
towards increasing the active durations of single receptors and slowing decay times of IPSCs 
in synaptic isoforms of GluClRs.  
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Materials and Methods 
Molecular biology. cDNAs encoding the α (avr-14b) (pcDNA 3.1+) or β (pUNIV) GluClR 
subunits of H. contortus were nuclear injected into oocytes (NASCO, WI USA) or transfected 
into HEK293AD cells (CellBank Australia) using a calcium phosphate-DNA co-precipitate 
method. Synapse formation between neurons and HEK293 cells was promoted by co-
transfecting neuroligin 2A or 1B and the cDNA encoding CD4 surface antigen was also added 
to the transfection mixture so as to identify transfected cells The. Oocytes and HEK cells were 
used for experiments 2-3 days after the introduction of the cDNAs. All experiments were done 
at room temperature (22 ± 1 0C). 
Oocyte preparation and two-electrode voltage-clamp. Xenopus laevis oocytes were 
harvested by surgical incision. The oocytes were then defolliculated with 1.5 mg/ml 
collagenase for 2 hours. Free oocytes were rinsed with calcium-free OR-2 solution containing 
(in mM) 82.5 NaCl, 2 KCl, 1 MgCl2, 5 HEPES, pH 7.4 and mature stage V or VI oocytes were 
isolated for experiments. The DNAs coding for α and β subunits were nuclear injected into the 
oocytes using a Nanoliter 2000 microinjector (WPI Inc) at a ratio of (α:β), 1:0, 0:1, 1:1 and 
1:50. The total amount of injected DNA in all combinations was 400 ng ml−1, including the 
1:50 (α:β) combination (8 ng of DNA encoding the α and 392 ng of DNA encoding β subunits). 
Injected oocytes were incubated in ND96 storage solution (in mM) 96 NaCl, 2 KCl, 1 
MgCl2.6H2O, 1.8 CaCl2, 5 HEPES, 50 μg ml−1 gentamicin, 2.5 sodium pyruvate, 0.5 
theophylline, pH 7.4 at 16°C for 2-3 days before experiment.  
For the two-electrode voltage clamp recordings, each oocyte was secured in a cell bath 
that was continually perfused with ND96 recording solution (ND96 storage solution without 
pyruvate, theophylline and gentamicin). Glutamate, IVM and IVM analogues were diluted in 
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ND96 recording solution and were applied to the oocyte via bath perfusion. The two 
microelectrodes contained 3 M KCl and had resistances of 0.2-2 MΩ. Recordings were done 
using Clampex 10.2 software (Molecular Devices) at a clamped voltage of −40 mV. Currents 
were low-pass filtered at 200 Hz, sampled at 2 kHz using a Gene Clamp 500B amplifier and 
digitised by a Digidata 1440A interface. The IVM (IVM B1a) concentration-response 
experiments were standardised by using an application protocol that consisted of applying 
increasing concentrations of IVM for, respectively, 3 min, 3 min, 3 min, 2 min, 1 min, 1 min 
and 0.5 min. The IVM-induced currents were normalised to a saturating glutamate 
concentration of 5 mM (see example, Fig. 2). 
Single channel recordings. Single-channel currents were recorded from outside-out excised 
patches at a clamped potential of −70 mV. The single channel conductance was calculated by 
dividing the mean current by the net driving force at a clamped potential of 70 mV, after 
accounting for reversal and liquid junction potentials (Atif et al. 2017). Excised patches were 
continuously perfused via a gravity-fed double-barrelled glass tube, which contained 
extracellular bath solution containing (in mM), 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 
and 10 D-glucose and titrated to pH 7.4. Glutamate and IVM were dissolved in this 
extracellular solution. Recording electrodes were pulled from borosilicate glass (G150F-3; 
Warner Instruments), coated with a silicone elastomer (Sylgard-184; Dow Corning) and heat-
polished to a final tip resistance of 4−15 MΩ when filled with an intracellular solution 
containing (in mM) 145 CsCl, 2 MgCl2, 2 CaCl2, 10 HEPES, and 5 EGTA, pH 7.4. Stock solutions 
of L-glutamate were also pH-adjusted to 7.4 with NaOH. A 10 mM stock of IVM (Sigma-Aldrich) 
was dissolved in 100% DMSO and kept frozen at −20oC. Fresh working stocks of IVM at 5 nM 
were prepared by dissolving the appropriate quantity directly in extracellular solution. 100% 
DMSO when dissolved in extracellular solution alone at the same concentration as was 
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present in working solutions containing 5 nM IVM had no effect on patches excised from cells 
transfected with GluClRs or from untransfected cells. 
Currents were recorded using an Axopatch 200B amplifier (Molecular Devices), filtered at 5 
kHz and digitized at 20 kHz using Clampex (pClamp 10 suite, Molecular Devices) via a Digidata 
1440A digitizer. 
Heteroculture preparation and IPSC recording. Primary neuronal cultures were prepared 
from cortices of E18 rat embryos, (University of Queensland Biological Services), which were 
triturated and plated at 100,000 cells per 18-mm poly-D-lysine-coated coverslip in DMEM 
with 10% fetal bovine serum. After 24 h the entire medium was replaced with Neurobasal 
medium that included 2% B27 and 1% GlutaMAX supplements. After one week half of this 
medium was replaced and the neurons were allowed to grow in vitro for 3-5 weeks before 
introducing the transfected HEK293 cells. Recordings of synaptic currents were done in 
whole-cell configuration at −70 mV using an Axopatch 200B amplifier (Molecular Devices), 
filtered at 5 kHz and digitized at 20 kHz using Clampex (pClamp 10 suite, Molecular Devices) 
via a Digidata 1440A digitizer. 
Microscopy. Membrane partitioning and FRAP experiments were performed on an LSM 710 
inverted 2-photon confocal microscope equipped with a 40X water immersion objective lens 
(1.2 NA/280 µM WD/0.208 µM/pixel and a GFP/Alexa 488 filter set. Untransfected HEK293 
cells at a confluency of 50-75% were plated onto 35-mm glass bottom dishes one day prior to 
experiments. The IVM-bdpy fluorophore was dissolved in 100% DMSO and stored at −20 0C 
at a concentration of 24 mM. 
A Mai Tai eHP 2-photon laser/760-1040 nm was used as an excitation source (power 
at 920 nm) for the FRAP experiments. The laser and bleaching power were set to 7% and 75% 
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respectively. Membrane partitioning images were taken for 35 min at 0.5 Hz after replacing 
the cell medium (extracellular solution) with one containing the IVM-bdpy probe at a 
concentration of 500 nM. FRAP images were taken at a frequency of 0.5 Hz for 10 min after a 
30 min equilibration period in 500 nM IVM-bdpy. 
Analysis and statistics. Group data were analysed in SigmaPlot 13.0 using one-way ANOVAs, 
where p < 0.05 was taken as the significance threshold and expressed as mean ± SEM. Tests 
for normally distributed data are built into the SigmaPlot software. Confocal images were 
captured and analysed with Zen 2012 SP2 (Zeiss) software. Oocyte concentration-response 
data were fit to a Hill equation to obtain an EC50 and Hill co-efficient for each oocyte recording. 
These parameters were then averaged across multiple oocyte experiments of the same type. 
Single channel recordings were analysed in QuB software. Single channel currents were 
idealised and separated into discrete activations by applying critical shut times of 50 ms in 
glutamate alone or 50-100 ms in glutamate plus IVM to separate and define single receptor 
active periods. Patches yielded between 30-250 individual active periods. Critical shut times 
were determined by generating an initial shut duration histogram to continuous data that 
included inactive periods corresponding to receptor desensitisation. The selected critical 
times eliminated periods of receptor desensitisation while retaining singe receptor active 
periods. Mean active period duration and intra-activation open probability was estimated 
from each patch. Group means were obtained by averaging across multiple patches for each 
recording condition. 
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Fig 1. Activity of glutamate and IVM at homo- and heteromeric GluClRs. A. Structure of the 
GluClR (3RIF, (Hibbs and Gouaux 2011)) showing the large extracellular domain with 
glutamate bound at interfaces between adjacent subunits. Also shown is the transmembrane 
domain, which consists of four helices (M1-M1) per subunit and IVM bound between the M1 
and M3 of adjacent subunits. B. Sequence alignments of selected invertebrate GluClRs 
subunits showing the IVM binding site, which consists of the first (M1) to third (M3) 
transmembrane domains. Boxed in red are sites of missense mutations that reduce IVM 
sensitivity. Abbreviations are H. cont., H. contortus, C. eleg., C elegans, P. xylos., P. xylostella, 
T. urtic., T. urticae (isoforms 1 and 3) and D. melan., D. melanogaster. C. Example currents 
obtained in oocytes injected with the β subunit (above) or the α and β subunits (ratio 1:50, 
below) in response to the indicated glutamate concentrations. D. Group concentration-
response data for the indicated GluClRs. Holding potential was –40 mV. 
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Fig 2. Activity of IVM at homo- and heteromeric GluClRs. (A-C) Representative 
concentration-response experiments at the indicated IVM concentrations in oocytes. IVM-
induced currents were normalised to the response elicited by a saturating concentration of 
glutamate (5 mM) for oocytes injected with cDNA encoding the α subunit (A) or α and β 
subunits at a ratio of 1:50 (B) or 1:1 (C). D. Group concentration-response data for the 
indicated GluClRs. Holding potential was –40 mV. 
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Fig 3. IVM analogue potency. A. Structures of IVM and the three analogues. Arrows indicate 
the synthesis reaction steps. MOMO represents a methoxymethyl ether group. A red broken 
border indicates the change in 5-OH configuration between IVM-2 and IVM-3. B. Example 
experiments in oocytes expressing α GluClRs that test IVM and analogues, IVM-1 and IVM-3. 
The IVM or analogue-induced current was normalised to the response elicited by a saturating 
concentration of glutamate (5 mM). C. Group bar plots comparing the potency between α 
and αβ (1:50) GluClRs for IVM and the three IVM analogues. *** p < 0.001, * p < 0.05. 
Numbers within the bars indicate the number of experiments (oocytes). Holding potential 
was –40 mV. 
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Fig 4. IPSCs mediated by α and αβ GluClRs. (A-B). A whole-cell recordings from HEK293 cell 
expressing α GluClRs (A) or αβ GluClRs (B) in co-culture with primary neurons. C. Expanded 
view of a segment from (A) showing isolated IPSCs that rise rapidly to a peak before decaying 
back to baseline. D. Expanded view of a segment from (B) showing isolated IPSCs that decay 
faster than those in (C). E. Inhibition of IPSCs mediated by α GluClRs by picrotoxin. (F-H). 
Group bar plot showing the mean IPSC decay time constant (F), 10-90% rise times (G) and 
peak amplitude (H) of α and αβ GluClRs. ** p < 0.01. Holding potential was –70 mV. 
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Fig 5. Effects of IVM at IPSCs mediated by α and αβ GluClRs. (A-B). A whole-cell recording 
from a HEK293 cell expressing α GluClRs (A) or αβ GluClRs (B) in co-culture with primary 
neurons in the continuous presence of 5 nM IVM. Note the steady increase in inward tonic 
current, which reaches a steady-state plateau at about 17 min in both (A) and (C). C. Expanded 
view of a segment from (A) showing isolated IPSCs, which have larger peak amplitudes and 
rise and decay more slowly than the corresponding IPSCs in the absence of IVM. D. Expanded 
view of a segment from (B) showing isolated IPSCs, which have larger peak amplitudes and 
rise and decay more slowly than the corresponding IPSCs in the absence of IVM. Note that 
the peak amplitude is smaller and the rise and decay times are faster than those in (C). E-G. 
Group bar plot showing the mean IPSC decay time constant (E), 10-90% rise times (F) and 
peak amplitude (G) of α and αβ GluClRs in the presence and absence of IVM. ** p < 0.01, * p 
< 0.05, ## p < 0.01. Holding potential was –70 mV. 
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Fig 6. Single channel properties of β and αβ GluClRs. A. Single receptor currents from patches 
expressing αβ (1:1) GluClRs at 2 µM and 3 mM glutamate and 2 µM glutamate plus 5 nM IVM. 
Note the increase in the duration of the active periods in the presence of IVM. B. Transfections 
of α and β subunits produced two distinct types of single channel activity based on current 
amplitude (1.2 and 0.7 pA). The 1.2 pA activity was the most prominent, accounting for 90% 
of the openings. The active durations of both types increase at higher glutamate 
concentrations and in the presence of IVM. C. Single receptors currents mediated by β GluClRs 
in the presence of the indicated concentrations of glutamate and in 2 µM glutamate plus 5 
nM IVM. Note only one amplitude level (0.4 pA). D. Amplitude histograms for single receptor 
activity from patches expressing αβ GluClRs showing the two main amplitude levels (left) and 
β GluClRs (left). E. Single receptor mean active period durations (left) and intra-activation 
open probability (right) for αβ GluClRs in response to the indicated ligands. F. Single receptor 
mean active period durations (left) and intra-activation open probability (right) for β GluClRs 
in response to the indicated ligands. * p < 0.05. Numbers within the bars indicate the number 
of experiments (patches). Holding potential was –70 mV. 
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Fig 7. IVM-bdpy fluorescent probe. A. Structures of free bdpy fluorophore and IVM-bdpy. B. 
The spectral emission properties of IVM-bdpy and the free bdpy fluorophore. C. IVM-bdpy 
retained activity as shown in the sample oocyte current mediated by α GluClRs. D. Group 
concentration-response plot (n = 6) for IVM-bdpy at α GluClRs, showing reduced potency 
relative to IVM. 
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Fig 8. Membrane partitioning and lateral diffusion of IVM-bdpy. A. Confocal image of a field 
of HEK293 cells before (left) and after 30 min exposure of 500 nM IVM-bdpy (right). B. Group 
plot (n = 5) of the change in fluorescence over time for IVM-bdpy (green) the free bdpy 
fluorophore (black) and the subtraction (IVM-1, yellow). These plots were fitted to 
exponential functions to yield time constants of 6.5 min for the IVM-bdpy, 8.2 min for the 
bdpy fluorophore and 6.0 min for IVM-1. C. An example of a FRAP experiment showing a cell 
after equilibrating in 500 nM IVM-bdpy for 30 min (left), after a circular region (demarcated) 
was pholobleached with laser energy (middle) and after recovery of the bleached region 
(right). D. Group plot (n = 5) of the rate of recovery after pholobleaching. The data were fitted 
to an exponential with a time constant of 1.3 min. 
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General Experimental Detail for Chemical Synthesis 
NMR experiments were performed on a Bruker Avance DRX600 spectrometer and referenced to 
residual 1H signals in the deuterated solvents. ESIMS experiments were carried out on an Agilent 1100 
series LC/MSD instrument. HR-ESIMS data were acquired on a Bruker micrOTOF mass spectrometer 
by direct infusion in MeCN at 3 μL/min using sodium formate clusters as an internal calibrant. All HPLC 
analyses and purifications were performed on Agilent 1100 series LC instruments with corresponding 
detectors, collectors and software inclusively. All chemicals were purchased from Merck, Sigma-
Aldrich or Fluka. Solvents used for general purposes were of at least analytical grade, and solvents 
used for HPLC were of HPLC grade. Phenomenex Luna C8, 10 µm, 210 × 250 mm column (preparative) 
columns were used for HPLC separations. Flash column chromatography was performed on silica gel 
LC60A (40–63 mm, Davisil). 
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Figure S1. Synthetic scheme for IVM analogs, bdpy and IVM-bdpy. Reagents and conditions: (a) 2% H2SO4, 
MeOH, rt, 16 h, (b) DMAP, imidazole, TBDMSCl, DCM, rt, 16 h, (c) MOMCl, DIPEA, DCM, rt, 16 h, (d) 
HF.pyridine, THF, rt, 16 h, (e) DIAD, PPh3, HCOOH, THF, rt, 16 h, (f) NaHCO3, MeOH/THF/H2O, rt, 16 h, (g) 
(1) NaN3, Acetone/H2O, reflux, 16 h, (2) KOH, MeOH/H2O, rt, 16 h, (h) (COCl)2, cat. DMF, DCM, rt, 3 h, (i) 
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TEA/DMAP, DCM, rt, 16 h, (j) 1% TsOH/MeOH, rt, 16 h, (k) (1) TFA, DCM, rt, (2) DDQ, rt, (3) Et3N/BF3, Et2O, 
rt, (l) CuSO4.5H2O, sodium ascorbate, CH3CN, 82 °C, 5 d. 
Preparation of IVM-1 
To a solution of IVM (100 g, 0.11 moL) in MeOH (1 L) was added concentrated sulfuric acid (20 mL) 
dropwise, and the reaction was stirred overnight. Thin layer chromatography (TLC) was utilised to 
monitor the reaction. After removal of the solvent in vacuo, the residue was poured into iced water 
and quenched with Na2CO3. The mixture was extracted with EtOAc (3 × 300 mL). The combined organic 
layers were washed with brine, dried over anhydrous MgSO4, filtered, concentrated in vacuo, and 
purified with silica gel chromatography (EtOAc/hexane = 1:1) to yield IVM-1 (51 g, 76%). 1H NMR (600 
MHz, CDCl3), see Figure S3: δH 5.83 (d, J = 12 Hz, 1H), 5.70 (m, 1H), 5.69 (m, 1H), 5.41 (s, 1H), 5.30 (m, 
1H), 5.29 (m, 1H), 4.70 (dd, J = 14.0, J = 2.0 Hz, 1H), 4.66 (dd, J = 14.0, J = 2.0 Hz, 1H), 4.32 (m, 1H), 4.01 
(br, 1H), 3.97 (d, J = 6 Hz, 1H), 3.67 (m, 1H), 3.25 (m, 1H), 3.20 (m, 1H), 2.53 (m, 1H), 2.30 (m, 2H), 1.98 
(m, 1H), 1.86 (s, 3H), 1.75 (m, 1H), 1.65 (m, 1H), 1.51 (m, 1H), 1.50 (s, 3H), 1.50 (m, 2H), 1.49 (m, 1H), 
1.48 (m, 1H), 1.42 (m, 2H), 1.33 (m, 1H), 1.17 (d, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 0.85 (d, J = 6.6 
Hz, 3H), 0.81 (m, 1H), 0.79 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3), see Figure S4: δC 173.4, 139.7, 
138.6, 137.6, 137.0, 124.7, 120.4, 118.1, 117.1, 97.4, 80.2, 79.2, 77.5, 77.2, 68.5, 68.4, 67.7, 67.3, 45.6, 
41.3, 40.0, 36.7, 35.7, 35.5, 34.2, 31.2, 28.0, 27.4, 19.9, 19.1, 17.4, 14.6, 12.5, 11.7. HRESIMS m/z 
609.3399 [M + Na] + (calcd for C34H50O8Na, 609.3398), see Figure S5. 
 
Preparation of IVM-2 
To a solution of IVM-1 (47.0 g, 0.08 moL), 4-dimethylaminopyridine (DMAP, 0.97 g, 0.008 moL) and 
imidazole (54.5 g, 0.8 moL) in DCM (1 L) at 0 °C was added tert-butyldimethylsilyl chloride (TBDMSCl, 
26.6 g, 0.176 moL), and the reaction was allowed to reach ambient temperature and stirred overnight. 
TLC was utilised to monitor the reaction. After washing with water (300 mL) and brine (300 mL), the 
organic layer was dried over anhydrous MgSO4, filtered, concentrated in vacuo, and purified with silica 
gel chromatography (EtOAc/hexane = 1:5), to yield (i) (47.7 g, 85%). 1H NMR (600 MHz, CDCl3): δH 5.77 
(d, J = 12.0 Hz, 1H), 5.71 (m, 1H), 5.69 (m, 1H), 5.32 (m, 1H), 5.32 (m, 1H), 5.26 (m, 1H), 4.66 (dd, J = 
14.0, J = 2.0 Hz, 1H), 4.56 (dd, J = 14.0, J = 2.0 Hz, 1H), 4.42 (br, 1H), 3.99 (br, 1H), 3.80 (d, J = 6.0 Hz, 
1H), 3.67 (m, 1H), 3.34 (m, 1H), 3.18 (m, 1H), 2.51 (m, 1H), 2.30 (m, 2H), 1.98 (m, 1H), 1.78 (s, 3H), 1.73 
(m, 1H), 1.64 (m, 1H), 1.52 (m, 1H), 1.52 (s, 3H), 1.50 (m, 2H), 1.49 (m, 1H), 1.47 (m, 1H), 1.41 (m, 2H), 
1.31 (m, 1H), 1.16 (d, J = 7.2 Hz, 3H), 0.94 (t, J = 7.2 Hz, 3H), 0.91 (s, 9H), 0.83 (d, J = 6.6 Hz, 3H), 0.82 
(m, 1H), 0.78 (d, J = 6.6 Hz, 3H), 0.12 (s, 6H); 13C NMR (150 MHz, CDCl3): δC 173.7, 140.3, 138.7, 137.3, 
136.5, 124.8, 119.3, 117.3, 117.1, 97.4, 80.1, 80.0, 77.6, 77.2, 69.4, 68.6, 67.9, 67.2, 45.7, 41.3, 39.9, 
36.6, 35.8, 35.5, 34.2, 31.2, 28.0, 27.4, 25.8, 19.9, 19.2, 17.4, 14.6, 12.5, 11.7, -4.6. 
 
To a solution of (i) (10.0 g, 14 mmoL) and N, N-diisopropylethylamine (DIPEA, 4.43g, 68 mmoL) in DCM 
(300 mL) at 0 °C was added chloromethyl methyl ether (MOMCl, 2.53 g, 62 mmoL), and the reaction 
was allowed to reach ambient temperature and stirred for 3 h. TLC was utilised to monitor the 
reaction. After washing with water (100 mL) and brine (100 mL), the organic layer was dried over 
anhydrous MgSO4, filtered, concentrated in vacuo, and purified with silica gel chromatography 
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(EtOAc/hexane = 1:5) to yield (ii) (9.7 g, 91%). 1H NMR (600 MHz, CDCl3): δH 5.78 (m, 1H), 5.71 (m, 1H), 
5.70 (m, 1H), 5.32 (m, 1H), 5.26 (m, 1H), 5.18 (m, 1H), 4.67 (dd, J = 14.0, J = 2.0 Hz, 1H), 4.59 (m, 2H), 
4.57 (dd, J = 14.0, J = 2.0 Hz, 1H), 4.43 (br, 1H), 4.11 (s, 1H), 3.89 (br, 1H), 3.81 (d, J = 6.0 Hz, 1H), 3.67 
(m, 1H), 3.42 (s, 3H), 3.34 (m, 1H), 3.18 (d, J = 8.8 Hz, 1H), 2.53 (m, 1H), 2.31 (m, 2H), 1.98 (m, 1H), 
1.78 (s, 3H), 1.74 (m, 1H), 1.64 (m, 1H), 1.53 (m, 1H), 1.51 (s, 3H), 1.51 (m, 2H), 1.49 (m, 1H), 1.47 (m, 
1H), 1.42 (m, 2H), 1.31 (m, 1H), 1.16 (d, J = 7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H), 0.92 (s, 9H), 0.83 (d, J = 
6.6 Hz, 3H), 0.82 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H), 0.12 (s, 6H); 13C NMR (150 MHz, CDCl3): δC 173.8, 
140.2, 137.5, 137.3, 135.2, 124.7, 119.3, 118.3, 117.3, 97.4, 95.5, 82.6, 80.1, 80.1, 77.2, 69.5, 68.6, 
67.9, 67.2, 56.1, 45.7, 41.3, 39.7, 36.8, 35.8, 35.5, 34.3, 31.2, 28.0, 27.4, 25.9, 20.0, 19.6, 17.4, 15.0, 
12.5, 11.7, -4.6. 
 
TsOH (2 g) was dissolved in methanol (200 mL), followed by the addition of (ii) (10.8 g, 14.5 mmoL), 
and the reaction was stirred at ambient temperature overnight. TLC was utilised to monitor the 
reaction. After removal of solvent in vacuo, the residue was purified by flash column chromatography 
(EtOAc/hexane = 1:2) to yield IVM-2 (7.9 g, 86%). 1H NMR (600 MHz, CDCl3), see Figure S6: δH 5.70 (m, 
1H), 5.70 (m, 1H), 5.40 (br, 1H), 5.30 (m, 1H), 5.18 (d, J = 12.0 Hz, 1H), 4.68 (dd, J = 14.0, J = 2.0 Hz, 
1H), 4.64 (dd, J = 14.0, J = 2.0 Hz, 1H), 4.59 (m, 2H), 4.28 (br, 1H), 4.08 (s, 1H), 3.95 (d, J = 6.0 Hz, 1H), 
3.89 (br, 1H), 3.67 (m, 1H), 3.42 (s, 3H), 3.25 (m, 1H), 3.18 (d, J = 8.8 Hz, 1H), 2.52 (m, 1H), 2.38 (d, J = 
7.2 Hz, 1H), 2.28 (m, 2H), 1.97 (m, 1H), 1.86 (s, 3H), 1.75 (m, 1H), 1.65 (m, 1H), 1.53 (m, 1H), 1.50 (s, 
3H), 1.50 (m, 2H), 1.50 (m, 1H), 1.47 (m, 1H), 1.42 (m, 2H), 1.31 (m, 1H), 1.16 (d, J = 7.2 Hz, 3H), 0.95 
(t, J = 7.2 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H), 0.80 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, 
CDCl3), see Figure S7: δC 173.6, 139.7, 138.0, 137.7, 135.1, 124.6, 120.4, 118.3, 118.1, 97.6, 95.5, 82.6, 
80.2, 79.1, 77.2, 68.5, 68.5, 67.7, 67.2, 56.1, 45.7, 41.3, 39.8, 36.8, 35.8, 35.5, 34.2, 31.2, 28.0, 27.4, 
19.9, 19.5, 17.4, 14.9, 12.5, 11.7. HRESIMS m/z 653.3661 [M + Na] + (calcd for C36H54O9Na, 653.3660), 
see Figure S8. 
 
Preparation of IVM-3 
To a solution of IVM-2 (500 mg, 0.8 mmoL), triphenylphosphine (1250 mg, 4.8 mmoL) and formic acid 
(220 mg, 4.8 mmoL) in THF (30 mL) at ambient temperature was added diisopropyl azodicarboxylate 
(DIAD, 962 mg, 4.8 mmoL), and the reaction was stirred overnight. TLC was utilised to monitor the 
reaction. After removal of the solvent in vacuo, the residue was purified by flash column 
chromatography (EtOAc/hexane = 1:4) to yield (iii) (422 mg, 81%).  1H NMR (600 MHz, CDCl3): δH 8.18 
(s, 1H), 5.89 (m, 1H), 5.72 (m, 1H), 5.71 (m, 1H), 5.62 (br, 1H), 5.40 (br, 1H), 5.35 (m, 1H), 5.18 (m, 1H), 
4.60 (d, J = 7.2 Hz, 1H), 4.60 (br, 2H), 4.57 (d, J = 7.2 Hz, 1H), 3.89 (br, 1H), 3.75 (s, 1H), 3.68 (m, 1H), 
3.43 (s, 3H), 3.20 (d, J = 9.0 Hz, 1H), 3.08 (m, 1H), 2.53 (m, 1H), 2.32 (m, 1H), 2.27 (m, 1H), 1.97 (m, 
1H), 1.78 (s, 3H), 1.77 (m, 1H), 1.64 (m, 1H), 1.54 (m, 1H), 1.51 (m, 1H), 1.50 (s, 3H), 1.50 (m, 2H), 1.47 
(m, 1H), 1.43 (m, 2H), 1.34 (m, 1H), 1.16 (d, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 0.85 (d, J = 6.6 Hz, 
3H), 0.80 (m, 1H), 0.79 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δC 173.1, 160.3, 138.2, 138.1, 
135.2, 133.2, 124.8, 121.7, 120.1, 118.3, 97.4, 95.5, 83.9, 82.6, 77.3, 75.8, 70.3, 68.6, 68.1, 67.3, 56.2, 
46.3, 41.3, 40.0, 36.8, 35.8, 35.5, 34.2, 31.2, 28.0, 27.4, 19.5, 18.9, 17.5, 14.9, 12.5, 11.7. 
 
94 
 
To a solution of (iii) (345 mg, 0.52 mmoL) in THF/MeOH/H2O (10/5/0.5 mL) at ambient temperature 
was added sodium bicarbonate (88 mg, 1.05 mmoL), and the reaction was stirred overnight. TLC was 
utilised to monitor the reaction. The mixture was extracted with DCM (3 × 15 mL). The combined 
organic layers were washed with brine, dried over anhydrous MgSO4, filtered, concentrated in vacuo, 
and purified with silica gel chromatography (EtOAc/hexane = 1:2) to yield IVM-3 (313 mg, 95%). 1H 
NMR (600 MHz, CDCl3), see Figure S9: δH 5.85 (m, 1H), 5.70 (m, 1H), 5.70 (m, 1H), 5.42 (br, 1H), 5.34 
(m, 1H), 5.18 (m, 1H), 4.59 (m, 2H), 4.59 (m, 2H), 4.12 (br, 1H), 4.01 (br, 1H), 3.89 (br, 1H), 3.83 (br, 
1H), 3.67 (m, 1H), 3.42 (s, 3H), 3.19 (d, J = 9.0 Hz, 1H), 3.04 (m, 1H), 2.52 (m, 1H), 2.32 (m, 1H), 2.26 
(m, 1H), 1.97 (m, 1H), 1.90 (s, 3H), 1.76 (m, 1H), 1.64 (m, 1H), 1.53 (m, 1H), 1.50 (m, 1H), 1.50 (m, 2H), 
1.50 (s, 3H), 1.47 (m, 1H), 1.42 (m, 2H), 1.32 (m, 1H), 1.16 (d, J = 7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H), 
0.85 (d, J = 6.6 Hz, 3H), 0.80 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3), see Figure S10: 
δC 173.7, 139.2, 137.8, 137.4, 135.1, 124.8, 120.9, 118.3, 117.0, 97.4, 95.5, 85.7, 82.6, 77.3, 76.0, 69.4, 
68.5, 68.2, 67.3, 56.2, 46.5, 41.3, 39.9, 36.9, 35.8, 35.5, 34.2, 31.2, 28.0, 27.4, 19.6, 19.3, 17.5, 14.9, 
12.5, 11.7. HRESIMS m/z 653.3660 [M + Na] + (calcd for C36H54O9Na, 653.3660), see Figure S11. 
 
Preparation of bdpy 
To a suspension of 4-hydroxybenzaldehyde (3.66 g, 30 mmoL) and potassium carbonate (16 g, 120 
mmoL) in acetone (250 mL) was added propargyl bromide (14.3 g, 120 mmoL), and the reaction was 
stirred at ambient temperature overnight. TLC was utilised to monitor the reaction. After filtration, 
the filtrate was evaporated in vacuo and the residue was partitioned between EtOAc (200 mL) and 
water (200 mL). The organic layer was washed with brine, dried over MgSO4, filtered, concentrated in 
vacuo to yield, and purified with silica gel chromatography (EtOAc/hexane = 1:4) to yield (iv) (4.2 g, 
88%). 1H NMR (600 MHz, CDCl3): δH = 9.91 (s, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 4.78 
(s, 2H), 2.57 (s, 1H); 13C NMR (150 MHz, CDCl3): δC = 190.8, 162.4, 131.9, 130.6, 115.2, 77.5, 76.4, 55.9. 
 
To a solution of (iv) (230 mg, 1.44 mmoL) and 3-ethyl-2, 4-dimethylpyrrole (v) (407 mg, 3.3 mmoL) in 
DCM (15 mL) was added TFA (110 mg, 0.96 mmoL). The dark mixture was stirred at r.t. until total 
disappearance of (iv) (TLC). Then DDQ (523 mg, 2.3 mmoL) was added, and 5 min later TEA (1170 mg, 
11.5 mmoL) and trifluoroborate etherate (2450 mg, 17.25 mmoL) were added successively. TLC was 
utilised to monitor the reaction. The mixture was filtered through a pad of silica. After removal of 
solvent in vacuo, the residue was purified by flash column chromatography (EtOAc/hexane = 1:15) to 
yield bdpy (130 mg, 20.8% over 3 steps). 1H NMR (600 MHz, CDCl3): δH = 7.19 (d, J = 8.0 Hz, 2H), 7.08 
(d, J = 8.0 Hz, 2H), 4.76 (s, 2H), 2.56 (t, J = 2.0 Hz, 1H), 2.53 (s, 6H), 2.30 (q, J = 7.6 2H), 1.33 (s, 6H), 
0.98 (t, J = 7.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δC = 158.0, 153.6, 139.9, 138.4, 132.7, 131.1, 129.5, 
128.9, 115.5, 78.1, 75.9, 56.0, 17.1, 14.6, 12.5, 11.8. 
 
Preparation of IVM-bdpy 
A solution of acetone/H2O (30 mL/10 mL) of ethyl 4-bromobutyrate (vi) (3.9 g, 20 mmoL) and sodium 
azide (2.6 g, 40 mmoL) was heated under reflux overnight. Then acetone was removed in vacuo and 
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the residue was partitioned between DCM (30 mL) and water (30 mL). The mixture was extracted with 
DCM (3 × 20 mL), and the combined organic extracts were washed with water, brine, dried over MgSO4 
and evaporated to dryness to give the azido ester as colourless oil. The obtained azido acid ethyl ester 
was dissolved in MeOH/water (30 mL/30 mL) solution, cooled to 0 °C and KOH (2.2 g, 40 mmol) was 
added. The reaction mixture was stirred at room temperature overnight. The methanol was removed 
in vacuo and the residue was partitioned between DCM (30 mL) and water (30 mL). The aqueous layer 
was extracted with DCM (2 × 20 mL), acidified to pH 1 with 1N aqueous HCl and extracted with EtOAc 
(4 × 30 mL). The combined organic layers were dried over MgSO4 and evaporated to dryness to afford 
(vii) (2.2 g, 85%) as colorless oil. To a solution of (vii) (500 mg, 3.88 mmoL) in DCM (10 mL) was added 
oxalyl chloride (1500 mg, 11.6 mmoL) at ambient temperature, followed by the addition of 3 drops of 
DMF. The mixture was stirred for another 3 h, and then the solvent was removed under N2 to yield 
(viii), which was used without further purification. 
 
To a solution of (i) (1360 mg, 1.94 mmoL), TEA (589 mg, 5.82 mmoL) and DMAP (710 mg, 5.82 mmoL) 
in DCM (20 mL) at ambient temperature was added (viii) (reaction mixture, 3.88 mmoL), and the 
reaction was stirred overnight. TLC was utilised to monitor the reaction. The mixture was poured into 
water (25 mL) and extracted with DCM (3 × 20 mL). The combined organic layers were washed with 
brine, dried over anhydrous MgSO4, filtered, concentrated in vacuo to yield, and purified with silica gel 
chromatography (EtOAc/hexane = 1:4) to yield (ix) (1200 mg, 76%). 1H NMR (600 MHz, CDCl3): δH 5.81 
(m, 1H), 5.77 (m, 1H), 5.67 (m, 1H), 5.32 (br, 1H), 5.30 (m, 1H), 5.16 (br, 1H), 4.98 (m, 1H), 4.68 (d, J = 
7.2 Hz, 1H), 4.58 (d, J = 7.2 Hz, 1H), 4.44 (m, 1H), 4.17 (s, 1H), 3.82 (d, J = 5.6 Hz, 1H), 3.63 (m, 1H), 3.39 
(t, J = 6.6 Hz, 2H), 3.37 (br, 1H), 3.19 (d, J = 9.0 Hz, 1H), 2.64 (m, 1H), 2.53 (m, 2H), 2.26 (m, 2H), 1.99 
(m, 1H), 1.96 (m, 2H), 1.79 (s, 3H), 1.71 (m, 1H), 1.64 (m, 1H), 1.58 (s, 3H), 1.55 (m, 1H), 1.51 (m, 1H), 
1.51 (m, 2H), 1.47 (m, 1H), 1.43 (m, 2H), 1.33 (m, 1H), 1.03 (d, J = 7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H), 
0.93 (s, 9H), 0.85 (d, J = 6.6 Hz, 3H), 0.84 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H), 0.13 (s, 6H); 13C NMR (150 
MHz, CDCl3): δC 173.9, 171.8, 141.2, 137.5, 136.2, 134.6, 125.4, 119.0, 117.7, 117.3, 97.5, 80.2, 80.1, 
78.9, 76.9, 69.4, 68.7, 67.9, 67.1, 50.6, 45.7, 41.3, 38.9, 36.7, 35.8, 35.5, 34.2, 31.2, 31.1, 28.0, 27.3, 
25.9, 24.3, 20.0, 18.9, 18.4, 17.4, 14.7, 12.5, 12.0, -4.6. 
 
TsOH (100 mg) was dissolved in methanol (10 mL), followed by the addition of ix (522 mg, 1.94 mmoL), 
and the reaction was stirred at ambient temperature overnight. TLC was utilised to monitor the 
reaction. After removal of solvent in vacuo, the residue was purified by flash column chromatography 
(EtOAc/hexane = 1:2) to yield (x) (350 mg, 78%). 1H NMR (600 MHz, CDCl3): δH 5.86 (m, 1H), 5.78 (m, 
1H), 5.68 (m, 1H), 5.42 (br, 1H), 5.33 (m, 1H), 5.16 (br, 1H), 4.98 (m, 1H), 4.70 (d, J = 7.2 Hz, 1H), 4.65 
(d, J = 7.2 Hz, 1H), 4.29 (d, J = 6.0 Hz, 1H), 3.97 (d, J = 6.6 Hz, 1H), 3.63 (m, 1H), 3.39 (t, J = 6.6 Hz, 2H), 
3.27 (m, 1H), 3.19 (d, J = 9.0 Hz, 1H), 2.64 (m, 1H), 2.53 (m, 2H), 2.25 (m, 2H), 1.98 (m, 1H), 1.95 (m, 
2H), 1.87 (s, 3H), 1.72 (m, 1H), 1.64 (m, 1H), 1.57 (s, 3H), 1.55 (m, 1H), 1.51 (m, 1H), 1.50 (m, 2H), 1.47 
(m, 1H), 1.43 (m, 2H), 1.34 (m, 1H), 1.04 (d, J = 7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H), 0.85 (d, J = 6.6 Hz, 
3H), 0.82 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δC 173.6, 171.8, 140.6, 137.9, 
136.7, 134.5, 125.3, 120.1, 118.0, 117.7, 97.5, 80.3, 79.1, 78.8, 76.9, 68.6, 68.4, 67.7, 67.0, 50.6, 45.6, 
41.2, 39.0, 36.8, 35.7, 35.5, 34.1, 31.2, 31.1, 28.0, 27.3, 24.3, 19.9, 18.8, 17.4, 14.6, 12.5, 12.0. 
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A mixture of (x) (69.7 mg, 0.1 mmoL), bpdy (43 mg, 0.1 mmoL), copper sulfate pentahydrate (2.5 mg, 
0.01 mmoL) and sodium ascorbate (2.0 mg, 0.01 mmoL) in acetonitrile (10 mL) was heated to 82 °C 
for 5 days under nitrogen. TLC were utilised to monitor the reaction. After removal of solvent in vacuo, 
the residue was purified by flash column chromatography (EtOAc/hexane = 1:1) to yield IVM-bdpy (81 
mg, 71%). 1H NMR (600 MHz, CD3OD), see Figure S12: δH 8.10 (s, 1H), 7.19 (s, 1H), 7.19 (s, 1H), 5.95 
(m, 1H), 5.81 (m, 1H), 5.67 (m, 1H), 5.42 (s, 1H), 5.24 (s, 2H), 5.20 (br, 1H), 5.13 (m, 1H), 5.00 (m, 1H), 
4.65 (d, J = 7.2 Hz, 1H), 4.58 (d, J = 7.2 Hz, 1H), 4.52 (t, J = 7.2 Hz, 2H), 4.23 (m, 1H), 3.77 (d, J = 6.0 Hz, 
1H), 3.68 (m, 1H), 3.24 (m, 1H), 3.23 (s, 1H), 2.78 (m, 1H), 2.51 (q, J = 7.2 Hz, 2H), 2.46 (s, 3H), 2.34 (q, 
J = 7.8 Hz, 2H), 2.25 (m, 2H), 2.25 (m, 2H), 2.20 (m, 1H), 1.89 (m, 1H), 1.82 (s, 3H), 1.60 (m, 1H), 1.59 
(s, 3H), 1.56 (m, 1H), 1.51 (m, 1H), 1.48 (m, 2H), 1.46 (m, 1H), 1.41 (m, 2H), 1.35 (s, 3H), 1.19 (m, 1H), 
1.05 (d, J = 7.2 Hz, 3H), 0.98 (t, J = 7.8 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.83 (m, 
1H), 0.78 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CD3OD), see Figure S13: δC 173.3, 173.1, 160.4, 154.6, 
144.8, 142.5, 142.0, 139.7, 137.1, 137.1, 136.2, 134.0, 132.3, 130.8, 129.5, 127.1, 125.4, 121.4, 120.1, 
118.9, 116.8, 98.9, 82.1, 81.8, 80.3, 77.9, 70.1, 68.9, 68.7, 68.6, 62.6, 50.5, 47.0, 42.8, 40.3, 37.7, 36.8, 
36.8, 35.0, 32.5, 31.6, 29.2, 28.4, 26.7, 19.8, 19.4, 17.8, 17.8, 15.1, 15.1, 13.0, 12.6, 12.5, 12.2. HRESIMS 
m/z 1154.6172 [M + Na] + (calcd for C64H84BF2N5O10Na, 1154.6172), see Figure S14. 
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Figure S2. 1H NMR (DMSO-d6, 600 MHz) spectra of IVM 
 
98 
 
 
Figure S3. 13C NMR (DMSO-d6, 150 MHz) spectra of IVM 
 
Figure S4. 1H NMR (CDCl3, 600 MHz) spectra of IVM-1 
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Figure S5. 13C NMR (CDCl3, 150 MHz) spectra of IVM-1  
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Figure S6. HRMS data for IVM-1 
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Figure S7. 1H NMR (CDCl3, 600 MHz) spectra of IVM-2 
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Figure S8. 13C NMR (CDCl3, 150 MHz) spectra of IVM-2 
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Figure S9. HRMS data for IVM-2 
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Figure S10. 1H NMR (CDCl3, 600 MHz) spectra of IVM-3 
 
 Figure S11. 13C NMR (CDCl3, 150 MHz) spectra of IVM-3 
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Figure S12. HRMS data for IVM-3 
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Figure S13. 1H NMR (MeOH-d4, 600 MHz) spectra of IVM-bdpy  
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Figure S14. 13C NMR (MeOH-d4, 150 MHz) spectra of IVM-bdpy  
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Figure S15. HRMS data for IVM-bdpy 
  
4 
Effects of glutamate and IVM on single 
glutamate-gated chloride channels of the 
parasitic nematode H. contortus 
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Background 
Many studies have been carried out on many pLGIC family including GlyRs and GABAARs to 
determine how agonists binds and activates the receptor. However, a detailed study on biophysical 
properties of GluClRs has not been performed. Previous studies shows that a substitution of G36’A 
in TM3 domain causes reduced sensitivity to IVM. To identify whether it is the binding of IVM 
molecule itself or the intrinsic properties of the receptor we employed single channel 
electrophysiology to determine the kinetic properties of α HcoGluClRs and α G36’A HcoGluClRs. 
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Abstract (250 words) 
Ivermectin (IVM) is a widely-used anthelmintic that works by binding to and activating glutamate-
gated chloride channel receptors (GluClRs) in nematodes. The resulting chloride flux inhibits the 
pharyngeal muscle cells and motor neurons of nematodes, causing death by paralysis or starvation. 
IVM resistance is an emerging problem in many pest species, necessitating the development of 
novel drugs. However, drug optimisation requires a quantitative understanding of GluClR activation 
and modulation mechanisms. Here we investigated the biophysical properties of homomeric α (avr-
14b) GluClRs from the parasitic nematode, H. contortus, in the presence of glutamate and IVM. The 
receptor proved to be highly responsive to low nanomolar concentrations of both compounds. 
Analysis of single receptor activations demonstrated that the GluClR oscillates between multiple 
functional states upon the binding of either ligand. The G36’A mutation in the third transmembrane 
domain, which was previously thought to hinder access of IVM to its binding site, was found to 
decrease the duration of active periods and increase receptor desensitisation. On an ensemble 
macropatch level the mutation gave rise to enhanced current decay and desensitisation rates. 
Because these responses were common to both glutamate and IVM, and were observed under 
conditions where agonist binding sites were likely saturated, we infer that G36’A affects the intrinsic 
properties of the receptor with no specific effect on IVM binding mechanisms. These unexpected 
results provide new insights into the activation and modulatory mechanisms of the H. contortus 
GluClRs and provide a mechanistic framework upon which the actions of drugs can be reliably 
interpreted. 
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Author Summary (165 words) 
IVM is a gold standard anti-parasitic drug that is used extensively to control invertebrate parasites 
pest species. The drug targets the glutamate-gated chloride channel receptor (GluClR) found on 
neurons and muscle cells of these organisms, causing paralysis and death. However, IVM resistance 
is becoming a serious problem in human and animal health, as well as human food production. We 
provide the first comprehensive investigation of the functional properties of the GluClR of H. 
contortus, which is a major parasite in grazing animals, such as sheep and goats. We compared 
glutamate and IVM induced activity of the wild-type and a mutant GluClR, G36’A, that markedly 
reduces IVM sensitivity in wild populations of pests. Our data demonstrate that the mutation 
reduces IVM sensitivity by altering the functional properties of the GluClR rather than specifically 
affecting the binding of IVM, even though the mutation occurs at the IVM binding site. This study 
provides a mechanistic framework upon which the actions of new candidate anthelmintic drugs can 
be interpreted. 
  
115 
 
Introduction 
Pentameric ligand gated ion channels (pLGICs) are membrane-bound receptors that facilitate the 
diffusion of ions across cell membranes in response to the binding of agonists. The glutamate-gated 
chloride channel receptor (GluClR), first identified in arthropods, such as insects and crustaceans [1-
3], is an anion-selective pLGIC found at neuronal and neuromuscular inhibitory synapses [4]. GluClRs 
are also present in other major metazoan phyla, including platyhelminths and nematodes [4], but 
have not yet been identified in vertebrates. GluClRs can exist as homo- or hetero-pentamers [5]. 
Crystal structures of the homomeric GluClR from the nematode, C. elegans, have recently been 
determined in ligand-bound [6] and apo [7] states. 
The mechanism of agonist activation has been studied extensively in vertebrate pLGIC 
members, such as the glycine (GlyR) [8], acetylcholine (AChR) [9-11], serotonin (5-HT3R) [12] and 
GABAA (GABAAR) [13-15] receptors, as well as ELIC, which is a bacterial pLGIC [16]. A detailed study 
of the biophysical properties of GluClR activation has not been undertaken, even though GluClRs 
constitute a major group of pLGICs, many organisms that express them are serious parasitic pests, 
or vectors for disease transmission and they are a major target for anthelminthic drugs. For instance, 
O. volvulus and W. bancrofti are nematodes that cause river blindness (onchocerciasis) and 
elephantiasis (lymphatic filariasis), respectively, in humans. Another nematode, H. contortus [17] is 
a serious pathogen in ruminant agricultural animals such as cattle, sheep and goats. The sea lice 
(arthropod) species C. rogercresseyi [18] and L. salmonis [19], ravage salmon and trout farming 
industries worldwide. The cereal cyst nematode H. avenae devastates broad acre cereal crops across 
temperate wheat-producing regions of the world [20, 21]. A. gambiae is the mosquito vector that 
transmits malaria in over 90% of world-wide cases [22]. Macrocyclic lactones (MLs) such as 
ivermectin (IVM), moxidectin, abamectin and emamectin are widely used to control all of these, as 
well as many other, nematode and arthropod pests [23]. IVM works by activating GluClRs in 
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pharyngeal muscle cells and motor neurons of these organisms, thereby causing death by flaccid 
paralysis or starvation [24]. Unfortunately, however, IVM resistance is emerging as a serious 
problem in many pest species [21, 25-28] prompting the need for new generation treatments. 
Functional and crystallographic studies have recently delineated the binding pocket of IVM 
and identified potential residues that IVM interacts with [6, 29, 30]. The main structure of the pocket 
is formed by first (TM1) and third (TM3) transmembrane domains of adjacent receptor subunits, at 
the level of the upper leaflet of the cell membrane [6]. Site-directed mutagenesis of transmembrane 
domains has identified critical residues that drastically affect IVM potency in the avr-14b subunit of 
H. contortus, such as TM3-G36’ [29] and TM1-P230 [30], and in the α subunit of C. elegans, such as 
TM1-L279 and TM1-F276 [31, 32]. The glutamate binding site and TM3 domain are also sites that 
harbour mutations in wild ML-resistant strains of C. elegans [26], whereas ML resistance in wild 
isolates of pest species have been attributed to mutations at, TM3-30’ in P. xylostella [33] and TM3-
36’ in T. urticae [34, 35]. Of particular note, a Gly at the 36’ position is thought to be essential for 
exquisite IVM [29] and abamectin [33] sensitivity, and larger substitutions at this location were 
proposed to reduce ML sensitivity by hindering access to its binding site [30, 33, 36]. However, the 
effects of these mutations are generally evaluated using functional assays that lack the resolution 
needed to distinguish discrete functional states in the activation process. A detailed mechanistic 
understanding of how wild-type and mutated receptors respond to glutamate is a prerequisite to 
understanding how IVM and other modulating ligands affect the receptor. This aim is best achieved 
through the study of single channel currents mediated by individual receptors [37]. Without a 
quantitative understanding of activation and modulation mechanisms of the receptor, attempts to 
design drugs with higher potency and selectivity for the receptor would be intractable. 
Four GluClR subunits have been identified in H. contortus [α3A (avr-14a), α3B (avr-14b), GLC-
3, GLC-5, GLC-6, β and α], all of which express on motor neuron commissures [38-41]. However, the 
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native stoichiometric combinations of these subunits is unknown [4]. Here we investigated 
homomeric receptors comprising the avr-14b subunit, which is also expressed in pharyngeal 
neurons [38, 39]. We will refer to this subunit as α (avr-14b). In heterologous expression systems, 
homomeric receptors comprising either α (avr-14b) [29, 42] or α subunits form high affinity IVM 
binding sites, whereas the β subunit homomers do not [43]. 
In this study we investigated the biophysical properties of the homomeric α (avr-14b) GluClR 
from H. contortus as: 1) H. contortus is a major parasitic pest of domestic ruminant animals, 2) IVM 
is used widely to control H. contortus, 3) IVM resistance has emerged as a major problem in this 
species [44], and 4) GluClRs comprising or containing the α (avr-14b) subunit are most likely the 
major biological IVM target in this species [4, 24]. Here we sought to quantify the activation 
properties of this receptor in the presence of glutamate and IVM, and to explore the mechanism by 
which the TM3-G36’A mutation reduces IVM sensitivity to a level that is similar to vertebrate GlyRs 
and GABAARs [29, 45-47]. 
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Results 
Single channel conductance and current-voltage (i-V) relations of (avr-14b) GluClRs 
Single receptor currents (Fig. 1A) were measured and plotted as a function of voltage (Fig. 1B) to 
determine the single channel conductance of the receptor. Using equation 1 and a mean current 
amplitude of 1.80 ± 0.03 pA (n = 7, at −70 mV), the estimated single channel conductance of the 
homomeric GluClR was 22.9 ± 0.3 pS. The i-V was nearly linear (Fig. 1B). The slight inward 
rectification and relatively small conductance of the homomeric GluClR is very similar to that 
determined for ternary GABAARs containing, α, β and γ subunits [13, 14]. A recent study has also 
estimated the current amplitude of the heteromeric GluClR of C. elegans at  90 mV to be ∼ 1.9 pA 
[31]. 
Glutamate concentration-dependent properties of wild-type GluClRs 
Single channel activity was recorded in the presence of a broad range of L-glutamate concentrations 
(10 mM – 5 nM) to determine the receptor’s sensitivity to glutamate, the active durations of single 
receptors, the total time spent in conducting configurations (PO) and the shut and open dwell 
characteristics within each active period. Continuous sweeps of single channel activity, recorded 
from a patch in the presence of 200 µM glutamate is shown in Fig. 1C. At this and higher 
concentrations the activity of single receptors occurred as clearly defined periods of variable 
duration, termed ‘activations’, where the receptor oscillated between conducting and non-
conducting configurations. These active periods were interrupted by relatively long intervals of 
inactivity where the receptor adopted desensitised states. These states are distinct from ligand-
bound shut states both structurally [48, 49] and functionally [50]. With few exceptions, desensitised 
states are much longer-lived than shut states. Mean dwell times of the shut and open durations 
within activations were generated by plotting histograms and fitting these to mixtures of 
exponentials (Fig. 1D). We employ widely used and up-to-date terminology here, and it is virtually 
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identical to the nomenclature as used by Changeux in his later publications. The shut dwell data 
were best described by two exponential components, whereas the open dwell histogram was best 
fit to three exponential components. The dwell time constants were similar when the receptors 
were exposed to 10 mM and 1 mM glutamate, but at 200 µM the time constant of the longer shut 
component increased (S1 Table). 
 Reducing the glutamate concentration to 30 µM resulted in similar single channel activity 
(Fig. 1E). The number of components and the time constants of both dwell histograms (Fig. 1F), 
appeared little changed, except for a further increase in the time constant of the longer shut 
component (S1 Table). In addition, the mean duration of the active periods appeared to become 
shorter as glutamate concentration decreased (S2 Table). 
 At low glutamate concentrations there appeared to be a transition from mostly tightly 
grouped to loosely grouped periods of activity and isolated open-shut events. For example, 2 µM 
glutamate elicited activity that comprised a mixture of isolated open-shut events and activations 
consisting of openings and shuttings in rapid succession, as with the higher glutamate 
concentrations. However, these latter more complex activations were more likely to occur in shorter 
bursts (Fig. 2A). The dwell histograms also exhibited two shut and three open components with 
similar time constants to those for the higher concentrations of glutamate, but the time constant of 
the longer shut component continued to increase and the fraction of the longest open time constant 
diminished (Fig. 2B, S1 Table). 30 nM glutamate elicited activations that occurred as bursts of loosely 
spaced openings and brief open-shut events (Fig. 2C). Moreover, long stretches of record 
corresponding to receptor desensitisation were mostly absent. The dwell histograms revealed 
changes to both shut and open components. Here both shut components increased and the longest 
open component disappeared (Fig. 2D, S1 Table). 
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 As 30 nM, glutamate was effective at eliciting single channel activity the concentration was 
lowered even further, to 5 nM. Remarkably, even at this concentration GluClRs were activated. Most 
of the activity comprised simple shut-open events, but the occasional activation of loosely spaced 
openings was also apparent. In contrast, in the absence of glutamate, receptor openings were 
extremely rare, brief and essentially negligible (Fig. 3A). These data show that 1) the homomeric 
GluClRs are exquisitely sensitive to glutamate and 2) from 2 µM glutamate and below, the activity 
becomes increasingly simple and brief, likely reflecting an effect consistent with agonist dissociation 
from partially liganded receptors. The dwell histograms derived from 30 nM and 5 nM glutamate 
showed distinct differences compared to those of higher concentrations. Here both the longer and 
briefer shut components increased (Fig. 3B) and the third, longest open component was absent, 
whereas the remaining two open components decreased (Fig. 3C, S1 Table). The invariant open 
dwell components for concentrations ≥ 2 µM glutamate are consistent with an optimal degree of 
ligation for receptor activation, as has been shown for the GlyR [8]. In contrast, the decrease in the 
remaining two open component time constants at nanomolar concentrations of glutamate is 
consistent with sub-optimal activation of receptors. We infer that at 30 nM and 5 nM each receptor 
is bound to fewer ligand molecules than at the higher concentrations, giving rise to openings with 
briefer lifetimes [51]. We also infer that the steadily increasing longer shut component at ≤ 200 µM 
glutamate is additional evidence that the receptors are able to activate without all glutamate 
binding sites being occupied [8]. 
The total time spent in open states was also compared across glutamate concentrations. This 
analysis demonstrates that PO increases as a function of glutamate concentration (Fig. 3D). 
Consistent with the inference that the receptors are highly sensitive to glutamate, the PO at 
glutamate concentrations ≥ 10 µM were all > 0.90. PO showed a significant decrease at 2 µM 
glutamate and dropped to 0.21 at 30 nM and 0.14 at 5 nM (Fig. 3D, S2 Table). A Hill fit to the PO plot 
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revealed a maximum of 0.99, an EC50 of 70 nM and a Hill coefficient of 0.82. The mean duration of 
activations was also plotted and showed that active durations declined from ∼500 ms to ∼330 ms 
between 10 mM and 30 µM glutamate. Fitting the data to a Hill equation produced an EC50 of 31 
µM, a Hill coefficient of 0.56, a maximum duration of 500 ms and a minimum of ∼80 ms (Fig. 3E). 
Macropatch recordings of glutamate-gated currents 
The activation properties of homomeric GluClRs were also investigated at an ensemble current level 
using rapid solution exchange [14, 52] of glutamate onto macropatches. As GluClRs are located at 
inhibitory synapses, these experiments were carried out to mimic synaptic activation conditions by 
determining the response of many (~20-100) receptors to rapid glutamate exposure. By avoiding 
the distorting effects of receptor desensitisation encountered with slower agonist application 
methods, rapid solution exchange techniques also establish a more accurate ligand concentration − 
peak current relationship. Peak current was achieved by rapidly applying glutamate for either 50 ms 
(5 mM – 20 µM) or 500 ms (10 µM – 0.5 µM, Fig. 4A). These data were fitted to a Hill equation, 
yielding an EC50 for glutamate of 43 μM and a Hill slope of 0.8 (Fig. 4B). Whole-cell experiments on 
the same GluClR produced an EC50 for glutamate of ∼15 μM and a Hill slope of ∼1.7 [29]. The 2-3 
fold difference in EC50 and Hill slope between whole-cell and macropatch data are consistent with 
open and desensitised states, which have a higher affinity for ligand, having made a significant 
contribution to the whole-cell data. 
Similar experiments were carried out to determine the relationship between the activation 
rate of the current and agonist concentration. Normalised examples of these recordings are 
illustrated in Fig. 4C and the group data are summarised in Fig. 4D. A Hill fit to this plot produced an 
EC50 of 0.95 mM and a Hill slope of 1.0. The upper asymptote of the activation plot was ~9000 s−1, 
representing the maximum activation rate [52, 53], whereas the lower level was ~10 s−1. 
Single channel properties of the G36’A mutation 
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Homomeric GluClRs containing the G36’A mutation exhibit a markedly reduced IVM sensitivity 
(EC50) when recorded in whole-cell configuration [29]. However, any changes to the intrinsic 
properties of the receptor conferred by the mutation have yet to be examined in mechanistic detail. 
G36’A-containing receptors were first examined on a single channel level. Applied glutamate 
elicited a similar current amplitude to wild-type receptors, suggesting the G36’A had no appreciable 
effect on channel conductance (Fig. 5A). A current amplitude of 1.81 ± 0.02 pA (n = 7) for the mutant 
at −70 mV yielded a conductance of 23.0 ± 0.2 pS, if it is assumed that under the same recording 
conditions the reversal potential is similar to that for wild-type. 
However, moderate to high (30 µM – 10 mM) concentrations of glutamate revealed two 
distinct types of activations in the mutant receptor (Fig. 5A), whereas the same concentration of 
glutamate elicited homogeneous activations in the wild-type receptor (Fig. 5B). The two activation 
modes mediated by the mutant GluClR were quantified on the basis of PO and duration only for 1 
mM glutamate. The analysis revealed a very low PO activation mode of 0.14 ± 0.02 (n = 6) and mean 
active periods of 1333 ± 222 ms duration and a higher, more wild-type like mode with a PO of 0.87 
± 0.05 and a mean active duration of 309 ± 62 ms (Fig. 5C). In contrast, 1 mM glutamate produced 
a single PO of 0.99 (S2 Table) in the wild-type receptor consistent with fewer shuttings within each 
activation (Fig. 5D). The two activation modes observed in the mutant receptors were pooled for 
further analysis for all concentrations where they were apparent so as to determine the net effect 
of the mutation on PO and active durations, and facilitate a more direct comparison to wild-type 
receptors. The dwell histograms for the mutant receptor at 1 mM glutamate required two shut and 
three open components (Fig. 5E), but the longer shut component was substantially increased 
compared to wild-type receptors (Fig. 5F) and the two longest open components were reduced (S1 
Table). 
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Two distinct gating modes were also observed at a moderate (30 µM) glutamate 
concentration (Fig. 6A), but were difficult to distinguish at a low (2 µM) concentration because the 
activations became too brief and simple (Fig. 6B). Over the concentration range tested, the mean 
duration of activations of the mutant receptor were considerably shorter than wild-type with a 
maximum mean duration of 200 ms, as was the mean PO, which peaked at 0.73 (Fig. 6C, S2 Table). 
Figure 6D summarises the dwell component data over the glutamate concentrations that were 
tested on the mutant receptors. Consistent differences to wild-type receptors include an increase 
in the long shut component and briefer open components (Fig. 6E). At 2 µM glutamate only one 
shut component and two open components were resolvable (Fig. 6F, S1 Table). 
The G36’A mutation induces faster desensitisation 
The briefer active periods exhibited by the G36’A mutant receptors is indicative of accelerated 
ensemble current deactivation [14, 54] and desensitisation [50]. To investigate whether receptor 
desensitisation was affected by the G36’A mutation, the long quiescent periods corresponding to 
desensitisation in single channel records were quantified, then corrected for channel number [50]. 
Sample recordings for wild-type and mutant receptors are shown in Fig. 7A and 7B, respectively. A 
saturating concentration of glutamate (10 or 1 mM) was first rapidly applied onto each patch, 
ensuring that all the receptors in the patch were activated, after which constant agonist perfusion 
was maintained over the patch for the remainder of the recording. Clearly defined steps 
corresponding to the single channel amplitude (~2 pA) became apparent as all the receptors 
desensitised back to baseline. The number of steps was then taken as an estimate of the total 
number of receptors contained in each recorded patch. Only patches expressing 1-10 steps 
(channels) were accepted for analysis. 
The long desensitised periods were estimated by plotting shut dwell histograms for the 
entire record, as is illustrated in Figs 7C and D. The shut events could be divided into two broad 
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components. The briefer component corresponded to shut events within active periods. This 
component could be subdivided into briefer components (as in Figs, 1, 2, 4 and 5). The longer 
component represented the mean desensitised lifetime, and it was this component that was 
corrected for channel number. This method of analysis produced a mean desensitised lifetime for 
wild-type receptors of 91 s (n = 5), and was used to determine a re-sensitisation transition rate 
constant (ω, Fig. 7E) of 0.011 s−1. Similarly, the desensitisation rate constant (δ) was estimated from 
the mean duration of the active periods at saturating glutamate concentrations (500 ms, Fig. 3B) to 
be 2.00 s−1 [50]. This produced an equilibrium constant (δ/ω) for desensitisation of 182 for wild-type 
receptors. A similar analysis for the G36’A mutant receptor produced a mean desensitised lifetime 
of 125 s (n = 8) and an ω of 0.008 s−1. However, a more significant change was estimated for the 
mean duration of active periods for the mutant, which saturated at 200 ms (S2 Table), producing a 
δ value of 5.00 s−1 and an equilibrium constant of 625. Thus, mutant receptors desensitised ~3.4 
times more rapidly than wild-type receptors. From this analysis it can be inferred that the G36’A 
mutation increases the likelihood of the receptors entering desensitised states. 
 
The G36’A mutation induces faster deactivation and desensitisation in ensemble currents 
To determine if the estimates of receptor desensitisation reflected current decay and 
desensitisation in ensemble currents, macropatches expressing wild-type or G36’A mutant GluClRs 
were exposed to a saturating (3 mM) concentration of glutamate for either ~1 ms or 500 ms. In 
response to a ~1 ms application, the deactivation phase of macropatch currents mediated by wild-
type GluClRs was adequately described by two standard exponential functions with a weighted time 
constant of 67 ± 4 ms (Fig. 8A, B). The individual time constants (and fractions) are tabulated in 
Table 2. To allow comparison with other, better characterised pLGICs, heteromeric α1β GlyRs and 
α5β3γ2L GABAARs were tested under similar conditions. A ~1 ms pulse of 3 mM glycine applied to 
125 
 
α1β GlyRs elicited macropatch currents that also exhibited a two component decay phase with a 
weighted mean of time constant of 22 ± 3 ms (Fig. 8A). In contrast, a ~1 ms pulse of 3 mM GABA 
applied to α5β3γ2L GABAARs activated macropatch currents that decayed considerably more slowly 
than those of GluClRs. They also deactivated with two components, with a weighted time constant 
of 275 ± 2 ms (Fig. 8A, B, Table 2). 3 mM glutamate was also rapidly applied for ~1 ms onto patches 
expressing the G36’A mutant GluClR (Fig. 8C). The weighted time constant from a two component 
fit was 11 ± 1 ms, which was 2-fold faster than those of the α1β GlyR and over 6-fold faster than the 
wild-type GluClR (Fig. 8B). 
Table 1. Macropatch deactivation and desensitisation 
 
n represents the number of patches. 
Deactivation, 1 ms, 3 mM agonist (glutamate, glycine or GABA) 
Receptor τ1 (ms) A1 τ2 (ms) A2 τw (ms) τact (ms) n 
Wild-type 
GluClR 90 ± 6 0.64 ± 0.04 20 ± 4 0.35 ± 0.05 67 ± 4 0.153 ± 0.012 12 
G36’A 
GluClR 
21 ± 3 0.32 ± 0.07 7.3 ± 0.9 0.68 ± 0.07 11 ± 1 0.195 ± 0.017 9 
α1β 
GlyR 
42 ± 4 0.37 ± 0.04 9.3 ± 1.5 0.62 ± 0.04 22 ± 3 0.125 ± 0.016 6 
α5β3γ2L 
GABAAR 
275 ± 2 0.59 ± 0.02 41 ± 10 0.41 ± 0.02 181 ± 24 0.133 ± 0.020 10 
Desensitisation, 500 ms, 3 mM glutamate 
Receptor τ1 (ms) A1 τ2 (ms) A2 τw (ms) n 
Wild-type 
GluClR 492 ± 38 − − − − 6 
G36’A 
GluClR 
266 ± 28 0.92 ± 0.02 22 ± 6 0.08 ± 0.01 252 ± 26 10 
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The activation phase of the currents was also measured by fitting 10-100% of the rising phase of the 
current to eqn. 2. The measurements, summarised in Fig. 8D, demonstrate that currents mediated 
by all receptors tested activate with similar time constants, which ranged between 0.1 − 0.2 ms. In 
contrast to the deactivation kinetics, the G36’A mutation had no significant effect on the ability of 
the receptor to activate upon exposure to glutamate. 
Ensemble desensitisation was examined by rapidly applying 3 mM glutamate onto 
macropatches for a duration of 500 ms (Fig. 8E). Wild-type GluClRs desensitized with single time 
constant of 492 ± 38 ms, whereas the G36’A mutant receptor required two exponential functions 
to adequately describe the desensitisation phase of the current (Table 1). The weighted 
desensitisation time constant for the mutant receptor was 252 ± 26 ms (Fig. 8F). We infer that the 
number of components that were needed to describe single receptor and ensemble desensitisation 
is related to modal activation in the mutant receptor. Consistent with this inference, estimates of 
the mean active durations for both receptors at saturating glutamate match very closely with the 
time constants of ensemble desensitisation (Tables 1 and S2). Overall, these data demonstrate that 
the G36’A mutation abbreviates single channel active periods, which manifest as accelerated 
deactivation and desensitisation in ensemble currents. These alterations to the intrinsic activation 
properties of the receptor are likely the underlying reasons for the order of magnitude rightward 
shift in the whole-cell concentration-response relationship for glutamate, reducing its sensitivity 
(EC50) from 15 µM to 154 µM. However, studies have also revealed a parallel shift in IVM sensitivity 
(EC50), from 40 nM to 1.2 µM in the G36’A-containing receptor [29, 46]. 
 
Direct activation by IVM at wild-type and G36’A GluClRs 
IVM is both a direct agonist and a potentiator of glutamate responses at the GluClR. In our final set 
of experiments we wished to test the hypothesis that the changes to the functional properties of 
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the receptors conferred by the G36’A substitution gives rise to the reduced sensitivity to IVM, as it 
does for glutamate. To test this idea, we recorded single channel currents in the presence of 5 nM 
IVM alone (direct activation) or in 5 nM IVM + 2 µM glutamate (potentiation). In both experiment 
types the receptors opened to an amplitude of 1.8 pA (e.g., Fig. 9A), suggesting that the presence 
of IVM had little effect on the permeation pathway. 
Wild-type receptors exhibited a substantial degree of potentiation and direct activation by 
IVM. However, the recordings also revealed that these experiments were not ‘steady state’. We 
confined our analysis of the steady-state phase of both experiments types (direct activation and 
potentiation). When membrane patches expressing wild-type receptors were exposed to 5 nM IVM 
alone, no receptor activity was apparent for the first 41 ± 4 ms. After this initial silent period the 
activations were initially well separated, but increased in duration for 47 ± 25 s, after which the 
active durations reached a steady-state equilibrium of almost continuous activity (Fig. 9A) of all the 
receptors present in each patch (between 1-4 receptors). The mean active duration of the receptors 
at steady-state was 9.5 ± 2.6 s and had a PO of 0.65 ± 0.07 (Table 2). The shut intervals were best 
described by three components whereas the open interval histograms required four exponential 
components for fitting (S3 Table). The presence of additional shut and open components suggests 
that IVM alone induces activity of greater complexity or exposes state lifetimes that are not easily 
resolvable when glutamate is present. Receptor desensitisation by IVM alone had a mean lifetime 
of 536 ± 140 ms (ω = 1.87 s−1). A mean active duration of 9.5 ± 2.6 s (δ = 0.105 s−1) yielded an 
equilibrium constant of 0.06. 
Direct activation of G36’A mutated receptors by 5 nM IVM produced a similar lag time before 
equilibrium was reached (Fig. 9C). At equilibrium the receptors were active for a mean duration of 
46 ± 8 ms and a PO of 0.85 ± 0.01 (Fig. 9D, Table 2). These active periods were much briefer than 
wild-type receptors when activated by IVM directly (9.5 s). Dwell histograms revealed two shut and 
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three open components, which is less complex than wild-type (S3 Table). Moreover, the mutated 
receptors desensitised for a mean of 2004 ± 268 ms, yielding a desensitisation equilibrium constant 
of 41.7 s1 (ω = 0.499 s−1 and δ = 20.8 s−1). The mean active durations and PO data are summarised 
as bar plots in Fig. 9 E and F, respectively.  
Potentiation by IVM at wild-type and G36’A GluClRs 
Wild-type receptors activated rapidly upon exposure to 5 nM IVM and 2 µM glutamate. For 
the first 66 ± 18 s after commencement of the recording, the active periods were well-separated 
increasing in duration over time (Fig. 10A), until an apparent steady-state equilibrium was reached 
(Fig. 10B).  
An analysis of the active durations, PO and the dwell time components at equilibrium 
produced a mean active duration of 15.9 ± 4.2 s and a PO of 0.88 ± 0.02 (Table 2) for potentiation of 
wild-type currents. The dwell histograms were best described by three shut and three open 
components (S3 Table). The time constants for the first two shut and open components were similar 
to those in the presence of low concentrations of glutamate (S2 Table). In contrast, the longest open 
component was at ~ 200 ms and represented about 40% of the total open intervals. To estimate 
receptor desensitisation, long stretches of record consisting of single receptor activity were 
analysed to obtain the main shut component that separated discrete active periods (Fig. 10B). This 
shut component produced a short-lived mean, after correcting for channel number, of 223 ± 36 ms 
and thus an ω of 4.48 s−1. Using a mean active duration of 15.9 s (δ = 0.063 s−1), the calculated 
equilibrium constant for receptor desensitisation was 0.01 in the presence of IVM and glutamate. 
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Table 2. IVM-dependent active durations and open probability (PO) 
 Active duration (ms) Po n 
wild-type GluClR 
Direct activation 9453 ± 2556 0.65 ± 0.07 6 
Potentiation 15940 ± 4210 0.88 ± 0.02 7 
G36’A GluClR 
Direct activation 48 ± 7* 0.82 ± 0.03* 7 
Potentiation 113 ± 25* 0.60 ± 0.04* 6 
 
n represents the number of patches. * p < 0.05 compared to the wild-type value. 
Similar experiments were carried out for the G36’A-containing mutant. Here too the active periods 
initially increased in duration (Fig. 10C), before equilibrating to steady-state activity (Fig. 10D). 
However, steady-state activity was not near continuous, as was observed for the wild-type 
receptors. Instead, individual receptors were active for a mean duration of 113 ± 25 ms and had a 
PO of 0.60 ± 0.04 (Table 2). Receptor desensitisation was also unlike that of wild-type receptors. The 
mean shut lifetime for long stretches of record was 2381 ± 657 ms (ω of 0.420 s−1). This yielded an 
equilibrium constant for desensitisation of 21.1. As for glutamate-gated activity, IVM produced 
briefer active periods and induced greater desensitisation in the G36’A GluClRs than wild-type. The 
summary of the mean active durations and PO is provided in Fig. 10E and F, respectively. The POs 
were significantly different between direct activation and potentiation for both wild-type and 
mutant receptors. However, because direct activation by IVM of the mutant receptors produced 
brief, simple activations, the PO determined for this activity was relatively high. 
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In summary, IVM acted as an agonist and potentiated currents in the presence of glutamate 
at wild-type and G36’A mutated GluClRs to elicit significantly longer active periods and markedly 
reduce receptor desensitisation. In addition, the sparse activity at the start of the recordings, which 
equilibrated to steady-state activity implies that, as with glutamate, additional binding of IVM 
molecules to each receptor saturates receptor activation. 
  
131 
 
Discussion 
Actions of glutamate 
The two broad aims of this study were firstly, to examine the activation properties of GluClRs 
expressed by a parasitic species in the presence of its physiological agonist and secondly, to explore 
the mechanism of IVM sensitivity. To achieve the first aim glutamate-gated currents were examined 
over a wide concentration range on single receptor and ensemble levels. The conductance of the 
receptor channel was determined to be ~23 pS, which is close to that of GABAARs that comprise α, 
β and γ subunits [13, 55]. Upon binding to glutamate, wild-type GluClRs activated rapidly (~9000 s−1, 
Fig. 4), comparable with the rate of other pLGICs, including the G36’A mutated GluClRs (Fig. 8). The 
experiments also revealed that wild-type GluClRs were highly responsive even at low nanomolar 
concentrations of glutamate and exhibited active durations and an open probability that was 
concentration-dependent. These parameters saturated at ~500 ms and 0.99, respectively (Fig. 3). 
Dwell interval analysis of active periods demonstrated that the receptors have multiple 
components, indicating that each receptor oscillates between multiple functional states during 
receptor activation [8, 11, 13]. The pattern of dwell components also indicated that at ≥ 2 µM 
glutamate an optimal number of bound glutamate molecules achieves efficient receptor activation. 
This is similar to GlyR activation, whereby fitting data to postulated kinetic schemes it was deduced 
that three bound glycine molecules are sufficient for optimal activation [8]. The decrease in open 
dwell times at nanomolar concentrations of glutamate clearly showed that at these concentrations 
fewer glutamate molecules were bound on average to each receptor [51]. 
Effects of the G36’A mutation 
The G36’D and G36’E mutations have been identified in the ML-resistant agricultural pest mite T. 
urticae [34, 35]. These mutations occur on different subunit isoforms, suggesting that heteromeric 
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GluClRs containing different substitutions to G36’ could work either individually or synergistically to 
reduce ML sensitivity [35, 56]. The G36’E mutation is particularly effective at reducing ML sensitivity 
on its own and homomeric receptors expressed in oocytes demonstrate complete insensitivity to 
two MLs (abamectin and milbemycine A4) [56]. Our data suggest that the G36’A mutation gives rise 
to significant functional changes, such as a reduced active duration and an increase in 
desensitisation of single receptors, which manifest as faster current decay and reduced sensitivity 
to glutamate and IVM. Whether these functional changes are also present in G36’D or E has yet to 
be determined. However, given that both substitutions contribute large side groups that are likely 
negatively charged, it is likely that these too would affect the activation properties of the receptors. 
The physico-chemical properties of aspartate and glutamate may also restrict access of IVM to its 
binding site. 
We chose to study the G36’A mutation because it dramatically decreases IVM sensitivity [29] 
and is located on the TM3 domain where crystallographic data show that it contributes one side of 
the IVM binding site [6] (Fig. 11). Given its location, it is tempting to hypothesise that the G36’A 
substitution reduces IVM sensitivity simply by disrupting the binding of IVM. However, the mutation 
also decreases the EC50 of glutamate [29], which binds at an extracellular domain site that is over 3 
nm from the site of the mutation. Another mechanism that could reconcile the parallel decrease in 
glutamate and IVM sensitivities is that the actions of both ligands reveal changes to the intrinsic 
activation properties of the receptor conferred by the mutation. Distinguishing between these two 
possibilities is critical to understanding the mechanism of action of IVM. This is of particular 
importance given that IVM resistance in H. contortus and other pest species is an emerging concern 
[21, 25, 28]. 
To help distinguish between these two possibilities we analysed glutamate- and IVM-gated 
currents in wild-type and G36’A mutated receptors. Clear evidence that the G36’A mutation 
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markedly compromised receptor activation was gleaned in the presence of glutamate alone. The 
mutation gave rise to two distinct and stable modes of activation; one that was similar to wild-type, 
and another with a much reduced PO (Figs. 5 and 6). The wild-type like mode was briefer than the 
activations mediated by wild-type receptors over the glutamate concentrations tested and both 
modes had lower POs than wild-type. When analysed together, the net effect of these modes 
produced a maximum mean active duration of ~200 ms and a PO of 0.70 (Fig. 6). These parameters 
underlie the reduced sensitivity to glutamate observed in the G36’A mutated receptors. Indeed, 
where 2 µM glutamate elicited robust activity in wild-type receptors, it produced only sparse, simple 
activity in the mutant. These results led to the hypothesis that the mutation impaired receptor 
desensitisation and ensemble current decay. This was tested at the single receptor level (Fig. 7) and 
in macropatches (Fig. 8). The single receptor experiments yielded desensitisation equilibrium 
constants of ~180 and ~625 for wild-type and mutant receptors, respectively, representing a 3.4-
fold greater likelihood of adopting desensitised states in the mutant. Ensemble deactivation and 
desensitisation rates were also much abbreviated in the mutant, producing mean time constants 
that corresponded well to the mean active durations of single receptors (Fig. 8). It is notable that 
other pLGICs, such as α1β GlyRs and α1β2γ2 GABAARs have a similar sensitivity to IVM [29, 45] and 
also exhibit similar rates of current decay [14, 52, 54] to the G36’A mutant. Moreover, pLGICs that 
exhibit low IVM sensitivity also contribute non-G36’-containing TM3 domains to their IVM binding 
sites [29, 36, 45]. 
Actions of IVM 
IVM acted as a ligand on its own and synergistically with glutamate to enhance currents elicited by 
glutamate. It did not affect the single channel conductance even though it binds at a site within the 
transmembrane segments and is predicted to interact with the pore-lining TM2 domain [6]. At 
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GABAARs it has been demonstrated that 10 nM IVM alone lengthens the durations of single receptor 
currents without changing single channel conductance [47]. 
2 µM glutamate applied alone at wild-type GluClRs gave rise to a mean active duration of 
~150 ms. When 5 nM IVM and 2 µM glutamate were applied together, current potentiation 
manifested as prolonged active durations with a mean of ~16 s, representing a two order of 
magnitude increase. The same combination of IVM and glutamate at G36’A mutated receptors 
produced active durations with a mean of 113 ms (Fig. 10), compared to a mean of ~11 ms elicited 
by 2 µM glutamate alone. This also represents an order of magnitude change, but the absolute 
durations were much briefer than in wild-type receptors. A similar pattern was observed between 
wild-type and G36’A receptors in the presence of 5 nM IVM alone. The mean duration of active 
periods for wild-type receptors was ~9.5 s, whereas that for the mutant was a mere 48 ms (Fig. 9). 
As for glutamate-gated currents, the active periods of the G36’A mutated receptor were much 
briefer when activated by IVM alone or in conjunction with glutamate compared to wild-type 
receptors. 
Receptor desensitisation in the presence of IVM was estimated by fitting shut histograms to 
long periods of record that contained successive single receptor activations (Figs. 9 and 10). 
Receptor saturation, where all the receptors in each patch became active, was then used to count 
active receptors and correct for the desensitisation time constant. This analysis revealed that 
desensitisation was nearly abolished at wild-type receptors, especially in the presence of IVM and 
glutamate. The mean lifetimes of desensitised states were between ~220 ms and ~540 ms and 
yielded equilibrium constants of ~0.01 for IVM plus glutamate and ~0.06 for IVM alone, respectively. 
IVM alone induced a mean desensitisation lifetime of 2002 ms and an equilibrium constant of ~42 
in the mutant receptors. This represents a significant increase in desensitisation compared to wild-
type receptors under the same recording conditions. These data demonstrate that in the presence 
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of each agonist alone and when they are co-applied, the G36’A mutated receptors exhibited briefer 
active periods and enhanced desensitisation compared to wild-type. Our data strongly support the 
inference that the loss of sensitivity reported for both agonists [29] is due to the same mechanistic 
process, and not fundamentally related to IVM binding interactions at the 36’ position. Although we 
cannot categorically rule out an IVM binding effect our data show that the wild-type and the G36’A 
mutant receptors are similarly affected even when receptor activation is at saturation throughout 
the recording. These conditions also correspond to ligand saturation where occupancy of receptors 
in unbound states is negligible. That this is the case for glutamate (Figs 5 and 6) and IVM (Figs 9 and 
10) strongly suggests that both agonists are less efficacious at activating the mutant receptors. 
Comparison of glutamate and IVM activation mechanisms 
A notable difference between the actions of glutamate and IVM was that the onset and equilibration 
of currents in the presence of IVM were much slower than observed for glutamate. A lag time of 
over ~11.5 minutes was apparent between the initiation of channel activity and the time when 
activations equilibrated to a constant mean duration for both mutant and wild-type receptors. 
Indeed, no activity was seen when IVM was applied alone for the first minute or so. Diffusion limited 
binding rates, calculated for ligands that encounter receptor binding sites directly from aqueous 
solution, including ligands of similar dimensions to IVM are in the range of ~57 x 109 M1s1 [57]. 
For instance, the upper limit of the diffusion rate for a small aqueous molecule like glutamate is ~109 
M1s1 [58]. The binding energy and correlated structural changes at binding sites can reduce these 
values by about two orders of magnitude (~106108 M1s1)[57]. These diffusion rates are far too 
high to account for the lag time observed in the recordings, suggesting the existence of other rate-
limiting factors [59]. Structural evidence indicates that IVM binds to an inter-subunit cavity in the 
upper leaflet of the lipid bilayer [6], as do other highly lipophilic ligands such as neurosteroids [60] 
and anaesthetics [61]. The IVM binding pocket in GluClRs is likely to be partly occupied by lipid, 
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requiring its displacement by IVM for access to the pocket [6, 7]. Due to its lipophilic nature, IVM is 
believed to partition into cell membranes [62] where it reaches a high local concentration, 
consistent with persistent whole-cell currents [29]. Thus, much of the ‘binding energy’ of IVM could 
be derived from the nonspecific free energy of membrane partitioning, giving rise to a high apparent 
affinity, whereas the actual ligand-channel interaction could be relatively weak [63]. Our data are 
consistent with IVM partitioning in the lipid membrane and diffusing to its binding pocket [64], 
where its concentration would increase to produce current saturation over the course of several 
minutes in patches of membrane. The increase in the active durations of individual receptors over 
the initial phase of the recordings and the emergence of a long open time constant at saturation 
also suggests that multiple IVM molecules bind to each receptor over course of the experiment to 
produce saturation. Heteromeric α1β2γ2 GABAARs have also been shown to bind multiple IVM 
molecules, to produce interface-specific potentiation and direct current activation [45]. 
Structural mechanism of the G36’A mutation 
It has been suggested that the flexible ‘hinge’ function of glycine residues found within K+ channels 
[65, 66] and pLGICs [67] can serve to isolate protein segments, or even entire domains, from 
surrounding protein conformational changes during channel activation [66]. According to their 
respective high resolution molecular structures, the TM3 domain backbones of the α1 GlyR (which 
contains an endogenous A36’ residue) and the GluClR are closely aligned in the shut state (Fig. 11A). 
However, upon IVM binding, the GlyR TM3 undergoes a larger displacement (Fig. 11B). This 
differential displacement is also observed when the TM3 domains corresponding to shut and IVM-
bound states are overlaid from the same receptor (Fig. 11C, D). This strongly suggests that the A36’ 
residue confers structural rigidity to the TM3. The structural comparisons in Fig. 11 illustrate that 
the G36’ acts to minimise deformation of the TM3 between state transitions during the 
conformational activation ‘wave’ of pLGICs [68]. Because the G36’A mutation causes briefer active 
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durations and an increased likelihood of adopting glutamate and IVM-induced desensitised states 
we conclude that the alanine destabilises open states via reduced backbone flexibility and a larger 
TM3 displacement. Functional studies have established that pLGIC activation and desensitization 
are mediated by structurally distinct sets of conformational changes at the both extracellular-
transmembrane domain interface [49, 50] and at the intracellular end of the pore [48]. The 
difference in IVM-induced TM3 displacement in the wild-type and G36’A mutant GluClRs will cause 
TM3 to interact differentially with one or both of these regions, and could thus explain the 
differential effect of the mutation on desensitization. 
Conclusion 
The H. contortus α (avr-14b) GluClR is an important biological target for IVM, although IVM 
resistance is emerging as a problem in this pest species. Here we quantified the effects of glutamate 
and IVM on these receptors with the aim of understanding the structural and functional bases of 
their modulatory effects. We found the receptor to be highly responsive to low nanomolar 
concentrations of both ligands. Dwell interval analysis of active periods demonstrated that the 
receptor oscillates between multiple functional states during activation by either ligand. However, 
we also observed that the duration of activations increased with increasing ligation of receptors by 
either ligand. The G36’A mutation, which was previously thought to hinder access of IVM to its 
binding site on the receptor, was found to decrease the duration of active periods and increase 
receptor desensitisation. On an ensemble macropatch level these changes gave rise to enhanced 
current decay and desensitisation rates. There are two main reasons why we consider these effects 
are due to impaired channel gating and not impaired IVM binding. First, the impairment to gating 
was quantitatively similar for the two ligands which bind to structurally distinct sites, and second, 
the impairment was observed at saturating concentrations of either ligand, thus ruling out a 
contribution to gating from binding and unbinding events. We infer that G36’A affects the intrinsic 
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properties of the receptor with no specific effect on IVM binding. These results provide new insights 
into the activation and modulatory mechanism of the GluClR and provide a mechanistic framework 
upon which the actions of new candidate anthelmintic drugs can be reliably interpreted. 
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Materials and Methods 
Cell Culture 
HEK AD293 cells (ATCC cell lines, VA USA) were seeded onto poly-D-lysine coated glass coverslips 
and transfected with cDNAs encoding the GluClR subunit avr-14B (pcDNA 3.1+) of H. contortus using 
a calcium phosphate-DNA co-precipitate method. The cDNA encoding the CD4 surface antigen was 
also added to the transfection mixture and acted as a marker of transfected cells. Cells were used 
for experiments 2-3 days after transfection. The point mutation, TM3-G36’A, was incorporated into 
the subunit using the QuickChange site-directed mutagenesis method. Successful incorporation of 
mutation was confirmed by sequencing the mutated DNA. 
Patch clamp electrophysiology 
All experiments were carried out at room temperature (21 – 24 oC). Single-channel and macropatch 
currents were recorded from outside-out excised patches at a clamped potential of −70 mV, unless 
indicated otherwise. The patches were continuously perfused via a gravity-fed double-barrelled 
glass tube. Out of one barrel flowed an extracellular bath solution containing (in mM), 140 NaCl, 5 
KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, and 10 D-glucose and titrated to pH 7.4. The adjacent barrel 
contained agonist dissolved in this extracellular solution. Glass electrodes were pulled from 
borosilicate glass (G150F-3; Warner Instruments), coated with a silicone elastomer (Sylgard-184; 
Dow Corning) and heat-polished to a final tip resistance of 415 MΩ when filled with an intracellular 
solution containing (in mM) 145 CsCl, 2 MgCl2, 2 CaCl2, 10 HEPES, and 5 EGTA, pH 7.4. Stock solutions 
of L-glutamate were also pH-adjusted to 7.4 with NaOH. A 10 mM stock of IVM (Sigma-Aldrich) was 
dissolved in 100% DMSO and kept frozen at 20oC. Fresh working stocks of IVM at 5 nM were 
prepared by dissolving the appropriate quantity directly in extracellular solution. 100% DMSO when 
dissolved in extracellular solution alone at the same concentration as is present in working solutions 
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containing 5 nM IVM had no effect on patches excised from cells transfected with GluClRs or from 
untransfected cells. 
Excised patches were directly perfused with extracellular solution by placing them in front of one 
barrel of the double-barrelled glass tube. Single channel currents were elicited by exposing the 
patch continuously to agonist containing solution, flowing through the adjacent barrel. 1-2 
glutamate concentrations were applied to most patches for single receptor experiments. A ~1 
minute wash with agonist-free extracellular solution was applied between each glutamate 
application. Because IVM does not readily wash out, either 2 µM glutamate + 5 nM IVM or 5 nM 
IVM alone were applied to a given patch. Macropatch currents were elicited by lateral translation 
of the tube from the agonist free to agonist containing barrel using a piezo-electric stepper 
(Siskiyou). This achieved rapid solution exchange (<1 ms). Currents were recorded using an Axopatch 
200B amplifier (Molecular Devices), filtered at 5 kHz and digitized at 20 kHz using Clampex (pClamp 
10 suite, Molecular Devices) via a Digidata 1440A digitizer. 
Data Analysis 
The experiments that were carried out can be broadly divided into 1) single receptor currents at 
steady-state and 2) ensemble currents, which are phasic. The two types or experiments are 
complimentary and provide different data. Single channel recordings yield information on receptor 
conductance and functional state complexity (eg. active durations and dwell histograms). The fast 
application (~1 ms) ensemble measurements mimic synaptic currents. 
Single-channel current amplitudes were measured in Clampfit. In current-voltage (i-V) 
experiments, the amplitude was measured at voltages of, ±70 mV, ±35 mV, ±15 mV and 0 mV. The 
data were fit to a polynomial function in Sigmaplot (Systat Software) and the reversal potential was 
read directly from the plots. Single-channel conductance (γ) was calculated from the single-channel 
amplitude (i) using Ohm’s law: 
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𝛾𝛾 = 𝑖𝑖
𝑉𝑉ℎ𝑜𝑜𝑜𝑜𝑜𝑜−𝑉𝑉𝑜𝑜𝑙𝑙𝑙𝑙−𝑉𝑉𝑟𝑟𝑟𝑟𝑟𝑟
   eqn. 1 
Where Vhold is the holding potential (−70mV), Vljp is the liquid junction potential and Vrev is the 
reversal potential. Vljp was calculated to be 4.7 mV for the solutions used in the experiments [69]. 
We confined our analysis to the largest, main conductance level. QuB software was used to analyse 
the kinetic properties of GluClR activations. Segments of single-channel activity separated by long 
periods of baseline were selected by eye and idealized into noise-free open and shut events using a 
temporal resolution of 70 μs. Idealized data were initially fit with a simple activation scheme in 
which open and shut states were added to a central shut state. This fit was used to determine the 
critical time (tcrit), which was taken from the shut interval durations and used to divide the idealized 
segments into clusters (or bursts at < 2 μM glycine) of single receptor activity. Clusters and bursts 
will be referred to as activations. tcrit applied to single channel records of wild-type activity varied 
between 5-30 ms for concentrations ≥ 2 µM and 120-180 ms for 30 nM and 5 nM glutamate. 
Activation mode analysis for G36’A-containing receptors at 1 mM glutamate required tcrit times of 
180-200 ms (low PO) or 15-50 ms (high PO). Pooled data obtained from G36’A-containing receptors 
were defined using tcrit times of 20-50 ms. Finally, IVM-induced single channel currents were defined 
using tcrit values of 50-120 ms for both wild-type and mutant receptors. This analysis yielded mean 
cluster durations and intra-activation open probabilities (PO). All data are presented as mean ± SEM 
of between 3 and 16 patches. The shut periods that correspond to receptor desensitisation were 
estimated by generating shut histograms for long stretches of record (several minutes) that 
exhibited single receptor activations. Receptor desensitisation was modelled as a single transition 
from an open conducting state (ARo) to a desensitised state (ARd). Where A is the agonist, R is the 
receptor and the superscripts denote open (o) or desensitised (d). δ denotes the desensitisation rate 
constant whereas the re-sensitisation (or re-activation) rate constant is denoted by ω. The 
equilibrium constant for desensitisation is δ/ω. 
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Macropatch currents were analysed by fitting the onset phase of the current to a single 
exponential of the form: 
𝐼𝐼(𝑡𝑡) = 𝐼𝐼𝑚𝑚𝑚𝑚𝑚𝑚(1 − 𝑒𝑒−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡)  eqn. 2 
Where I(t) is the current at time t, Imax is the maximum current amplitude and kobs is the pseudo-first 
order rate constant for current activation. The decay phase of the macropatch currents were fit to 
two standard exponential functions. 
Data are presented as mean ± SEM. Power analysis of our data sets for IVM revealed power levels 
of 0.91.0. Two-tailed, unpaired t-tests were used to compare wild-type and mutant current 
parameters in the presence of IVM and p < 0.01 was taken as the significance threshold. 
3D Structure alignments of TM3 domains 
The alignments of TM3 domains of the GluClR and GlyR were done using the Internal Coordinate 
Mechanics software (ICM-Pro Molsoft LLC, San Diego, CA). The α-carbon atoms of the N-terminal 
residues from TM3-29’ to TM3-36’ were superimposed and used as a fixed reference. The 
displacement between α-carbon atoms at position TM3-56’ were then measured between two 
given TM3 domains The structures used for this analysis were, the GluClR in a non-conducting 
conformation (PDB, 4TNV [7]), the GluClR in complex with IVM (PDB, 3RHW [6]), the α1 GlyR in a 
non-conducting conformation in complex with strychnine (PDB, 3JAD [70]), and the structure of the 
α1 GlyR in complex with IVM (PDB, 3JAF [70]). The final representations were created using the 
Pymol Molecular Graphics System, Version 1.3. 
  
143 
 
Fig. 1. Single channel conductance and kinetic properties of GluClRs in response to glutamate activation. A) Sample 
traces of single channel activity recorded in outside-out patches at indicated holding potentials. Channels were activated 
by 10 µM glutamate. B) Mean current-voltage relationship averaged from 6 patches. Error bars were smaller than 
symbol size. Vrev = reversal potential (4.0 mV). C) Examples of single channel activity in response to 200 µM glutamate. 
In this and all subsequent figures, recordings were performed at 70 mV and channel openings are downward 
deflections from the baseline. D) Shut and open dwell histograms for data obtained at 200 µM glutamate. The 
histograms show that the receptors have two shut and three open components. E) Examples of single channel activity 
recorded in response to 30 µM glutamate, indicating the presence of shorter activations. F) Shut and open dwell 
histograms for data obtained at 30 µM glutamate, again revealing the presence of two shut and three open components, 
but the longest shut component is slightly increased. 
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Fig. 2. Kinetic properties of GluClRs at low glutamate concentrations. A) Examples of continuous single channel activity 
recorded from an outside-out patch in response to 2 µM glutamate. B) Shut and open dwell histograms for data 
obtained at 2 µM glutamate. The histograms show that despite the reduced length of active periods, the receptors have 
two shut and three open components, but the longest shut component is increasing with decreasing concentration. C) 
Examples of single channel activity recorded in response to 30 nM glutamate, indicating the presence of mostly brief 
activations. D) Shut and open dwell histograms for data obtained at 30 nM glutamate, revealing the presence of two 
shut and two open components. 
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Fig. 3. Concentration-dependence of glutamate effects on GluClRs. A) Examples of how intra-activation open 
probability (PO) increased as glutamate concentration was increased. In the absence of glutamate single receptor activity 
was negligible. Activations of similar duration were selected to facilitate comparison. B) Effect of glutamate 
concentration on the time constants of the long (red symbols) and short (black symbols) shut-state dwell components. 
C) Effect of glutamate concentration on time constants of the open-state dwell components. The symbols denote the 
long (green symbols), intermediate (red symbols) and short (black symbols) time constants Note the disappearance of 
the longest open component and the reduction in length of the shorter open components at nanomolar glutamate. D) 
Mean intra-activation open probability (PO) plotted as a function of glutamate concentration. The curve represents a 
Hill equation fit with an EC50 of 70 nM. E) Mean active period duration plotted as a function of glutamate concentration. 
The curve represents a Hill equation fit with an EC50 of 31.2 µM. The data in B-E are means from 3-12 patches (see S2 
Table). 
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Fig. 4. Ensemble glutamate-induced activation properties of GluClRs. A) Superimposed recordings revealing the effects 
of 50 ms (above) or 500 ms (below) applications of indicated glutamate concentrations onto macropatches expressing 
multiple GluClRs. B) Mean glutamate concentration-response relationship of peak currents as determined by fast 
agonist application. The curve represents a Hill equation fit with an EC50 of 43 µM. C) Normalised currents showing the 
concentration dependence of the activation phase of the current. The activation phase of each current trace was fitted 
to equation 2. D) Mean glutamate concentration-response relationship of the activation rate (kact). The curve represents 
a Hill equation fit with an EC50 of 0.95 µM. The numbers with arrows in A and C are the glutamate concentrations (in 
µM) that correspond to the currents. The arrows point to the peak current in A and the corresponding current onset in 
C. The data in B and D are means from 6-15 patches. 
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Fig. 5. Comparison of the effect of 1 mM glutamate on wild-type and G36’A mutant GluClRs. A) Examples of continuous 
single channel activity recorded from G36’A mutant GluClRs. Note the emergence of a ‘spiky’ activation mode (red 
boxes) that is not observed in wild-type GluClRs. Wild-type-like activations are termed ‘mode 1’ or ‘high Po’, whereas 
spiky activations are termed ‘mode 2’ or ‘low Po’. B) Examples of continuous single channel activity recorded from wild-
type GluClRs included for comparison. C) Comparison of mean active durations (upper panel) and Po (lower panel) of 
low (LPO) and high (HPO) PO events recorded from G36’A mutant GluClRs (n = 6 patches). D) Examples of activations 
demarcated by a grey bar in A and B. These activations are of the high PO mode for the G36’A mutant (above) and normal 
mode for wild-type (below). The comparison indicates that there are more numerous open-shut events within the 
activations of G36’A compared to wild-type. E) Shut and open dwell histograms for data obtained from G36’A mutant 
GluClRs at 1 mM glutamate. This plot combined LPO and HPO activations of G36’A receptors at 1 mM glutamate. The 
histograms show that the mutant receptors have two shut and three open components. F) Shut and open dwell 
histograms for data obtained from wild-type GluClRs at 1 mM glutamate, revealing two shut and three open 
components. 
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Fig. 6. Concentration-dependence of glutamate effects on G36’A mutant GluClRs. A) Examples of continuous single 
channel activity recorded at 30 µM glutamate. Note the presence of mode 1 and 2 events. B) Examples of single channel 
activity recorded in response to 2 µM glutamate, indicating the presence of brief activations only. C) Upper panel: Mean 
PO plotted as a function of glutamate concentration. The corresponding curve for the wild-type receptor is included as 
a dashed line. Lower panel: Mean active period duration plotted as a function of glutamate concentration. The 
corresponding curve for the wild-type receptor is included as a dashed line. Data represent mean from 3-7 patches. D) 
Upper panel: Effect of glutamate concentration on long (red symbols) and short (black symbols) shut-state dwell 
components. Lower panel: Effect of glutamate concentration on long (green symbols), intermediate (red symbols) and 
short (black symbols) open-state dwell components. Data represent mean ± SEM from 4-8 patches. E) Shut and open 
dwell histograms for data obtained at 30 µM glutamate, revealing two shut and three open components. F) Shut and 
open dwell histograms for data obtained at 2 µM glutamate, revealing two shut and two open components. 
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Fig. 7. Estimation of desensitisation rate in patches expressing a known number of wild-type or G36’A mutant 
channels. A) Continuous recording from a patch expressing wild-type receptors in response to rapid application of 1 
mM glutamate. 9 channels were present in this patch. B) Corresponding recording from a macropatch expressing G36’A 
receptors. 6 channels were present in this patch. C) Shut dwell histogram of the activity shown in A. The longer 
component represented a mean desensitised lifetime of 12780 ms and it was this component that was corrected for 
channel number (12780 x 9 = 115020 ms or 115 s). D) Shut dwell histogram of the recording shown in B, which yielded 
a desensitised lifetime of 70 s. E) Desensitisation scheme for calculating equilibrium constant (δ/ω) for desensitisation. 
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Fig. 8. Outside-out macropatch recordings of currents mediated by the indicated receptors. A) Sample recordings from 
macropatches expressing α (avr-14b) GluClRs, α1β GlyRs and α5β3γ2 GABAARs in response to ~1 ms applications of 
saturating (3 mM) agonist (glutamate, glycine or GABA). B) Mean weighted current deactivation time constants for the 
receptors indicated in A. The individual time constants and their relative magnitudes are summarised in Table 1. C) 
Sample recordings from macropatches expressing wild-type and G36’A mutant GluClRs in response to ~1 ms applications 
of saturating (3 mM) glutamate. Note the substantial decrease in deactivation time in the mutant. D) Mean activation 
rates reveal no significant difference between the four receptor isoforms (n = 6-12 patches). E) Sample recordings from 
macropatches expressing wild-type and G36’A mutant GluClRs in response to 500 ms applications of saturating (3 mM) 
glutamate. F) Mean desensitisation rates as calculated from n = 6-10 patches. The mutant plot represents a weighted 
mean of two components. 
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Fig. 9. Direct activation by 5 nM IVM. A) Four segments of recording illustrating the progressive increase (early, 
intermediate and late) in active durations upon first exposure to 5 nM IVM alone for wild-type GluClRs. B) Steady-state 
currents mediated by wild-type GluClRs in the continuous presence of 5 nM IVM. C) Four segments of record showing 
the progressive increase (early, intermediate and late) in active durations upon first exposure to 5 nM IVM alone for 
G36’A mutant GluClRs. The late phase precedes the steady-state phase. D) Steady-state currents mediated G36’A 
GluClRs in the continuous presence of 5 nM IVM alone. Note the much briefer activations compared to wild-type. E) Bar 
plots summarising the mean active durations for wild-type and G36’A mutant GluClRs (n = 6 patches each). F) Bar plots 
summarising the mean POs for wild-type and G36’A mutant GluClRs (n = 6 patches each). * p< 0.01 
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Fig. 10. Current potentiation in the presence of 2 M glutamate and 5 nM IVM. A) Three segments of record showing 
the progressive increase (early, intermediate and late) in active durations upon exposure to both ligands for wild-type 
GluClRs. The late phase precedes the steady-state phase. B) Continuous sweeps of recording showing the equilibrated 
or steady-state phase of the recordings for wild-type GluClRs. These segments were used to determine receptor 
desensitisation. C) Three segments of record showing the progressive increase (early, intermediate and late) in active 
durations upon exposure to both ligands for G36’A mutant GluClRs. D) The steady-state phase of currents mediated by 
G36’A mutant GluClRs mostly consisted of relatively brief activations, along with the occasional longer activations. E) 
Summary of the mean active durations for wild-type (n = 7 patches) and G36’A mutant (n = 6 patches) GluClRs. F) 
Summary of the mean POs for wild-type and G36’A mutant GluClRs. * p < 0.01 
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Fig. 11. Structural representations of TM3 domains in shut and IVM bound configurations. A) TM3 domains of 
homomeric GluClRs and α1 GlyRs in shut configurations. B) TM3 domains of homomeric GluClRs and α1 GlyRs in IVM-
bound configurations. C) TM3 domains of the GluClR in shut and IVM-bound configurations. D) TM3 domains of the α1 
GlyRs in shut and IVM-bound configurations. In all cases residues between 29’ and 36’ were fixed as a reference and the 
extent of displacement (in Angstrom units) was measured at the 56’ position. The pdb files used in the figure were, the 
GluClR in a shut conformation (PDB, 4TNV), the GluClR in complex with ivermectin (PDB, 3RHW), the α1 GlyR in a shut 
conformation in complex with strychnine (PDB, 3JAD), and the structure of the α1 GlyR in complex with ivermectin (PDB, 
3JAF). IVM is shown as a stick-ball structure in green. 
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S1 Table. Dwell time components for wild-type and G36’A mutant GluClRs for glutamate. 
α wild-type GluClR 
[E] mM τS1 FS1 τS2 FS2 τO1 FO1 τO2 FO2 τO3 FO3 
10 0.59 ± 0.06 88 ± 3 2.0 ± 0.3 16 ± 4 1.70 ± 0.22 24 ± 5 37 ±13 36 ± 9 109 ± 8 40 ±4 
1 0.56 ± 0.09 82 ± 9 2.0 ± 0.4 18 ± 19 1.64 ± 0.24 26 ± 9 28 ± 9 35 ± 2 149 ± 28 40 ± 14 
0.2 0.53 ± 0.02 80 ± 3 2.6 ± 0.6 20 ± 6 1.59 ± 0.07 22.± 3 16 ± 1 33 ± 6 99 ± 9 45 ± 6 
0.03 0.47 ± 0.03 86 ± 5 3.1 ± 0.5 14 ± 6 1.91 ± 0.12 27 ± 5 16 ± 2 33 ± 4 94 ± 4 40 ± 3 
0.01 0.50 ± 0.07 80 ± 3 3.8 ± 0.8 20 ± 3 1.92 ± 0.40 22 ± 5 18 ± 4 26 ± 6 107 ± 9 52 ± 5 
0.002 0.51 ± 0.03 75 ± 5 6.5 ± 0.4 25 ± 5 1.75 ± 0.16 36 ± 4 18 ± 2 39 ± 5 111 ± 7 26 ± 3 
0.00003 1.22 ± 0.19 45 ± 14 34.5 ± 4.3 55 ± 14 1.12 ± 0.20 77 ± 6 13 ± 4 23 ± 6 − − 
0.000005 1.22 ± 0.11 43 ± 8 86.3 ± 9.8 57 ± 8  0.75 ± 0.04 78 ± 11 4 ± 1 22 ± 4 − − 
α(G36’A) GluClR 
10 0.60 ± 0.06 56 ± 7 13.7 ± 1.0 44 ± 7 1.31 ± 0.34 34 ± 7 12 ± 4 34 ± 6 62 ± 20 32 ± 6 
1 0.85 ± 0.09 53 ± 6 11.6 ± 2.0 47 ± 5 1.14 ± 0.14 42 ± 6 8 ± 1 29 ± 6 45 ± 11 29 ± 4 
0.03 0.57 ± 0.09 58 ± 8 18.0 ± 2 42 ± 8 1.46 ± 0.11 40 ± 8 6 ± 1 32 ± 6 23 ± 2 28 ± 2 
0.002 0.54 ± 0.07 − − − 1.10 ± 0.15 11 ± 5 5 ± 1 89 ± 3 − − 
 
Data represent mean ± SEM from 3-12 patches 
160 
 
S2 Table. Glutamate-dependent active durations and open probability (PO) 
 
[E] mM Active duration (ms) Po n 
wild-type GluClR 
10 494 ± 42 0.99 ± 0.03 7 
1 437 ± 37 0.99 ± 0.02 7 
0.2 374 ± 29 0.98 ± 0.06 12 
0.03 328 ± 21 0.95 ± 0.02 7 
0.01 206 ± 11 0.93 ± 0.01 5 
0.002 146 ± 6.5 0.74 ± 0.02 10 
0.00003 102 ± 36 0.21 ± 0.02 3 
0.000005 82 ± 21 0.14 ± 0.03 3 
G36’A GluClR 
10 198 ± 18 0.71 ± 0.06 7 
1 188 ± 12 0.66 ± 0.06 8 
0.03 114 ± 17 0.41 ± 0.06 3 
0.002 11 ± 1 ND 4 
n represents the number of patches. ND not determined. 
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S3 Table. Dwell time components for wild-type and G36’A mutant GluClRs for IVM. 
 
Wild-type 
GluClRs 
τS1 FS1 τS2 FS2 τS3 FS3 τO1 FO1 τO2 FO2 τO3 FO3 τO4 FO4 
Direct activation (5 nM IVM) 
1.50 ± 
0.22 60 ± 5 
6.02 ± 
0.56 32 ± 5 
17.5 ± 
0.8 8 ± 2 
1.43 ± 
0.19 50 ± 5 
5.48 ± 
0.99 28 ± 2 
30.5 ± 
4.5 13 ± 2 
217 ± 
41 9 ± 5 
Potentiation (5 nM IVM + 2 µM glutamate) 
1.30 ± 
0.22 82 ± 2 
9.62 ± 
3.01 18 ± 2 − − 
1.94 ± 
0.43 34 ± 4 
17.8 ± 
4.1 29 ± 5 
180 ± 
18 37 ± 5 − − 
G36’A 
GluClRs 
Direct activation (5 nM IVM) 
1.47 ± 
0.27 34 ± 8 
36.7 ± 
1.7 66 ± 8 − − 
1.83 ± 
0.41 35 ± 7 
14.3 ± 
3.7 35 ± 8 
52.1 ± 
4.6 30 ± 7 − − 
Potentiation (5 nM IVM + 2 µM glutamate) 
1.19 ± 
0.20 40 ± 9 
35.8 ± 
4.5 60 ± 8 − − 
1.02 ± 
0.28 40 ± 6 
8.99 ± 
1.37 38 ± 6 
49.7 ± 
15.7 22 ± 9 − − 
 
Data represent mean ± SEM from 6-7 patches 
  
  
5 
 
 
Pharmacological characterization of lindane, 
fipronil and PTX on two GluClR splice variants of 
Anopheles gambiae 
 
 
 
 
 
 
 
 
 
 
163 
 
Introduction 
On an average, around 200 million cases of malaria were reported worldwide from 
the year of 2013-2017. Out of which, on an average 500,000 resulted in death every year 
according to the WHO world malaria report. Africa, where A. gambiae is the primary vector 
of malaria, accounted for approximately 90% of these deaths (WHO World Malaria Report, 
2014-2018), (Phillips et al. 2017; Ashley et al. 2018). Insecticide-treated mosquito bed nets 
and indoor residual spraying of pyrethroid-based insecticides forms the current malaria 
control program. Pyrethroid resistance however is becoming widespread across the African 
A.gambiae population (Ranson et al. 2011; Trape et al. 2011; Hemingway et al. 2016; Bhatt et 
al. 2015; Phillips et al. 2017). The mosquito is long-lived, thrives in human environments and 
prefers human blood (Killeen et al. 2017; White et al. 2014). The efforts to control malaria 
transmission through vector-targeting interventions with a new mode of action, led to the 
identification of IVM as a new malaria control candidate. Malaria vectors after having 
ingested host treated blood meals laced with IVM effectively killed or disabled A.gambiae, by 
interfering with the feeding patterns, both in and outside lab conditions (Kobylinski et al. 
2010; Sylla et al. 2010). A temporary reduction in the proportion of Plasmodium falciparum-
infected A.gambiae was seen recently after a mass drug administration of IVM at multiple 
sites across West Africa (Kobylinski et al. 2011; Alout et al. 2014). An impairment in the flight 
patterns and inhibition of sporogony of P. falciparum in A. gambiae was noticed at sub-lethal 
doses of IVM. Clinical trials, involving a combination of artemether-lumefantrine, reduced the 
likelihood of malaria transmission by killing the mosquitoes (Ouedraogo et al. 2015). These 
above studies demonstrate that IVM can be a promising tool to control malaria transmission. 
The majority of research on IVM targets has been done in nematodes or other model 
organisms (Omura 2008), however thorough functional characterization of GluClRs in 
mosquito vectors of A. gambiae has not yet been performed. mRNA from the female 
mosquitoes of A. gambiae were cloned to give four splice isoforms of AgGluClR contrary to a 
previous prediction of only three isoforms (Megy et al. 2012; Meyers et al. 2015). 
Here we characterized the effects of lindane, fipronil, picrotoxin (PTX) and IVM on two 
splice variants i.e., AgGluClR-a1 and AgGluClR-b from A. gambiae in order to understand the 
function and pharmacology of GluClRs from this important pathogenic organism. We 
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expressed AgGluClR isoforms in X. laevis oocytes to measure their electrophysiological activity 
in response to glutamate, IVM, lindane, fipronil and PTX. 
Difference between nomenclatures of different splice variants from AgGluClRs.  
 Table 5.1 compares the names of AgGluClR splice variants clone by Meyers et al., 
(2015) and the NCBI database.  
Table 5.1: The below table depicts the different nomenclature used in a paper by Meyers et 
al., (2015) and the nucleotide database. The nomenclature in parentheses refers to the 
nucleotide GenBank accession number. 
Nomenclature by Meyers et. al Nomenclature on database 
AgGluClR a1 AgGluClR b1 (KC902519.1) 
AgGluClR a2 AgGluClR b2 (KC902520.1) 
AgGluClR b AgGluClR c (KC902521.1) 
AgGluClR c AgGluClR a (KC902518.1) 
 
 In order to avoid confusion I will employ the nomenclature from the paper by Meyers 
et al., (2015).   
Results 
Glutamate and IVM dose-response relationship of two isoforms of A. gambiae GluClRs: 
 Although the effect of glutamate and IVM on AgGluClR-a1 and AgGluClR-b was 
characterised by Meyers et al., (2015), the study lacked a more thorough pharmacological 
characterization of these two splice variants. In order to address this deficiency, the first set 
of experiments involved testing the efficacy of glutamate and IVM at AgGluClR-a1 and 
AgGluClR-b. Glutamate evoked rapidly activating inward currents from homomeric GluClRs 
comprising either one or the other splice isoform. The current amplitude saturated at 1000 
µM glutamate suggesting that the all the channels were completely saturated at this 
concentration. The glutamate EC50 values for AgGluClR-a1 and AgGluClR-b were similar, being 
19 ± 1 µM and 27 ± 1 µM with Hill co-efficient of 3.4 ± 0.3 and 2.1 ± 0.1 (n= 6 and 7 
respectively, Figure 5.1-a,b,c, Table 5.2). The above data compared reasonably well with the 
results of Meyers et al., (2015). A similar concentration response experiment was performed 
by using IVM; however as IVM is a quasi-irreversible agonist, we employed the protocol 
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whereby increasing IVM concentrations were successively applied to the recorded oocyte at 
steady-state current levels. As we did not find any comparable difference in the EC50 values 
for glutamate in our experiments and the study done by Meyers et al., (2015) on AgGluClR-
a1 and AgGluClR-b, we were expecting that we would get a similar set of results for IVM. 
However, oocytes expressing AgGluClR-a1 and AgGluClR-b both produced slow activating 
inward currents when subjected to IVM application. This result contradicted the findings from 
the study of Meyers, where they showed that AgGluCl-a1 was sensitive to IVM whereas 
AgGluCl-b was not. AgGluClR-a1 had an EC50 of 145 ± 13 nM and AgGluClR-b had an EC50 of 
202 ± 50 nM for IVM which were not statistically significant (Figure 5.1-d,e,f, Table 5.2).  
Table 5.2: EC50 values and Hill co-efficient for glutamate and IVM at two splice isoforms of 
AgGluClRs. ns= not significant, compared with AgGluClR-a1 using unpaired t-test 
Receptor 
subtype 
Glutamate IVM 
LogEC50 (µM) nH N LogEC50 (nM) nH N 
AgGluClR-a1 19 ± 1 3.4 ± 0.3 6 145 ± 13 1.3 ± 0.1 6 
AgGluClR-b 27 ± 1ns 2.1 ± 0.1 7 202 ± 50ns 1.2 ± 0.2 6 
 
Figure 5.1: The above figure depicts the effect of glutamate and IVM on two splice variants of A. 
gambiae i.e., AgGluClR-a1 (green) and AgGluClR-b (orange). Panels A, B and C shows the effect of 
glutamate on AgGluClR-a1 and AgGluClR-b and a dose response graph for both the splice isoforms 
respectively. Panel D, E and F shows cumulative concentration response traces of IVM on AgGluClR-
a1 and AgGluClR-b and a dose-response graph that was normalised to their maximum glutamate 
elicited currents, respectively. All the values mean ± S.E.M (n=6, at least). 
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Differential effects of lindane and fipronil on AgGluClR isoforms 
Having established that IVM does indeed activate both AgGluClRs made of either one-
splice variant or the other we wanted to see whether insecticides such as lindane and fipronil, 
which target GluClRs, would have any differential efficacy between these two splice variants. 
As these splice variants have minimal difference from each other any differential activity that 
would be observed will be helpful in characterizing a drug that can target GluClRs in a specific 
manner. 
In order to discern the effects of lindane and fipronil on AgGluClR-a1 and AgGluClR-b, 
we performed a direct inhibition experiment by applying 30 µM lindane or fipronil at both 
isoforms. In another set of experiments, we determined the effect of co-application of lindane 
or fipronil with an EC50 concentration of glutamate at both splice variants of AgGluClRs. A 
steady-state inhibition relationship was quantitated for lindane and fipronil by measuring the 
percentage of glutamate current remaining after a closed state drug application. A 2-minute 
drug application in a closed state followed by an immediate application of EC50 glutamate was 
used to determine the extent of inhibition (Figure 5.2-A); this was used to compare the 
relative magnitude of lindane and fipronil inhibition at AgGluClR-a1 and AgGluClR-b.  
Inhibitory profile of lindane, fipronil and PTX 
An inhibitory concentration-response experiment for lindane and fipronil in a closed 
receptor state were quantitated at their respective EC50 glutamate concentrations. Panels A, 
and B in figure 5.2 shows the sample inhibitory response traces for lindane at AgGluClR-a1 
and AgGluClR-b from a single oocyte, respectively, whereas panel C shows their averaged 
inhibitory profile (n=6). Glutamate-gated currents mediated by both the splice variants were 
inhibited by lindane in a dose-dependent manner with an IC50 of 9 µM and 5 µM, respectively 
(Table 5.3). Notably, lindane was able to completely inhibit the glutamate currents induced 
by AgGluClR-b whereas only 65% of peak current was blocked at α AgGluClRs-a1 at the 
maximum lindane concentration (Table 5.3). 
Similar experiments were done using fipronil. However, the maximum concentration 
used was 30 µM as fipronil started to precipitate at a higher concentration in the working 
solution. Contrary to the inhibitory effect that was seen by lindane, fipronil blocked glutamate 
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currents completely with equal efficacy at both the splice isoforms (AgGluClR-a1= 0.5 µM and 
AgGluClR-b= 0.9 µM, n=6, Figure 5.2-D, E, F, Table 5.3). 
As PTX is an open pore blocker, we had to vary the method by which we measured the 
inhibitory profile. We employed an open state application where glutamate was co-applied 
at its EC50 concentration along with increasing concentrations of PTX. Similar to the effect that 
was seen with lindane, PTX was also able to block glutamate-mediated currents, however, a 
differential efficacy was seen between AgGluClR-a1 and AgGluClR-b. PTX blocked 
approximately 80% of currents mediated by glutamate at AgGluClR-a1 at a maximum 
concentration of 300 µM whereas complete inhibition of glutamate currents was observed at 
AgGluClR-b when same concentration was used (Table 5.3). In addition, there was a significant 
difference in the IC50 values (Figure 5.2-G, H, I, AgGluClR-a1 = 23.0 ± 3.0 µM, AgGluClR-b = 7.1 
± 0.2 µM, n=6 each). 
Table 5.3: The table below depicts the different IC50 values and an approximate percentage of 
inhibition for lindane, fipronil and PTX at AgGluClR-a1 and AgGluClR-b. All the values are 
represented as mean ± S.E.M, *p<0.05, ***p<0.001 compared to AgGluClR-a1 using unpaired t-test. 
Receptor 
subtype 
Lindane Fipronil PTX 
LogIC50 
(µM) 
% Inhibition n LogIC50 
(µM) 
% Inhibition  n LogIC50 (µM) % 
Inhibition 
n 
AgGluClR-a1 8.0 ± 1.0  65 ± 5 6 0.5 ± 0.1  99 ± 1  6 23.0 ± 3.0  80 ± 9 6 
AgGluClR-b 5.8 ± 1.3 ns 99 ± 1* 6 0.8 ± 0.1 ns 99 ± 1 ns 6 7.1 ± 0.2 *** 97 ± 1* 6 
 
Recovery profile from lindane- and fipronil-mediated inhibition 
After testing the inhibitory efficacy of lindane, fipronil and PTX, we wanted to see if 
there would be a difference in their recovery profile. As experiments done in our lab 
previously showed that α1, α2, α3 and α1β GlyRs recover to a different extent after lindane 
and fipronil application (Islam and Lynch 2012), it would be interesting to see whether the 
same effects would be observed at the GluClRs.  
A time-dependent recovery from inhibition by lindane and fipronil was measured at 
the EC50 glutamate concentration. Recovery was analysed by bathing the oocyte with an EC50 
concentration of glutamate for a period of 20 seconds, separated by 2-minute washes in the 
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Figure 5.2:  Mean inhibitory dose response relationship for lindane, fipronil and PTX at AgGluClR-a1 and AgGluClR-b at EC50 glutamate. (A) & (B), sample 
traces of lindane inhibition at AgGluClR-a1 and AgGluClR-b. (D) & (E) Corresponding traces for fipronil, (G) & (H) effect of PTX. (C), (F) & (I) averaged dose-
response relationships for lindane, fipronil and PTX, respectively.  
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extracellular control solution, which was preceded by a 2-minute application of 30 µM 
of either lindane or fipronil (Figure 5.3A). 
 A sample recovery trace for lindane at AgGluClRs-a1 and AgGluClRs-b is shown in 
Figure 5.3A, B respectively, along with the averaged recovery profile for lindane at AgGluClR-
-a1 and AgGluClRs-b (Figure 5.3C). A differential efficacy that was observed while 
characterizing the inhibitory profile of lindane was also seen while characterizing its recovery 
profile. A maximum recovery of current of around 70% was observed following inhibition by 
lindane at the AgGluClRs-a1. However, the recovery was much smaller and slower at the β 
AgGluClRs with a maximum current recovery of about 40% (Figure 5.3C, Table 5.4). A similar 
trend was seen with fipronil recovery, where AgGluClRs-a1 recovered to about 50% 
whereas AgGluClRs-b had a smaller recovery of less than 20% (Figure 5.3D,E,F).  
Table 5.4: The table below depicts the time dependence recovery from lindane and fipronil induced 
inhibition using EC50 glutamate at AgGluClR-a1 and AgGluClR-b. All the values are represented as 
mean ± S.E.M, *p<0.05, **p<0.01 compared to AgGluClR-a1 using unpaired t-test. 
 
Receptor 
subtype 
Lindane Fipronil 
% Recovery  n % Recovery n  
AgGluClR-a1 71.5 ± 2.1  6 37.3 ± 6.4 6  
AgGluClR-b 42.3 ± 3.2*  6 18.1 ± 2.1** 6  
 
Differential efficacy of lindane, fipronil and picrotoxin at inhibiting currents mediated by an 
EC50 IVM concentration: 
 From the above experiments, we know that lindane, fipronil and PTX effectively inhibit 
currents activated by glutamate. As IVM is an irreversible agonist, we wanted to see whether 
these three drugs could inhibit the IVM-mediated currents at AgGluClRs-a1 and AgGluClRs-b. 
The effect of lindane on currents mediated by IVM at AgGluClRs-a1 and AgGluClRs-b is shown 
in figure 5.4 A, B, C. Among the 3 drugs, lindane was the least efficacious inhibiting currents 
by only 20-25% at AgGluClRs-a1 and AgGluClRs-b, with IC50s of 3.0 ± 0.9 µM and 11.0 ± 0.5 
µM, respectively (n=6, each, Table 5.5). Fipronil, on the other had was the most effective in 
inhibiting currents mediated by IVM, inhibiting the currents by approximately 50% or more 
for both the splice variants of AgGluClRs (Figure 5.4D, E, F, Table 5.5). The IC50 values for 
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Figure 5.3: Time dependence recovery of lindane and fipronil induced inhibition at EC50 glutamate. A & B, a sample recovery profile for AgGluClRs-a1 and 
AgGluClRs-b following inhibition by 30 µM lindane. Recovery was monitored by applying glutamate at 2-minute intervals. D & E, similar experiments for 
fipronil. C & F, averaged recovery profiles for lindane and fipronil respectively (n=6). 
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fipronil at AgGluClRs-a1 and AgGluClRs-b were 0.23 ± 0.1 µM and 0.56 ± 0.1 µM, respectively 
(n=6, each). PTX was unique in its effect, where it had differential efficacy between the two 
splice variants. PTX inhibited IVM mediated currents at AgGluClRs-a1 by more than 40% with 
an IC50 value of 5.9 ± 1 µM (n=6) whereas the inhibitory effect of PTX was not prominent at 
AgGluClRs-b with an IC50 of 16.2 ± 0.5 µM (n=6, Figure 5.4G, H, I, Table 5.5). The order of 
efficacy of the three drugs is fipronil > PTX > lindane.  
Table 5.5: The table below depicts the different IC50 values and an approximate percentage of IVM 
currents that were inhibited by lindane, fipronil and PTX at AgGluClR-a1 and AgGluClR-b. All the 
values are represented as mean ± S.E.M, *p<0.05, **p<0.01 compared to AgGluClR-a1 using 
unpaired t-test. ns = not significant. 
 
Receptor 
subtype 
Lindane Fipronil PTX 
LogIC50 (µM) % Inhibition n LogIC50 (µM) % Inhibition  n LogIC50 
(µM) 
% Inhibition n 
AgGluClR-
a1 
3.0 ± 0.9 17.1 ± 3.4 6 0.23 ± 0.1 50 ± 6 6 5.9 ± 1  19.9 ± 2.3 6 
AgGluClR-b 11.0 ± 0.5ns 19.2 ± 5.9ns 6 0.56 ± 0.1 ns 68 ± 10* 6 16 ± 5 ns 45.3 ± 7.3* 6 
 
Discussion and conclusion 
In conclusion, it is evident from the inhibitory and recovery profiles of lindane, fipronil 
and PTX at AgGluClRs-a1 and AgGluClRs-b, that these drugs have different efficacies at the 
two splice variants. Preliminary characterization of both the splice variants of AgGluClRs 
against glutamate and IVM proved that they were equally sensitive. Lindane showed 
differential efficacy between the two splice variants where it only blocked partial glutamate-
mediated currents of AgGluClR-a1 in comparison to AgGluClR-b where a total block of 
currents was seen. Both fipronil and PTX almost completely inhibited glutamate-mediated 
currents except in case of PTX at AgGluClR-a1 where only 80% of currents were inhibited. 
Time-dependent recovery profiles were also interesting where neither AgGluClR-a1 nor 
AgGluClR-b recovered to their original peak amplitude after being inhibited by a single 
concentration of lindane or fipronil. On the other hand inhibition of IVM-mediated currents 
by lindane, fipronil and PTX were different compared to the inhibition produced by these 
drugs on glutamate-mediated currents. Lindane and fipronil were not significant in inhibiting  
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Figure 5.4: Ability of lindane, fipronil and PTX to block currents mediated IVM. (A) & (B), Inhibitory properties of lindane at AgGluClR-a1 and AgGluClR-b. 
Lindane was the least efficacious drug in inhibiting IVM mediated currents. (D) & (E) Similar experiments done using fipronil at AgGluClR-a1 and AgGluClR-b, 
fipronil was the most effective in inhibiting IVM invoked currents. (G) & (H) Sample traces for PTX at AgGluClR-a1 and AgGluClR-b. PTX was unique where it 
was more efficacious at AgGluCl-a1 compared to AgGluClR-b. (C), (F) & (I) averaged inhibitory dose-response relationships for lindane, fipronil and PTX, 
respectively. 
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the IVM-mediated currents on the two AgGluClRs splice variants, whereas fipronil was 
significant in inhibiting IVM-mediated currents in comparison to lindane and fipronil.  The 
order of efficacy for inhibiting IVM-mediated currents is fipronil > PTX > lindane.  
One of the contributing reasons for this difference could be the molecular 
determinants of the drug binding sites. (Chen et al. 2006) predicted that lindane and fipronil 
bind to the 2’ and 6’ pore-lining residues of human β3 homomeric GABAARs. This result was 
confirmed in D. melanogaster RDL GABAARs, which showed reduced sensitivity to lindane and 
fipronil at naturally occurring mutations of A2’S and A2’G (Cole et al. 1995; Hosie et al. 1995). 
The role of 2’ and 6’ in the binding of lindane and fipronil was also supported by the results 
from (Islam and Lynch 2012) in α1 glycine receptors. However, both splice variants have a 
serine and a threonine at 2’ and 6’, respectively. Future work should concentrate on why the 
drugs exhibit altered sensitivities at one isoform compared to the other. 
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Discovering new drugs selectively targeting α5 containing GABAARs 
Introduction  
This project aimed at screening a library of fractions that were isolated from Australian and 
Antarctic marine invertebrates and algae in order to discover a novel lead compound that is 
selective for α5 GABAARs. The crude extracts were first tested using ToxFinder. ToxFinder is 
an equipment to perform high-throughput screening (HTS). In ToxFinder, we use a yellow 
fluorescent protein (YFP)-based anion influx assay. This system involves transfecting HEK 293 
cells with the desired receptor isoform along with the YFP I52’L. The I52’L mutation imparts 
high sensitivity to iodide (I-) quench (Gilbert et al. 2009).  Drugs dissolved in sodium iodide 
(NaI) solution results in quenching of the YFP based on the properties of the drug either 
potentiating or inhibiting the fluorescence (Refer chapter 2 – high-throughput yellow 
fluorescent protein (YFP)-based anion influx assay).  
As the extract quantity was minimal, we limited our screening only on α5β3γ2L GABAAR. 
The reason for choosing this subtype is its prevalence in hippocampus (Sieghart and Sperk 
2002; Sur et al. 1998). Hippocampus is a region of brain that is associated with learning and 
memory (Chambers et al. 2003). α5 containing GABAARs account for 20% of total GABAARs in 
the hippocampus, implicating its role in learning and memory (Sur et al. 1998). Both positive 
and negative modulators of α5 GABAARs have the potential to be clinically useful, unlike other 
GABAAR subtypes (Soh and Lynch 2015). Professor Robert Capon (Institute of Molecular 
Bioscience, The University of Queensland, Australia) kindly provide the compound library. 
Compounds that show selectivity for α5 GABAARs can be used as leads to design drugs that 
selectively target α5 GABAARs. After finding potential hits from ToxFinder they were re-
assessed using automated Patchliner. This device permits complete exchange of the solution 
bathing the cells with 25 μL of new solution. This later feature was particularly important as 
the Capon lab provided us with only minute amounts of extracts and pure compounds (Refer 
chapter 2 – automated electrophysiology). 
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Results: 
Preliminary marine extract screening 
This project initially screened approximately 2800 (Figure 6.1 and 6.2) crude marine 
extracts on the ToxFinder at α5β3γ2L GABAARs, by a previous member of our lab (Ming Soh). 
This screening yielded 36 hits that were further partitioned, triturated and fractionated using 
different solvents. This process gave us about 180 compounds that were partitions, triturates 
and fractions of these 36 hits.  
Figure 6.1: Flow chart showing the partition and trituration of ethanol crude extracts. Based 
on the polarity, crude extracts were partitioned into n-butanol and H2O soluble portions, 
numbered as -1 and -2 respectively. Where the (-1) n-butanol partition was further 
triturated into hexane (-1-1), dichloromethane (DCM) (-1-2), methanol (MeOH) (-1-3) and 
H2O (-1-4) soluble triturates. The (-2) H2O soluble partition was triturated into aqueous 
methanol (Aq. MeOH) (-2-1) and H2O (-2-2) soluble triturates. 
 
Screening of partitions and triturates 
Partitioning and trituration of crude extracts using n-butanol and water-soluble parts yielded 
36 compounds (Figure 6.2). These 36 compounds were further partitioned and triturated to 
give 180 compounds (Figure 6.1). The 180 partitions and triturates were tested on the 
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ToxFinder using a 384 well plate, at the α5β3γ2L GABAARs in triplicates (one well per 
partition/triturate per screen).  
Figure 6.2: Summary of marine extract screening 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells were pre-incubated with a partition or triturate at a final concentration of 4 
µg/µL that were dissolved in 5.3% DMSO. During experiments, each well was subjected to 
EC20 GABA dissolved in NaI solution that were already pre-treated with a partition or a 
triturate for half an hour. No significant GABA quench was observed in control experiments 
where only 5.3% DMSO was applied to the cells. We were looking for partitions or triturates 
that either potentiated or inhibited the EC20 GABA quench. The criteria for selecting a partition 
or a triturate was that it should modulate the of EC20 GABA quench by at least 50%. Out of 
the 180 compounds that belonged to 36 crude extracts, compounds belonging to 32 crude 
extracts returned with non-active partition/triturate i.e., their GABA EC20 quench was less 
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than 50%). 14 compounds belonging to 4 crude extracts had at least one active 
partition/triturate, and the results listed in table 6.1. 
 The four crude extracts that were identified had active partitions in them and are 
CMB-01871, -02130, -03405, and -03208 (Refer to appendices, section 2 for all the traces from 
these extracts on the Patchliner). These four crude extracts, after partitioning and trituration, 
gave 14 compounds (fractions). The fractioned products from CMB-02130 (Genus: Theonella) 
and CMB-03405 (Genus: Axinella) i.e., CMB-02130-1-2, CMB-02130-1-3 and CMB-03405-1-3 
respectively were the most significant inhibitors of α5β3γ2L GABAAR mediated currents. 
Further partitioning and trituration of fractions from CMB-02130-1-3 and CMB-03405-1-3 
yielded 19 sub-fractions (Refer to appendices, section 2 for the traces from these sub-
fractions on the Patchliner). 
After the initial screening on the ToxFinder, the crude extracts were further subjected 
to partitioning and trituration. The partitions and triturates of 32 crude extracts that did not 
show any substantial activity. This could be due to two reasons; first, ToxFinder screens 
compounds quickly but not accurately. Second, there might have been synergistic effect 
between the active compounds in the whole extract, which was lost once the compounds 
were partitioned and triturated. Although this was unlikely, the fractions from the pure 
compounds were re-tested using automated patch clamp (Patchliner) method. Only one pure 
compound was successfully identified from the all the partitions, triturates, fractions and sub-
fractions due to scarcity of the crude extracts. This pure compound was isolated from the 
fraction CMB-02130-1-2 and identified as Aurantoside A (Figure 6.3). This compound has 
shown cytotoxicity against P388 and L1210 leukaemia cell lines and potent antifungal activity 
against Aspergillus fumigatus and Candida albicans (Matsunaga et al. 1991; Sata et al. 1999). 
Due to its limited availability we were only able to screen this compound against one subtype 
of GABAARs i.e., at α5β3γ2L. Even though the effect of Aurantoside A was prominent (IC50 0.19 
± 0.01 µM) (Figure 6.3), we decided not to go ahead with the screening on other subtypes 
due to obvious reasons of availability and time invested in the screening.  
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Table 6.1: Percentage modulation by the active marine extracts, partitions and triturates from the 
14 fractions belonging to four crude extracts screened on ToxFinder. Numbers represent the 
modulation of GABA EC20 quench by the extracts. Partitions and triturates that modulated the GABA 
EC20 quench by >50% are shown.  Indicates the partition/triturate either were inactive or had no 
significant effect (The complete list of compounds tested on the ToxFinder is detailed in appendices, 
section 3.2). 
 
CMB-code 
Percentage modulation of EC20 GABA-mediated quench (%) 
Crude 
extract 
n-BuOH 
(-1) 
n-Hexane 
(-1-1) 
DCM 
(-1-2) 
MeOH 
(-1-3) 
Aq. MeOH 
(-2-1) 
CMB-02130 98.0 92.0 76.6 70.9 96.1 58.6 
CMB-01871 76.6 68.8 89.2 63.3 98.9 87.8 
CMB-03208 89.2  65.6 97.4 91.2  
CMB-03405 58.6    56.9     
 
Figure 6.3: A) Concentration response of Aurantoside A against α5β3γ2L GABAARs. A sample 
trace from automated patchliner recording of a single cell shows the inhibiting effect of 
increasing concentrations of Aurantoside A on the GABA EC20-induced current. B) Chemical 
structure of Aurantoside A. C) Inhibitory dose-response graph for Aurantoside A (n=4).  
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Quinazoline alkaloids against GABAAR  
Apart from testing the fractions and sub-fractions, quinazoline alkaloids derived from 
Penicillium sp. was provided by Prof. Robert Capon were also tested on α5β3γ2L GABAARs. 
These two compounds, named as CMB-TSF015-C02 and –C03, showed significant inhibition 
of α5β3γ2L GABAARs. 
These pure compounds were identified as Fumiquinazolines. Fumiquinazolines consist 
of a pyrazino [2, 1-b] quinazoline-3, 6-dione core which is linked with an indole moiety. An 
anticancer agent, Idelalisib has structural similarity to that of the quinazolinone scaffold 
(Resende et al. 2018). Alantrypinone (+)-1, a compound having a structural resemblance to 
fumiquinazoline C  (Kuriyama et al. 2004) was shown to inhibit currents induced by GABA in 
cockroach neurons (Watanabe et al. 2009). Out of the two compounds, CMB-TSF015-C03 was 
more potent towards α5β3γ2L GABAARs and identified as Fumiquinazoline J, a complete dose 
response on α5β3γ2L GABAARs shown below Figure 6.4.  
Figure 6.4: A) Concentration response of Fumiquinazoline J against α5β3γ2L GABAARs. A sample trace 
from whole cell patch clamp recording of a single HEK 293 cell shows the inhibiting effect of 
increasing concentrations of Fumiquinazoline J on the GABA EC20-induced current. B) Chemical 
structure of Fumiquinazoline J. C) Inhibitory dose-response graph for Fumiquinazoline J (n=6).  
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Effect of GT-002 on IPSCs mediated by different GABAAR isoforms 
 As a part of my thesis, I decided to screen a drug GT-002 kindly provided by Dr. Mogens 
Nielsen, CSO, Gabather, on GABAAR isoforms. Gabather is a small company based in Sweden, 
where they are trying to develop novel drug candidates for disorders related to central 
nervous system (CNS). Gabather has previously done in vitro and in vivo experiments on 
GABAARs using two drugs developed by their company i.e., GT-001 and GT-006, both of which 
showed promising results in models of psychosis and anxiety without having any side effects 
by targeting α5 containing GABAARs. Now their focus is GT-002 as one of the potential 
antipsychotic drug. A study done in collaboration with Gabather and University of New South 
Wales (UNSW), Australia, has shown that GT-002 has positive allosteric effect on α5 
containing GABAARs. It is different from other positive allosteric modulators in that it does 
not affect neuronal populations containing other than α5 containing GABAARs thereby 
minimizing sedative and convulsive effects. Apart from that, in vitro studies have shown it to 
be a highly selective drug for α5 containing GABAARs. Therefore, the aim here was to see if 
GT-002 would have differential effect if we substituted three different β isoforms i.e., β1, β2 
and β3 in α5βxγ2L GABAARs. For this purpose we used the co-culture method wherein we 
allowed the growth of cortical neurons from E18 pregnant rat embryos on coverslips with 
HEK293 cells transfected with the desired GABAAR isoform and measured the spontaneously 
evoked GABA mediated inhibitory postsynaptic currents (IPSCs). Only the cells that were 
transfected with GABAARs subunits in co-culture with neurons produced synaptic currents 
consisting of fast rise to peak, which was followed by a slower exponential decay back to 
baseline.  
 We tested the efficacy of GT-002 at two different concentrations (10 nM and 1 µM) at 
α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs (Figure 6.5). Application of either 10 nM or 1 µM GT-
002 at α5β1γ2L had no significant effect on peak amplitudes, rise times, or their decay times 
(n=5), when compared with the control numbers (Figure 6.5 & 6.6) (Table 6.2). By contrast, 
applying GT-002 at a concentration of 10 nM to cells expressing α5β2γ2L, increased the rate of 
decay from 100 ms to approximately 200 ms. Increasing the concentration of drug applied 
from 10 nM to 1 µM did not increase the decay rates any further (n=5) (Figure 6.5 & 6.6) 
(Table 6.2). Other kinetic parameters such as peak amplitude and rise time did not change 
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significantly.  Application of 10 nM and 1 µM GT-002 at α5β3γ2L had some visible effect on its 
decay rates but were not statistically significant.  
 The results suggests that GT-002 is a specific modulator for α5β2γ2L and that 
substituting a single subunit of β with a different isoform can result in loss of activity of GT-
002. This could be useful in treating disorders that are known to be involve α5β2γ2L GABAARs, 
thereby eliminating any side effects that arise from the drugs that target other β receptor 
isoform.  
Figure 6.5: Properties of spontaneous IPSCs recorded from heterosynapses incorporating 
α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. (A) Mean IPSC decay time constants from cells 
expressing the indicated isoform. (B) Mean IPSC peak amplitudes from cells expressing 
indicated isoforms. (C) Mean 10-90% rise times from cells expressing the indicated isoforms. 
All the values are averaged from 5 cells with at least 10-100 events. Values were tested for 
significance using one-way ANOVA, where *p<0.05 and ns= not significant.  
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Table 6.2: Effect of 10 nM and 1 µM GT-002 on IPSC parameters for three different GABAAR isoforms. 
GABAAR 
isoform 
Rise time (ms) Decay time constant (ms) Amplitude (pA) 
Control GT-002 
10 nM 
GT-002 
1 µM 
Control GT-002 
10 nM 
GT-002 
1 µM 
Control GT-002 
10 nM 
GT-002 
1 µM 
α5β1γ2L 3.4 ± 0.2 3.2 ± 0.3 2.9 ± 0.3 108 ± 13 128 ± 10 121 ± 20 104 ± 21 98 ± 14 99 ± 16 
α5β2γ2L 6.1 ± 0.7 5.1 ± 0.3 5.4 ± 0.7 128±9 198±11* 192±13* 426±64 330±50 329±55 
α5β3γ2L 4.7 ± 0.7 4.4 ± 0.2 3.9 ± 0.3 206±33 175±25 165±45 271±121 264±94 244±52 
Figure 6.6: Representative recordings of IPSCs from HEK293 cells expressing each isoform. (A1), (B1) 
& (C1) Sample traces showing the effect of GT-002 at two different concentrations on IPSCs recorded 
from HEK293 on α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs, respectively. (A2), (B2) & (C2) Averaged (from 
10 to 100 events) normalised IPSCs from individual cells expressing α5β1γ2L, α5β2γ2L and α5β3γ2L 
GABAARs, respectively. 
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Discussion 
An increasing numbers of drug discovery studies are discovering natural compounds 
that target CNS ion channel receptors. Some of these studies have been fruitful, such as the 
discovery a subunit-selective α3 GlyR modulator for treatment of chronic inflammatory pain 
(Balansa et al. 2010). Drugs that specifically target α5β3γ2L GABAARs have potential to be 
useful in treating many CNS-related disorders such as Down syndrome, post-stroke recovery 
and Alzheimer’s (Soh and Lynch 2015).  
Screening of fractions and sub-fractions using ToxFinder and Patchliner, we were able 
to isolate aurantoside A from the marine sponge Theonella sp. (code CMB-02130) (Fusetani 
et al. 1990; Fusetani et al. 1991; Matsunaga et al. 1991). Generally, aurantosides are 
halogenated hydrocarbons from sponges and were previously only found in species of 
Manihinea Pulitzer-Finali and Theonella Gray (Hall et al. 2010). Aurantosides comprises a 
number of compounds, ranging from aurantoside A to K. Aurantoside A and B have been 
shown to possess cytotoxic activity (Matsunaga et al. 1991; Sata et al. 1999). Aurantoside J 
and K showed potential antifungal activity (Angawi et al. 2011; Kumar et al. 2012). However, 
as the cytotoxic effect of aurantoside A is known we decided to discontinue further testing of 
this isolated compound, as it would have meant investing more time without a fruitful result.  
In addition to the aurantosides, other products derived from Penicillium sp. i.e., 
quinazoline alkaloids were also tested on α5β3γ2L GABAARs. The two compounds i.e., CMB-
TSF015-C02 and –C03 were alantrypinone and fumiquinazoline analogues, respectively. GABA 
induced currents in cockroach neurons were inhibited by alantrypinone and their derivatives, 
whereas derivatives of fumiquinazolines (Fumiquinazoline F) possess antifungal activity (Li et 
al. 2012). Although the fumiquinazoline derivative had prominent activity because of its 
complicated structure, we did not see it as a viable therapeutic option and therefore decided 
not to screen it on different GABAAR subtypes.  
Apart from all the preliminary screening from the ToxFinder and Patchliner, I also 
tested a drug, GT-002, on three different GABAAR isoforms. This drug has shown selective 
modulation at α5 containing GABAARs. β subunits have been shown to have an important role 
in mediating modulatory effects of the anxiolytic drug, etifoxine, on GABAARs (Hamon et al. 
2003). Our results show that the effects of GT-002 on GABAARs is determined by the identity 
187 
 
of the β subunit, which played a major role in potentiating the spontaneously evoked IPSCs. 
As GT-002 specifically targets α5β2γ2L GABAARs, it could be used as a candidate lead in 
developing drugs that target diseases involving this specific subunit.  
To summarise, a number of CNS related disorders including autism, schizophrenia, 
cognitive impairment in Down syndrome and Alzheimer’s disease have α5 containing 
GABAARs as their targets. Therefore, it is important for us to continue the search for drugs 
that specifically target GABAARs. This chapter has provided some insights relevant to these 
goals.  
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General discussion 
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a) The β Subunit: a potential cause of IVM resistance in H. contortus 
The parasitic nematode H. contortus has a major detrimental impact on primary 
production animals including sheep, cattle and goats. Previous studies of GluClRs from C. 
elegans have demonstrated that receptors comprising different subunit isoforms exhibit 
different sensitivities to glutamate and IVM (Cully et al. 1994). However, there is no evidence 
of β subunit of HcoGluClR involved in IVM resistance in field isolates. In order to characterize 
the different agonist sensitivities of the different receptor isoforms, fixed quantities of α 
homomer or β homomer and αβ heteromers of H. contortus GluClRs subunits were injected 
into oocytes from X. laevis. 
 Glutamate concentration responses for α homomeric, β homomeric and αβ 
heteromeric (1:1 and 1:50) HcoGluClRs did not show a marked difference in their EC50s (20-
40 µM), except for the β homomer, which was significantly less sensitive to glutamate (EC50= 
394 µM). As an additional means of determining whether β subunits were incorporated in the 
heteromer, we also used IVM. The α homomers were extremely sensitive towards IVM (EC50= 
20 nM), whereas the β homomers were insensitive. αβ (1:50) heteromers on the other hand 
showed moderate IVM sensitivity which was intermediate between those of the α and β 
homomers (EC50= approx. 150 nM). IVM showed a trend of decreasing sensitivity from α, to 
αβ (1:50) and finally β homomers. These results gave an indication that IVM sensitivity was a 
function of the subunit composition of the receptors, with higher incorporation of β subunit 
corresponding to lower sensitivity to IVM. This brings us to our hypothesis, that the subunit 
stoichiometry of receptor determines its sensitivity towards glutamate and IVM.  
 The functional properties of IPSCs mediated by native GluClRs in invertebrates’ 
neurons or muscle cells have never been reported. For the first time using heterocultures of 
neurons and transfected HEK293 cells, we characterized the properties of recombinant IPSCs 
mediated by α and αβ GluClRs in response to spontaneous presynaptic glutamate release. 
Using this technique, we defined the IPSC kinetics mediated by both GluClR isoforms, how 
different drugs effect the IPSCs mediated by different GluClR isoforms, and how the 
posttranslational modifications and mutations that impart IVM resistance to the organism 
affect the formation and function of synapses. In general, produced an increase in IPSC peak 
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amplitudes and a slowing of IPSC kinetics, in particular the decay rates. A dbeecreased 
sensitivity might be due to intrinsic activation properties of β – containing receptors. 
 Single channel data on αβ and β HcoGluClRs revealed that mean active durations are 
shortened when the concentration of β is increased thereby rendering the receptors less 
sensitive to potentiation by IVM when compared to α GluClRs. 
 The time course of action of IVM was attributed to its interactions with cell 
membranes. In order to see how IVM accumulates and diffuses in the membrane a 
fluorescent-tagged IVM (IVM-bdpy) was synthesised. In these experiments, the IVM-bdpy 
needed about 18 minutes to equilibrate in the whole cell membrane, which was similar to the 
tonic current equilibrium time in our IPSC recordings where IVM-mediated changes take 
about 17 minutes to plateau. Apart from this, using FRAP we measured the slow lateral 
diffusion rate of IVM that contributes to the association rates of IVM to the binding sites at 
GluClRs. The data suggests that rather than inducing a slow conformational rearrangement to 
the receptor by directly binding from the aqueous portion the major pathway for IVM to reach 
its target site at GluClRs is membrane partitioning and lateral diffusion. 
 Finally using structure activity relationship, we identified important receptor-drug 
interactions that determine IVM analogue potency at α and αβ GluClRs that may be useful in 
refining the design of anthelmintic drugs so that they target specific GluClR isoforms.   
 To summarise, based on the above results we conclude that the HcoGluCl β subunit 
confers IVM resistance without altering glutamate sensitivity when incorporated into 
heteromeric receptors with the α subunit. This is achieved by reducing the durations of active 
periods of single receptors and decay times of IPSCs. Based on our data, drug design strategies 
should be targeted towards increasing the active durations of single receptors and slowing 
the decay rates of IPSCs in synaptic isoforms of GluClRs 
G36’A affects the intrinsic properties of the receptor and not IVM binding.  
A decreased sensitivity for glutamate at the mutated α homomeric, TM3-G36’A 
GluClRs prompted us to investigate the action of IVM towards this mutation. IVM was able to 
activate these receptors directly as well as in combination with glutamate without having an 
effect on the channel conductance. 2 µM glutamate alone at the WT receptors elicited single 
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receptor active periods that had a mean duration of ~ 150 ms but when co-applied with 5 nM 
IVM gave rise to prolonged active periods of ~ 16 s. Even though the same combination of 
agonists was applied towards the G36’A mutated receptors the mean active durations were 
about 125 ms which were small in comparison to the WT receptors. However, they were large 
compared to glutamate 2 µM alone (~11ms) on the G36’A receptors.  
 Direct activation by 5nM IVM alone had similar patterns on the WT and the G36’A 
receptors, with the WT receptors having a mean activation duration of ~ 6 s and the mutant 
with just 50 ms.  
In contrast, the active periods of the G36’A mutated receptor were much briefer when 
activated by IVM alone or when co-applied with glutamate when compared with WT 
receptors. Receptor desensitisation was also examined in WT and TM3-G36’A mutant 
receptors. In order to correct the desensitisation time constant, the number of active 
receptors present in the patch were counted by saturating them with glutamate (Atif et al. 
2017). Based on the above analysis we inferred that the WT receptors exhibit little 
desensitisation, especially when glutamate and IVM were co-applied. At WT receptors, 
glutamate plus IVM induced a mean desensitised lifetime of ~ 200 ms with an equilibrium 
constant of 0.01 whereas IVM alone had a mean desensitised lifetime of ~ 550 ms, which gave 
an equilibrium constant of ~0.1 ms.. On the other hand, the TM3-G36’A mutation enhanced 
receptor desensitisation with a mean desensitised lifetime of 1964 ms and an equilibrium 
constant of ~39 ms in IVM alone. Whereas a co-application of glutamate and IVM to TM3-
G36’A produced a mean desensitised lifetime of 1786 ms and an equilibrium constant of ~14.3 
ms 
 In summary, the above experiments show that be it direct activation or potentiation 
by IVM, the G36’A mutant receptors exhibited shorter active durations and increased 
desensitisation in comparison to the WT receptors for both agonists (glutamate and IVM). 
From these data, we infer that the G36’A mutation affects the intrinsic activation properties 
of the receptor and these alterations underlie the reduced sensitivity to IVM at the G36’A 
mutant GluClRs. This directly contradicts the established paradigm which proposes that the 
G36’A mutation hinders IVM from accessing its binding site (Lynagh and Lynch 2010). This 
provides an important new insight into understanding and distinguishing the binding and 
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activation mechanisms of IVM. This in turn will help to define exactly how new IVM analogues 
affect the receptor binding and activation, and will thus help in tailoring of new anthelminthic 
compounds to particular GluClR isoforms. 
Management strategies to delay development of resistance: 
Pasture management and isolation of animal populations are two of the management 
strategies that are currently employed in primary production with an exclusive purpose of 
preventing infestation and/or keeping the level of infestation pressure to a bare minimum. 
These strategies would thereby decrease the dependence on anthelmintics, consequently 
delaying the development of resistance. The following comprise some of the strategies used 
to delay resistance. 
Correct use of anthelmintics 
No matter how effective a drug is at its target, each time a helminth population is 
exposed to anthelmintics they pose a risk of developing resistance. The periodic use of 
anthelmintics belonging to the same class and/or repeated under-dosing increases the risk of 
developing anthelmintic resistance (Sargison 2011). In order to delay the development of 
resistance, a policy involving rotation of anthelmintic classes has been recommended. One of 
the contributing factors towards increased selection pressure is excess deworming which 
leads to the use of unwanted treatment. The best way to ensure that there is no selection 
pressure is pasture management and appropriate treatment in order to maintain low refugia 
(De Graef et al. 2013).  
Refugia 
One of the important tools advocated to slow down the progress of anthelmintic 
resistance is “Refugia” (van Wyk 2001). Refugia refers to an area where the population of 
organisms can escape a period of hostile conditions. In this case, it means that the parasites 
in refugia have not been subjected to an anthelmintic. This includes parasites present as free-
living stages in environment, at any lifecycle stage in the host that are stubborn to 
anthelmintic treatment and in untreated individuals (Fleming et al. 2006; van Wyk 2001). A 
strategy that aims to slow the rate of development of anthelmintic resistance is maintenance 
of a population of parasites in refugia. This method of maintaining a population of parasites 
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in refugia has been demonstrated to slow down the development of anthelmintic resistance 
in sheep model (Pech et al. 2009). 
Different anthelmintic products 
Apart from the methods mentioned above, another strategy to delay development of 
resistance might include the use of a combination of active anthelmintic products containing 
either two or more molecules having similar activity but a different mechanism of action. This 
method was suggested to delay the development of resistance to anthelmintics that were 
indicated in modelling studies and some field studies (Learmount et al. 2012; Leathwick 2012; 
Leathwick et al. 2012).  
Other methods 
Pasture management forms the other management measures aimed to reduce helminth 
infestation e.g. removal of animal droppings from pasture to decrease the level of infective 
larvae, preventing high degree of infestation, decreasing stocking densities or improving the 
drainage of pastures to minimised the risk of liver fluke infestations (Sargison 2011). Apart 
from these methods, there are other biological methods under development (Heckendorn et 
al. 2006; Hertzberg and Sager 2006; Waller et al. 2006), one of which is to select genetically 
less susceptible livestock (Stear et al. 2007). 
b) Differential effects of lindane, fipronil and PTX at AgGluClR-a1 and AgGluClR-b. 
 The original motivation for this study came from a study by (Meyers et al. 2015) that 
reported that AgGluClR-a1 and AgGluClR-b have different sensitivities to IVM. We were 
interested in understanding the underlying mechanism given our finding that IVM exhibits 
different sensitivities at different HcoGluClRs isoform. Given their higher amino acid sequence 
homology, we considered the residues responsible for the differential IVM sensitivity may be 
easier to characterize in the AgGluClR splice variants. First, we needed to perform a thorough 
characterization of glutamate and IVM responses on the two splice variants of AgGluClRs.  
 Pharmacological characterization revealed an interesting finding; AgGluClR-a1 and 
AgGluClR-b were both equally sensitive to IVM contrary to what was reported by (Meyers et 
al. 2015). However, there was differential efficacy for IVM, where the AgGluClR-a1 was more 
sensitive than the AgGluClR-b. As GluClRs are known targets for insecticides, it would be 
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interesting to determine if some of the known insecticides such as lindane and fipronil had 
differential affinities towards one of the splice variants of GluClRs from A. gambiae. This 
information would help us in refining drug discovery strategies to better target specific GluClR 
isoforms of A. gambiae.  
 GlyRs present in the cultured cerebellar granule cells were inhibited by lindane with 
an IC50 of 5 µM (Vale et al. 2003), whereas a complete block by (300 µM lindane) at GlyRs 
isoforms expressed in HEK293 cells was shown by (Islam and Lynch 2012). It was also shown 
to have partial (50%) antagonistic activity against a number of recombinant GABAARs with IC50 
in a range of 1-2 µM (Aspinwall et al. 1997; Maskell et al. 2001).  We found that lindane 
inhibited glutamate mediated currents with an IC50 of 8 µM and 6 µM against AgGluClR-a1 
and AgGluClR-b, respectively, however, the extent with which it inhibited glutamate currents 
differed between the two splice variants. At AgGluClR-b, a complete block of glutamate 
currents was observed, however, a partial block of  ̴65% was seen at AgGluClR-a1. The two 
splice variants were extremely sensitive to fipronil, with IC50s in a range of 0.5-0.8 µM. These 
values were similar to what was reported for GlyRs (Islam and Lynch 2012) and GABAARs 
(Ikeda et al. 2001; Li and Akk 2008). Unlike lindane, fipronil did not possess differential 
potency at the two isoforms and completely blocked glutamate activated currents in both. 
PTX on the other hand was somewhat similar to lindane in its action, where a complete block 
was seen at AgGluClR-b and only 80% block on AgGluClR-a1.  
 Time-dependent recovery experiments helped us to confirm that both lindane and 
fipronil exhibit slow recovery rates, suggesting that possibly a low (nM) concentration of drugs 
might be accumulating at the binding sites and producing the significant inhibitory effects.  
 IVM produces an extremely slow and irreversible current as shown in neuronal 
preparations of HcoGluClRs, as shown in chapter 3. Lindane and fipronil have been shown to 
bind in the GlyR channel pore (Islam and Lynch 2012). This is consistent with a mutation in 
the pore lining the TM2 segment (S2’A) in M. domestica GluClRs that enhanced lindane and 
fipronil sensitivity (Hirata et al. 2008). As these binding positions are close to IVM binding site, 
any data on how lindane, fipronil and PTX inhibiting IVM mediated currents in these two 
AgGluClR splice variants would help to better understand how these drugs act. Lindane was 
the least sensitive at inhibiting IVM mediated currents, followed by PTX, whereas as fipronil 
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was the most effective at blocking IVM currents. These differential effects of lindane, fipronil 
and PTX at inhibiting both glutamate and IVM provides a starting point for understanding how 
these drugs act and help us in refining drugs that are used as insecticides.  
c) Other projects as part of my thesis 
 Effective treatment for present or emerging clinical conditions is the primary aim of 
drug discovery. The drug development program takes approximately 16 years from 
identification of a lead molecule to its clinical use and is divided into two main stages namely 
preclinical research and clinical trials. The cost for identifying a single drug and developing it 
ranges in the billions of dollars (Roses 2008). Modulation of a physiological pathway or a 
specific protein involved in a clinical condition is usually the starting point for drug discovery. 
Then comes the validation of the modulatory protein or the pathway that may lead to a 
potential therapy. However, the first step in this pipeline is the process of identifying lead 
compounds and developing these using screening methods. High-throughput screening that 
utilises automated screening machines is one of such approaches to screen through libraries 
of compounds all of which are made up of diverse chemical structures.  
 Our focus was the preclinical stage where we aimed to discover novel molecules that 
specifically target α5 containing GABAARs. (Soh and Lynch 2015) identified this target receptor 
to be involved in a number of clinical conditions such as post-stroke recovery, cognitive 
impairments in Down syndrome and Alzheimer’s, schizophrenia and autism. Drugs targeting 
this receptor subtype should minimise the side effects due to non-selective receptor 
modulation of other GABAARs isoforms. Using a high-throughput YFP based assay, in a short 
time duration, we initially screened a large number of natural compounds derived from 
Australian and Antarctic marine sponge and algae on the target receptor expressed in 
mammalian HEK293 cells (Balansa et al. 2010; Gilbert et al. 2009). A number of hits were 
filtered in order to prioritise the ones with largest effect, best selectivity profile and 
appropriate chemistry, for further assessment using Nanion Patchliner, an automated planar 
chip patch clamp device. Reconfirming the hits in secondary electrophysiological assays took 
some time and employed relatively large quantities of the compounds. This incomplete 
project is currently stalled due to insufficient quantities of hit compounds. Further supplies 
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are required to determine the chemical structure, potency and selectivity of promising hit 
compounds. 
 Nevertheless, our high-throughput screening has identified some modulators 
targeting α5 containing GABAARs that might be helpful in future drug development for this 
receptor. In particular, we identified a quinazoline alkaloid that demonstrated very high 
potency for α5 containing GABAARs. As this compound was able to inhibit GABAAR mediated 
currents in the nanomolar range, we hypothesised that this compound has the potential to 
be developed and improved further as a lead to therapeutic development and a probe to 
investigate the functional properties of α5 containing GABAARs.  
 Despite the large number of clinical conditions for which α5 GABAAR modulation has 
been implicated, only a few α5 GABAARs selective modulators have been identified based on 
synthetically-derived structures (Soh and Lynch 2015). Subsequently only one has managed 
to make it to clinical trials. Originally known as RG-1662, Basmisanil is currently in phase 2 of 
clinical trials, to treat cognitive impairments in adults and adolescents with Down syndrome. 
In short, our study has identified new GABAAR modulators through natural product screening 
that might be useful as clinical leads and/or pharmacological probes of GABAARs. 
Drug discovery strategies: 
The field of drug discovery and design has seen remarkable advances despite it being 
a complex and an interdisciplinary process. Natural products have been out of the spotlight 
in favour of artificial chemical structures over the last five decades in the drug discovery 
paradigm as sources for new drugs (Harvey et al. 2015). Most of these artificial structures 
were often based on clinically effective drugs with similar structural scaffolds or integrated 
with chemical motifs from clinically successful compounds. Compounds generated using this 
click chemistry often failed to yield much needed effective new therapies and the rate of 
success of these compounds in clinical trial was extremely poor (Kola and Landis 2004). The 
limited structural diversity inherent in the conventional combinatorial libraries was a major 
reason for the failure of artificial chemical structures (Butler et al. 2014; Carter 2011; Harvey 
et al. 2015). This has prompted renewed interest in the development of leads and drugs from 
natural sources, as they possess the structural diversity not usually found in synthetically 
based corporate screening libraries (Abet et al. 2014). Ever since the natural products gained 
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traction in drug discovery and development, a total of 25 natural product-derived drugs 
(NPDDs) were launched in the market during 2008 - 2013 (Butler et al. 2014). These drugs 
were sourced from fungus, sponge, plants and bacteria metabolites, and were approved for 
treating a number of disorders ranging from diabetes to cancer (Butler et al. 2014).  
As the resupply of raw materials in NPDDs is usually the rate-limiting factor (Abet et 
al. 2014), more recently, hybrid techniques have been developed whereby combinatorial 
libraries incorporate the broader chemical diversity of natural products (Lachance et al. 2012; 
van Hattum and Waldmann 2014). Recent advances include the use of ligand-directed 
chemistry to design semisynthetic biosensors for GABAARs, by coupling chemical labelling 
with a biomolecular fluorescence quenching and recovery (BFQR) system (Yamaura et al. 
2016). The potential for generating new generations of α5 GABAARs-specific modulators, as 
well as other therapeutic drugs looks promising, when coupled with complementary 
approaches such as fragment-based discovery (Wang et al. 2015), diversity-oriented synthesis 
(O' Connor et al. 2012), and dynamic combinatorial chemistry (Li et al. 2013). 
However, as most of the drugs lack selectivity, the two most sought-after properties 
for drug molecules is extremely high affinity and selectivity. For most drugs, selectivity has 
been difficult to achieve, as the various targets are often large families of proteins with 
closely-related structures and functions (Kawasaki and Freire 2011). Selectivity of drugs 
during lead optimization can be maximised in two ways: improving the affinity towards the 
targets than to off-target molecules by chemical modification of the lead compound: and/or 
lowering the affinity of the hit compound towards off-target molecules using chemical 
modification (Kawasaki and Freire 2011). A combination of both the mechanisms can help in 
achieving maximal selectivity. Apart from this, binding affinity can be improved by 
introduction of nonpolar functionalities that fill a binding cavity (Kawasaki and Freire 2011). 
All these methods surely will help in better optimization of drug molecules in the near future.  
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Effect of Glutamate and IVM at two β homomeric mutants of H. contortus 
 Our first set of experiments in chapter 3 (GluClRs comprising homo- and heteromeric 
combinations of α and β subunits of H. contortus) we found that β HcoGluClRs is insensitive 
to IVM. However, as we do not know the molecular determinants of IVM insensitivity in 
reason β HcoGluClRs for that, we hypothesised that nonconserved residues in the TMDs could 
be the cause for this insensitivity as IVM binds at the interface of TM3 and TM1 of two 
adjacent subunits. We then aligned the TMDs of α, β subunits of H.contortus and α subunit 
of C.elegans to find any potential residues that could differ between α and β subunits of 
HcoGluClR. We identified two residues in the TMDs of β subunits; one was in TM1 where we 
mutated it from an isoleucine to leucine at -18’ position (I-18’L) and the second was a TM3 
mutation where we substituted the glutamine with leucine at 39’ position (Q39’L). These 
mutated β subunits were expressed as homomeric receptors in oocytes for functional 
investigations. 
Figure A1: Effect of glutamate on WT and two β HcoGluClR mutants using TEVC. (A) A sample dose-
response trace for glutamate on WT β HcoGluClRs (B) A sample dose-response trace for glutamate 
on TM1 mutation of I-18’L. (C) A sample concentration response trace for glutamate on Q39’L. (D) 
Glutamate concentration-response graphs for WT, I-18’L and Q39’L (n=6 at least). 
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Figure A2: Effect of IVM on I-18’L. (A) A cumulative dose-response trace for IVM at β I-18’L 
using TEVC. (B) Concentration-response graph for IVM at β I-18’L (n=6). 
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Table A1: Table showing the EC50 values of glutamate and IVM at two mutants from β 
homomeric HcoGluClRs (n=6 at least) 
 
 
Agonist 
H. contortus 
β WT (EC50) β I-18’L (EC50) β Q39’L (EC50) 
Glutamate 394 ± 57 µM 16 ± 2 µM 2.8 ± 0.3 mM 
Ivermectin >10 µM 344 ± 42 nM > 10 µM 
 
 
  
 
 
 
 
 
 
 
Section 2 
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Discovering new drugs selectively targeting α5 containing GABAARs 
Table A5: GABA EC50 values from ToxFinder 
Receptor EC50 (µM) Hill slope n 
α1β2γ2L 1.0 ± 0.1 1.1 ± 0.1 10 
α5β2γ2L 0.4 ± 0.1 1.2 ± 0.1 9 
α5β3γ2L 0.2 ± 0.1 1.1 ± 0.1 9 
 
Table A6: GABA EC50 values from whole cell patch clamp recordings 
 
Receptor EC50 (µM) Hill slope n 
α1β2γ2L 17.5 ± 0.1 1.4 ± 0.3 6 
α5β2γ2L 8.8 ± 0.1 1.9 ± 0.1 6 
α5β3γ2L 5.1 ± 0.1 1.6 ± 0.1 6 
 
Figure A3: GABAAR concentration responses. Graph (A) illustrates the GABA concentration-
responses recorded in HEK 293 cells expressing α1β2γ2L, α5β2γ2L and α5β3γ2L GABAARs on the 
ToxFinder. Graph (B) shows the GABA concentration-responses obtained from whole cell 
patch clamp recordings in α1β2γ2L, α5β2γ2L and α5β3γ2L GABAARs expressed in HEK 293 cells. 
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Table A7: Full list of crude extracts with more than 50% activity on the ToxFinder. The 
subsequent activities of fractions also included. Numbers in the bracket represent the % 
extent of potentiation (+) or (-) inhibition compared to control GABA EC20 quench. The 
fractions were n-butanol (n-BuOH), n-hexane, dichloromethane (DCM), methanol (MeOH) 
and aqueous methanol (Aq. MeOH, refer to main text figure 6.1). Green shade: 
potentiation; blue shade: inhibition; red shade: cell death; white shade: no activity or no 
significant activity. 
 
CMB-code 
Percentage Modulation (%) 
Crude 
extract 
n-BuOH 
(-1) 
n-Hexane 
(-1-1) 
DCM 
(-1-2) 
MeOH 
(-1-3) 
Aq. MeOH 
(-2-1) 
CMB-02130 +98.0 +92.0 +76.6 +70.9 +96.1 +58.6 
CMB-03706 +83.1 +82.6 +82.0 +73.8   
CMB-01871 +76.6 +68.8 +89.2 +63.3 +98.9 +87.8 
CMB-03208 +89.2  +65.6 +97.4 +91.2  
CMB-02736 +71.8 +69.6 +53.7  +60.6 +56.1 
CMB-01699 +52.3     +53.2  +57.6 +61.9 
CMB-03217 +50.9 +65.2    +57.2 
CMB-03552 +72.5 +66.4 +73.0 +69.9 +56.4  
CMB-02999 +68.9 +67.6 +63.0 +73.9   
CMB-02031 +75.4 +81.6  +57.4 +73.8 +54.5 
CMB-02968 +78.9 +60.5 +83.2 +70.1 +64.9 +82.5 
CMB-02671 -35.5      -12.0    
CMB-03456 +55.7 +52.4 +55.2 +53.3  +49.9 
CMB-02733 +72.0   +75.8 +63.2 +59.3 
CMB-02628 +45.3 -22.0  +53.2  +49.1 
CMB-01900 +50.0 +60.8  -1.5 +73.2  
CMB-01534 +21.1      
CMB-02633 +28.9      
CMB-01565 +27.3      
CMB-03157 +22.5      
CMB-03242 +69.3 +68.2 +72.8 +75.1 +69.4  
CMB-02996 +70.0 +69.7  +64.8  +66.7 
CMB-03210 +65.8 +63.5  +72.8 +61.0 +61.5 
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CMB-01700 +60.0 +55.1 +63.5  +61.9  
CMB-03405 +58.6    +56.9     
CMB-02571 +45.3 -10.8  -16.4 +53.1 +53.4 
CMB-02758 +50.1 -7.0 +54.8 +63.1 +55.7 +54.3 
CMB-03077 +71.1 +72.2   +67.8 +61.5 
CMB-03247 +50.3   +62.1   
CMB-03457 +62.5 +61.7   +59.3 +72.5 
CMB-01845 +65.9 +61.9  +67.8  +59.8 
CMB-03251 +53.5    +56.9     
CMB-02709 -42.7 -13.1     
CMB-03216 +35.3      
CMB-03357 +62.3 +70.4  +58.3  +65.0 
CMB-02997 +45.9      
 
 
Table A8: Different fractions tested on the Patchliner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMB-01871 
-1-1 (Figure A3-A) 
-1-2 (Figure A3-B) 
CMB-03405 -1-2 (Figure A4-A) 
-1-3 (Figure A4-B) 
CMB-03208 -1-1 (Figure A5-A) 
-2-1 (Figure A5-B) 
CMB-02130 -1-3 (Figure A5-C) 
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Figure A4: (A) A sample dose response trace for GABA at α5β3γ2L GABAARs using the 
Patchliner. (B) Concentration response graph for α5β3γ2L GABAARs (n=6). 
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Figure A5: Traces from the fractions belonging to the CMB-01871 group. (A) A sample trace 
depicting the effect of n-Hexane (-1-1) fraction at α5β3γ2L GABAARs when co-applied at a 
concentration of 0.2 µg/µL with 1 µM GABA. Three control applications of GABA EC20 were 
done in order to determine the quality of the cell. (B) Similar experiment done with the 
DCM (-1-2) fraction at α5β3γ2L GABAARs.  
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Figure A6: Traces from the fractions belonging to the CMB-03405 group. (A) A sample trace 
from the Patchliner showing the effect of the DCM (-1-2) fraction at α5β3γ2L GABAARs when 
co-applied at a concentration of 0.2 µg/µL with 1 µM GABA. Three control applications of 
GABA EC20 were done in order to determine the quality of the cell. (B) Similar experiment 
done with methanol (-1-3) fraction. 
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Figure A7: Traces from the fractions belonging to the CMB-03208 and CMB-02130 group. (A) 
& (B) Traces from the Patchliner showing the effect of n-Hexane (-1-1) and aqueous 
methanol (-2-1) fraction from the CMB-03208 group, respectively, at α5β3γ2L GABAARs when 
co-applied at a concentration of 0.2 µg/µL with 1 µM GABA. Three control applications of 1 
µM GABA were done in order to determine the quality of the cell. (B) Inhibitory effect of 
CMB-02130-1-2 (DCM fraction) at 0.2 µg/µL along with 1 µM GABA. 
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Table A9: Table depicts the products of further partitioning from the fractions belonging to 
the CMB-02130-1-3 and CMB-03405-1-3 groups.  
CMB-02130-1-3 CMB-03405-1-3 
-1 -2 -3 -4 -5 -6 -7 -8 -1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 
 
Figure A8: Bar graph showing the different sub-fractions from the CMB-02130-1-3 and CMB-
03405-1-3 groups and their effects on α5β3γ2L GABAARs when normalised to 1 µM GABA. All 
the sub-fractions were tested on the Patchliner. Out the 19 sub-fractions only 9 were 
significant when compared to 1 µM GABA (highlighted in either green or blue corresponding 
to CMB-02130-1-3 or CMB-03405-1-3 fractions respectively). All the values were averaged 
from at least five different experiments. *p<0.05, **p<0.01, using One-way ANOVA.   
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Figure A9: Traces from the sub-fractions belonging to fractions CMB-02130-1-3. (A), (B) & 
(C) Traces from the Patchliner showing the effect CMB-02130-1-3-2, CMB-02130-1-3-6 and 
CMB-02130-1-3-8 at α5β3γ2L GABAARs when co-applied at a concentration of 0.2 µg/µL with 
1 µM GABA, respectively.  
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Figure A10: Traces from the sub-fractions belonging to fractions CMB-03405-1-3. (A), (B) & 
(C) Traces from the Patchliner showing the effect CMB-03405-1-3-1, CMB-03405-1-3-5 and 
CMB-03405-1-3-6 at α5β3γ2L GABAARs when co-applied at a concentration of 0.2 µg/µL with 
1 µM GABA, respectively.  
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Figure A11: Traces from the sub-fractions belonging to fractions CMB-03405-1-3. (A), (B) & 
(C) Traces from the Patchliner showing the effect CMB-03405-1-3-7, CMB-03405-1-3-9 and 
CMB-03405-1-3-11 at α5β3γ2L GABAARs when co-applied at a concentration of 0.2 µg/µL with 
1 µM GABA, respectively.  
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Animal Ethics Approval Certificate for the 
use of oocytes from Xenopus Laevis 
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Amphibians (Marsabit Clawed Frog (Xenopus borealis) (breed), Female, Adults, ) 
2016  Apr  20 Initial approval 22 22 
Amphibians (Xenopus Laevis (breeder), Female, Adults, ) 
2016  Apr  20 Initial approval 58 58 
Description Amount Balance 
Approval Details 
UQ Research and Innovation 
Director, Research Management Office 
Nicole Thompson 
Animal Ethics Approval Certificate Apr -2016 20- 
Please check all details below and inform the Animal Welfare Unit within 10 working days if anything is incorrect. 
Activity Details 
Chief Investigator: Professor Joseph Lynch, Queensland Brain Institute 
Title: Investigating the effects of new drugs for pain, stroke and anxiety on neuronal ion channels 
AEC Approval Number: QBI/AIBN/087/16/NHMRC/ARC 
Previous AEC Number: 
Approval Duration: 20- Apr-2016 to 20-Apr -2019 
Funding Body: ARC, NHMRC 
Group: Anatomical Biosciences 
Other Staff/Students: Lachlan Rash, Natalie Saez, Irene Chassagnon, Angelo Keramidas, Mohammed Atif, Jessie  
Er, Linlin Ma, Ming Soh, Ben Cristofori-Armstrong, Argel Estrada, Nela Durisic, Glenn  
King, Jennifer Smith, Sharifun Islam 
Summary 
Subspecies Strain Class Gender Source Approved Remaining 
Amphibians Xenopus Laevis  
( breeder ) 
Adults Female 58 58 
Amphibians Marsabit Clawed  
Frog (Xenopus  
borealis) (breed) 
Adults Female 22 22 
Permits 
Provisos 
Pest Species (Xenopus frogs) Proviso: 
a)   Xenopus frogs must have permanent identification marks and be housed according to the DNR permit regulations 
b)  The CI must ensure that the toads are well identified and accurate records are kept of their use. 
The CI is required to ensure that no animal is used for oocyte collection more than  6 times. 
Location(s): St Lucia Bldg 75 - AIBN 
Cumbrae-Stewart Building 
Research Road 
Brisbane Qld 4072 Australia 
Animal Welfare Unit 
UQ Research and Innovation 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animalwelfare@research.uq.edu.au 
uq.edu.au/research 
P  1 f 2 
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration 
1 . When ordering animals from Animal Breeding Houses 
2 . For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and  
contact phone number. 
3 . When you need to communicate with this office about the project. 
It is a condition of this approval that all project animal details be made available to Animal House OIC. 
( UAEC Ruling  14/12/2001) 
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied  
for this project. 
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 20-Apr-2016) 
Please use this Approval Number: 
Cumbrae-Stewart Building 
Research Road 
Brisbane Qld 4072 Australia 
Animal Welfare Unit 
UQ Research and Innovation 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animalwelfare@research.uq.edu.au 
uq.edu.au/research 
P  2 f 2 
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Animal Ethics Approval Certificate for the 
use of rat embryos 
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Rats - non genetically modified (Wistar, Female, Adults, Institutional Breeding Colony) 
 Jun  2016 2 Initial approval 150 150 
2016  Dec  31 Use in 2016 (from 2017 MAR; AEMAR25405) -17 133 
31 2017 Dec  Use in 2017 (from 2018 MAR; AEMAR38049) -20 113 
Rats - non genetically modified (Wistar, Unknown, Prenatal / Embryo, Institutional Breeding Colony) 
2016  Jun  2 Initial approval 2400 2400 
2016  Dec  31 Use in 2016 (from 2017 MAR; AEMAR25405) -229 2171 
31 Dec  2017 Use in 2017 (from 2018 MAR; AEMAR38049) -271 1900 
Description Amount Balance 
Approval Details 
Office of Research Ethics 
Director 
Nicole Shively 
Animal Ethics Approval Certificate 21- -2018 Mar 
Please check all details below and inform the Animal Ethics Unit within 10 working days if anything is incorrect. 
Activity Details 
Chief Investigator: Professor Joseph Lynch, Queensland Brain Institute 
Title: Generating artificial synapses for the purpose of evaluating new drugs for neurological  
disorders 
AEC Approval Number: QBI/142/16/NHMRC/ARC 
Previous AEC Number: QBI/203/13/ARC 
Approval Duration: -2019 Jun-2016 to 10-Jun 10- 
Funding Body: ARC 
Group: Anatomical Biosciences 
Other Staff/Students: Nela Durisic, Maleeha Waqar, Dejan Gagoski, Edmund Cotter, Angelo Keramidas,  
Parnayan Syed, Xiumin Chen, Mohammed Atif, Trish Hitchcock 
Summary 
Subspecies Strain Class Gender Source Approved Remaining 
Rats - non  
genetically  
modified 
Wistar Adults Female Institutional  
Breeding Colony 
150 113 
Rats - non  
genetically  
modified 
Wistar Prenatal / Embryo Unknown Institutional  
Breeding Colony 
2400 1900 
Permits 
Provisos 
Location(s): St Lucia Bldg 79 - Queensland Brain Institute 
Cumbrae-Stewart Building 
Research Road 
St Lucia Qld 4072 Australia 
Animal Ethics Unit 
Office of Research Ethics 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animal.ethics@research.uq.edu.au 
uq.edu.au/research 
P  1 f 2 
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration 
1 . When ordering animals from Animal Breeding Houses 
2 . For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and  
contact phone number. 
3 . When you need to communicate with this office about the project. 
It is a condition of this approval that all project animal details be made available to Animal House OIC. 
( UAEC Ruling  14/12/2001) 
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied  
for this project. 
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 21-Mar-2018) 
Please use this Approval Number: 
Cumbrae-Stewart Building 
Research Road 
St Lucia Qld 4072 Australia 
Animal Ethics Unit 
Office of Research Ethics 
The University of Queensland 
+61 7 336 52925 (Enquiries ) 
+61 7 334 68710 (Enquiries ) 
+61 7 336 52713 (Coordinator ) 
animal.ethics@research.uq.edu.au 
uq.edu.au/research 
P  2 f 2 
